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ABSTRACT 
 
 
To identify the genes involved in the process of thyroid carcinogenesis we 
have analysed the gene expression profiles of six thyroid carcinoma cell lines 
compared with normal human thyroid primary cell culture using an Affymetrix 
HG_U95Av2 oligonucleotide array representing ~10.500 unique genes. These 
studies led to the identification of genes whose expression was up- or down-
regulated in the carcinoma cell lines compared with a primary cell culture of 
normal thyroid origin.  
We identified 510 up-regulated transcripts and 320 down-regulated transcripts 
with a fold change higher than 10 in all of the carcinoma cell lines. In particular 
our interest was focused on the genes whose expression was drastically (at least 
10 fold) up- or down-regulated in all the cell lines, assuming that the genes altered 
in their expression in all of the thyroid carcinoma cell lines might represent 
candidate genes involved in thyroid cell transformation: these genes were 
UbcH10 (up-regulated) and CBX7 (down-regulated). 
The UbcH10 gene, coding for a protein that belongs to the ubiquitin-
conjugating enzyme family, was up-regulated by 150 fold in all of the carcinoma 
cell lines. CBX7, conversely, encodes a chromatin protein, probably involved in 
the compaction of heterochromatin: CBX7 resulted down-regulated about 20 fold 
in all the carcinoma cell lines analysed. 
Expression analyses performed using several techniques such as RT-PCR and 
immunohistochemistry showed that the deregulation of these two genes was 
linked to the rising of a highly malignant phenotype of thyroid carcinomas. 
Moreover, functional studies performed on thyroid carcinoma cells clearly 
demonstrated that the deregulated expression of UbcH10 and CBX7 is really 
involved in the process of thyroid carcinogenesis and not only related to the 
malignant phenotype. 
Taken together these results would indicate that UbcH10 and CBX7 expression 
is involved in thyroid cell proliferation and might represent a marker of thyroid 
malignant transformation, therefore, in conclusion, UbcH10 and CBX7 
monitoring could contribute to thyroid cancer diagnosis and prognosis. 
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1. BACKGROUND 
 
 
1.1 The thyroid gland 
The thyroid gland is the largest endocrine organ in humans (Kondo et al. 
2006). It is located in the neck region, on the anterior surface of the trachea, and is 
formed by two distinct cell types, the follicular cells (TFC) and the parafollicular 
or C cells (De Felice and Di Lauro 2004). The TFC constitute the most numerous 
cell population and form the thyroid follicles, spherical structures that store and 
release the thyroid hormones (Mauchamp et al. 1998). The C cells are located 
between follicles, mostly in a parafollicular position (Figure 1). 
 
 
 
Figure 1 The general architecture of the thyroid gland. In the figure is shown the general 
architecture of the thyroid gland with the parafollicular cells interspersed in small groups among 
the follicles in the intermediate part of the thyroid lobes. 
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 These two cell types take origine from two different embryological structures: 
the thyroid anlage for the TFC and the ultimobranchial bodies for the C cells. The 
thyroid anlage is an area enclosing a small group of endodermal cells, and it is 
located on the midline of the embryonic mouth cavity in its posterior part. The 
ultimobranchial bodies are a pair of transient embryonic structures derived from 
the fourth pharyngeal pouch and located symmetrically on the sides of the 
developing neck: C cell precursors migrate from the neural crest (Le Douarin et 
al. 1974) in these structures (Fontaine J 1979). The cells of the thyroid anlage and 
the ultimobranchial bodies migrate from their respective sites of origin and 
ultimately merge in the definitive thyroid gland. Once merged, the thyroid anlage 
and the ultimobranchial bodies disappear and their cells disperse in the adult 
thyroid gland. At this point the cells from the anlage continue to organize the 
thyroid follicles, whereas the C cells scatter within the interfollicular space. 
Interestingly, in some animals the ultimobranchial structures remain distinct from 
the rest of the thyroid gland (Gorbman A 1986).  
 In the adult human, the gland has a butterfly shape and has a weight 15–25 g. It 
is comprised of aggregates (lobules) of spherical follicles that are filled with 
colloid. The follicles range in size from 50–500 μm and are lined by cuboidal-to-
flat follicular epithelial cells. The main functions of the thyroid gland are 
synthesis, storage and secretion of thyroid hormones, L-triiodothyronine (T3) and 
L-thyroxine (T4) (Kondo et al. 2006). This mechanism is under the control of the 
hypothalamic-pituitary axis with negative feedback by the thyroid hormones: 
thyrotropin releasing hormone (TRH), secreted from the hypothalamus, stimulates 
the release of thyroid-stimulating hormone (TSH) from the anterior pituitary 
gland. TSH, then, stimulates the follicular cells to synthesize and secrete thyroid 
hormones. Disruption of thyroid hormone homeostasis results in hypothyroidism, 
goiter and in childhood cretinism (Kondo et al. 2006). 
 The parafollicular C-cells secrete calcitonin, which is important for the bone 
formation. Its secretion is stimulated by elevate calcium concentration in the 
serum (Lin et al. 1991; Nicholson et al. 1986). 
 
1.2 Thyroid follicular cell carcinomas 
 Thyroid carcinomas that originates from TFC are mainly divided into well-
differentiated, poorly differentiated and undifferentiated carcinomas on the basis 
of clinico-pathological parameters such as prevalence, sex ratio, age, local/distant 
metastasis and survival rate (Kondo et al. 2006). Papillary (PTC) and follicular 
(FTC) thyroid carcinomas are considered well-differentiated carcinomas (Kondo 
et al. 2006). Although initially defined by architectural criteria, the histological 
diagnosis of PTC rests on a number of nuclear features that predict the propensity 
for metastasis to local lymph nodes (World Health Organization Classification of 
Tumours 2004). The diagnosis of this most frequent type of thyroid malignancy 
(85–90% of thyroid malignancies) has been increasing, possibly owing to the 
changing recognition of nuclear morphological criteria. On the other hand, FTC is 
characterized by haematogenous spread, and the frequency of its diagnosis has 
been decreasing (Li Volsi and Asa 1994). Most well-differentiated thyroid 
cancers behave in an indolent manner and have an excellent prognosis. By 
contrast, anaplastic (ATC) thyroid carcinoma (undiffererntiated) is highly 
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aggressive and always fatal (World Health Organization Classification of 
Tumours 2004; Kebebew et al. 2005). For this type of cancer there is not an 
effective treatment and, usually, the prognosis is poor and death occurs within one 
year from the diagnosis. Finally, poorly differentiated (PDC) thyroid carcinomas 
are intermediate forms between well-differentiated and undifferentiated, 
morphologically and behavioural (World Health Organization Classification of 
Tumours 2004; Carcangiu et al. 1984; Rodriguez et al. 1998). 
 Thyroid neoplasms, therefore, represent a good model for studying the events 
involved in epithelial cell multistep carcinogenesis (Figure 2), because they 
comprise a broad spectrum of lesions with different degrees of malignancy from 
benign adenomas (FA) (not invasive and very well differentiated) to the ATC 
(very aggressive and always fatal), with the intermediate forms represented by 
PTC and FTC (differentiated and with a good prognosis) (Hedinger et al. 1989; 
Wynford-Thomas 1997; Kondo et al. 2006). 
 
 
Figure 2 Model of multi-step carcinogenesis of thyroid neoplasms. On the basis of 
clinical, histological and molecular observations, three distinct pathways are proposed for 
neoplastic proliferation of thyroid follicular cells, including hyper-functioning follicular thyroid 
adenoma (tumours that are almost always benign lesions without a propensity for progression), 
follicular thyroid carcinoma and papillary thyroid carcinoma. Genetic defects that result in 
activation of RET or BRAF represent early, frequent initiating events that can be associated with 
radiation exposure. Most poorly differentiated and undifferentiated thyroid carcinomas are 
considered to derive from pre-existing well-differentiated thyroid carcinoma through additional 
genetic events, including p53 inactivation, but de novo occurrence might also occur.  
 
 Point mutations, rearrangements that activate proto-oncogenes, and loss-of-
function in tumor suppressor genes have been identified in thyroid tumors (Kondo 
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et al. 2006). The involvement of several oncogenes has been demonstrated in 
PTC: activation of the RET/PTC oncogene, caused by rearrangements of the RET 
proto-oncogene, occurs in about 30% of cases (Kondo et al. 2006), whereas the B-
RAF gene is mutated in about 40% of cases (Xing 2005). These tumors have also 
been associated with TRK gene rearrangements (Pierotti and Greco 2006) and 
MET gene overexpression (Di Renzo et al. 1992). RAS gene mutations (Suarez et 
al. 1990) and PAX8-PPAR-γ rearrangements (Kroll et al. 2000) are frequent in 
FTC, whereas impaired function of the p53 tumor suppressor gene is typical of 
ATC (Ito et al. 1992; Donghi et al. 1993; Fagin et al. 1993). Other genes have 
been implicated in thyroid neoplasias. Even though critical molecular mechanisms 
of thyroid carcinogenesis have been clarified, other molecular steps of neoplastic 
progression need to be investigated. 
 
1.3 Microarray analysis of human carcinomas 
 Dna microarray technology was introduced in the scientific community in the 
mid-1990s as a mean to check the expression levels of thousands of genes 
simultaneously (Lipshutz et al. 1995; Schena et al. 1995). This kind of analysis 
was quickly adopted by the research community for the study of a wide range of 
biologic processes. Most of the early studies were performed simply to compare 
two biologic classes in order to identify the differential expression of the genes in 
them - genes with potential relevance to a wide range of biologic processes, such 
as the progression of cancer (De Risi et al. 1996; Welford et al. 1998; Khan et al. 
1998; Agrawal et al. 2002), the causes of asthma (Rolph et al. 2006; Erle et al. 
2003; Syed et al. 2005), heart disease (Heymans et al. 2005; Ohki et al. 2005; Li 
et al. 2003), neuropsychiatric disorders (Evans et al. 2003; Pierce et al. 2004; 
Zvara et al. 2005), and the analysis of factors associated with infertility (Chin et 
al. 2002; Zhang et al. 2005).  
 Soon after its introduction, mycroarray technology was used to find new 
subclasses in disease states (Alon et al. 1999; Perou et al. 1999) and to identify 
biologic markers (biomarkers) associated with disease (Moch et al. 1999) 
establishing that even the expression patterns of the genes could be used to 
distinguish subclasses of disease (Khan et al. 1998; Golub et al. 1999; Bloom et 
al. 2004; Eschrich et al. 2005).  
 This realization resulted in a proliferation of searches for patterns of expression 
that could be used to classify types of tumors (Sorlie et al. 2001) and predict the 
outcome (Beer et al. 2002; Van De Vijver et al. 2002) and response to 
chemotherapy (Van ’t Veer et al. 2002; Kihara et al. 2001). In fact, gene 
expression profiling studies based upon this new technology has been successfully 
used to discover consistent gene expression patterns associated with a histological 
or clinical phenotype (Alizadeh et al. 2000; Van De Vijver et al. 2002; Bullinger 
et al. 2004; Dave et al. 2004; Lapointe et al. 2004; Valk et al. 2004; Lee et al. 
2004; Roepman et al. 2005) and also to predict the clinical outcome and survival 
as well as to classify different types of cancer (Bittner et al. 2000; Beer et al. 
2002; Van’t Veer et al. 2002; Valk et al. 2004; Lee et al. 2004; Roepman et al. 
2005). The research focus has now shifted toward identifying genetic 
determinants that are components of the specific regulatory pathways altered in 
cancers, leading to the discovery of novel therapeutic targets. In this view, our 
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group, recently, investigated the Ras-dependent modulation of gene expression in 
thyroid cells (Visconti et al. 2006 Accepted). However, it is not easy to select few 
candidate genes for further studies from the lengthy gene lists generated from 
gene expression profiling studies (Lee and Thorgeirsson 2006). This approach, 
however, promises to provide diagnostic and prognostic markers that can be 
clinically used in the near future (Lossos et al. 2004). 
 Therefore, to identify candidate genes involved in the process of thyroid 
carcinogenesis, we analysed a microarray, that represents 12.625 sequences, with 
RNAs extracted from normal human thyroid primary cell culture (NTPC), and six 
human thyroid carcinoma cell lines of different histotype (1 from a follicular 
carcinoma, 3 derived from papillary carcinomas and 2 from anaplastic 
carcinomas). We focused our interest on the genes whose expression was 
drastically (at least 10 fold) up- or down-regulated in all of the six thyroid 
carcinoma cell lines in comparison to the normal thyroid primary cell culture 
assuming that the genes altered in their expression in all of the thyroid carcinoma 
cell lines might represent candidate genes involved in thyroid cell transformation.  
 
1.4 UbcH10 and the Ubiquitin-Proteasome proteolityc pathway 
 Among these genes, our attention was focused on the UbcH10 gene that was 
up-regulated about 150 fold in all of the cell lines tested by the cDNA microarray. 
The UbcH10 gene belongs to the E2 gene family and codes for a protein of 19.6 
kDa that is involved in the ubiquitin-dependent proteolysis (Hershko et al. 1998; 
Joazeiro et al. 2000).  
 Like all macromolecular components of an organism, the proteome is in a 
dynamic state of synthesis and degradation. During proteolysis, the peptide bonds 
are hydrolyzed and free amino acids are released: the energy invested in the 
synthesis of the peptide bond is released. The process is carried out by a diverse 
group of enzymes termed proteases. Distinct proteolytic mechanisms serve 
different physiological requirements and allow the organism to accommodate to 
changing environmental and pathophysiological conditions (Glickman and 
Ciechanover 2002). 
 Degradation of a protein via the ubiquitin-proteasome pathway involves two 
discrete and successive steps: (1) tagging of the substrate by covalent attachment 
of multiple ubiquitin molecules and (2) degradation of the tagged protein by the 
26S proteasome complex with release of free and reusable ubiquitin. This last 
process is mediated by deubiquitinating enzymes (DUB) that allow the recycling 
of the ubiquitin (Glickman and Ciechanover 2002). Ubiquitin is a highly 
evolutionarily conserved 76-residue polypeptide that is conjugated to the protein 
substrate via a cascade mechanism that involve three principal steps (Figure 3). 
 In the first step the ubiquitin activating enzyme E1 activates ubiquitin: this 
enzyme requires ATP and the reaction generates a high-energy thiol ester 
intermediate, E1-S-ubiquitin. Subsequently, several ubiquitin-carrier proteins E2 
enzymes (or ubiquitin-conjugating enzymes, UBC) transfer the activated ubiquitin 
from E1, to the substrate that is specifically bound to a member of the ubiquitin-
protein ligase family, E3. This reaction proceds via an additional high-energy 
thiol ester intermediate, E2-S-ubiquitin (Peters et al. 1998; Hilt and Wolfe 2000). 
There are a number of different classes of E3 enzymes and they catalyze the last 
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step in the conjugation process: covalent attachment of ubiquitin to the substrate 
(Deshaies 1999; Jackson et al. 2000). 
 
 
 
Figure 3 The ubiquitin proteolytic pathway. 1: Activation of ubiquitin by the ubiquitin-
activating enzyme E1, a ubiquitin-carrier protein, E2 (ubiquitin-conjugating enzyme, UBC), and 
ATP. The product of this reaction is a high-energy E2-ubiquitin thiol ester intermediate. 2: 
Binding of the protein substrate, via a defined recognition motif, to a specific ubiquitin-protein 
ligase, E3. 3: Multiple (n) cycles of conjugation of ubiquitin to the target substrate and synthesis of 
a polyubiquitin chain. E2 transfers the first activated ubiquitin moiety directly to the E3-bound 
substrate, and in following cycles, to previously conjugated ubiquitin moiety. Direct transfer of 
activated ubiquitin from E2 to the E3-bound substrate occurs in substrates targeted by RING 
finger E3s. 3’: As in 3, but the activated ubiquitin moiety is transferred from E2 to a high-energy 
thiol intermediate on E3, before its conjugation to the E3-bound substrate or to the previously 
conjugated ubiquitin moiety. This reaction is catalyzed by HECT domain E3s. 4: Degradation of 
the ubiquitin- tagged substrate by the 26S proteasome complex with release of short peptides. 5: 
Ubiquitin is recycled via the activity of deubiquitinating enzymes (DUBs) (Glickman and 
Ciechanover 2002).  
 
By successively adding activated ubiquitin molecules to lysine residues on the 
previously conjugated ubiquitin molecule, a polyubiquitin chain is synthesized. At 
this point the 26S proteasome complex is able to recognize the ubiquitin chain. 
Thus E3s play a key role in the ubiquitin-mediated proteolytic cascade since they 
serve as the specific recognition factors of the system. The simplified view of the 
hierarchical structure of the ubiquitin conjugation machinery is that a single E1 
activates ubiquitin for all conjugation reactions. E1 interacts with all E2s. 
Typically, each E2, interacts with several E3s. Each E3 targets several substrates. 
However, the interactions of the conjugating enzymes among themselves and with 
many of the target substrates may differ from this “classical” cascade. (Glickman 
and Ciechanover 2002). 
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 The proteasome is a large multicatalytic protease (26S) that degrades 
polyubiquitinated proteins to small peptides. It is composed of two subcomplexes: 
a 20S core particle (CP) that carries the catalytic activity and a regulatory 19S 
regulatory particle (RP). The catalytic sites are localized to some of the CP 
subunits. Each extremity of the 20S barrel can be capped by a 19S RP. One 
important function of the 19S RP is to recognize ubiquitinated proteins and other 
potential substrates of the proteasome, moreover because a folded protein would 
not be able to fit through the narrow proteasomal channel, it is assumed that the 
19S particle unfolds substrates and inserts them into the 20S CP. After 
degradation of the substrate, short peptides derived from the substrate are 
released, as well as reusable ubiquitin (Bochtler et al. 1999; Glickman 2000; 
Voges et al. 1999). 
 Ubiquitin-mediated proteolysis plays an important role in many basic cellular 
processes: regulation of cell cycle and division, differentiation and development, 
involvement in the cellular response to stress and extracellular effectors, 
morphogenesis of neuronal networks, modulation of cell surface receptors, ion 
channels and the secretory pathway, DNA repair, transcriptional regulation, 
transcriptional silencing, long-term memory, circadian rhythms, regulation of the 
immune and inflammatory responses, and biogenesis of organelles (Glickman and 
Ciechanover 2002). The number of cellular proteins that are targeted by ubiquitin 
is growing rapidly. Among them are cell cycle regulators such as cyclins, cyclin 
dependent kinase inhibitors, and proteins involved in sister chromatid separation, 
tumor suppressors, as well as transcriptional activators and their inhibitors. Cell 
surface receptors and endoplasmic reticulum proteins are also targeted by the 
system. Finally, mutated and denatured/misfolded proteins are recognized 
specifically and are removed efficiently. In this capacity, the system is a key 
player in the cellular quality control and defense mechanisms. 
 With the numerous substrate proteins targeted and the multitude of processes 
involved, it is not surprising that aberrations in the ubiquitin system have been 
implicated in the pathogenesis of many inherited and acquired human pathologies 
(Glickman and Ciechanover 2002). 
 
1.5 UbcH10 involvement in cancer 
 As it was in precedence staten, the progression through the eukaryotic cell 
cycle is accomplished by the degradation of key cell-cycle regulators by the mean 
of ubiquitin-proteasome pathway (Pickart 2001). The E3 anaphase-promoting 
complex/cyclosome (APC) (Figure 4) is the central coordinator of cell-cycle 
progression in mitosis and G1 (Peters 2002). This complex is activated at the 
onset of mitosis through cyclin B/Cdk1-dependent phosphorylation and the 
binding of its activator Cdc20.  
 Moreover, APC becomes active only after that sister chromatid separation is 
initiated, after all kinetochores have been correctly attached to the mitotic spindle. 
During anaphase, Cdc20 is replaced by Cdh1, a homologous activator. By 
promoting the sequential degradation of key regulators, APC-Cdh1 orchestrates 
exit from mitosis and events in G1. 
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Figure 4 The Anaphase Promoting Complex (APC). The anaphase-promoting 
complex/cyclosome (APC/C) is a ubiquitin ligase that controls cell-cycle progression by targeting 
proteins for destruction by the 26S proteasome. The APC/C is active throughout late mitosis and 
G1 phase but APC/C substrates are degraded in a specific order. 
 
Before entry into S phase the APC is inactivated by degradation of its E2 
UbcH10 and by the E2F-dependent expression of the inhibitors cyclin A and 
Emi1 (Lukas et al. 1999; Hsu et al. 2002; Rape and Kirschner 2004). The correct 
sequence of APC-mediated ubiquitinations ensures the orderly progression of 
mitosis and G1. Substrates are mainly recognized by Cdc20 and Cdh1 but in this 
process also direct interactions between APC and substrates are important (Burton 
et al. 2005; Kraft et al. 2005; Yamano et al. 2004). The recognition is due to short 
stretch of aminoacids within substrates, the D-box and the Ken-box (Glotzer et al. 
1991; Pfleger and Kirschner 2000). During the recognition process APC-Cdh1 
discriminates between substates and catalyzes their multiubiquitination in a 
sequential manner: Cdc20 is ubiquitinated shortly after APC-Cdh1 activation in 
anaphase, Plk1 and Aurora A are ubiquitinated later, after they have functioned in 
telophase and cytokinesis, and UbcH10 autoubiquitination is promoted in G1 after 
these substrates have been degraded. Additionally, the degradation of UbcH10 
stabilizes cyclin A, while APC-Cdh1 substrates, such as securin or geminin, can 
still be degraded (Rape et al. 2006). It is clear that APC regulates the cell cycle 
transition through mitosis, triggering the timely destruction of key regulatory 
molecules such as cyclins and protein involved in the chromatid separation 
(Harper et al. 2002; Peters 2002). Securin and cyclin B ubiquitination also appears 
to require the E3 ligase proteins contained within the APC and the E2 conjugating 
enzyme UbcH10. 
 So, it is not surprising to find that mutation of the active site cysteine of 
UbcH10 confers a dominant-negative phenotype that results in metaphase arrest, 
demonstrating that this protein is essential for cell cycle progression (Townsley et 
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al. 1997). Although clearly associated with regulation of the cell cycle, the 
potential role of UbcH10 in cancer development has only recently been explored. 
Expression of the mouse ortholog of human UbcH10, mEC-2, was reported up-
regulated in NIH3T3 cells transformed by EWS/FLI1, activated cdc42, v-ABL or 
c-myc, but not in a nontransformed NIH3T3 clone expressing EWS/FLI1 (Arvand 
et al. 1998). Recently, a comparison of expression levels of 17 E2 ubiquitin ligase 
genes in normal and tumor tissues identified UbcH10 as most specifically 
associated with cancer and, consistent with this notion, overexpression of UbcH10 
in NIH3T3 cells led to an increased proliferative capacity (Okamoto et al. 2003). 
Moreover, in expression profiling studies, it was reported that the levels of 
UbcH10 transcript are highly elevated in different types of cancers (Welsh et al. 
2001; La Tulippe et al. 2002; Wagner et al. 2004). It was demonstrated that 
overexpression of UbcH10 in some carcinomas may be due, at least in part, to 
genomic amplification of the UbcH10 locus (Wagner et al. 2004). It was also 
reported that the silencing of UbcH10 by RNA interference (RNAi), in 
combination with TRAIL/DR5 agonistic antibodies, resulted in enhanced cell 
death in neoplastic but not nonmalignant human cells (Wagner et al. 2004). 
 15
 
1.6 CBX7 and Polycomb group genes 
 Within the context of this microarray study, we found that the CBX7 
(Chromobox homolog 7) gene was down-regulated in the thyroid carcinoma-
derived cell lines and also in thyroid fresh tumors. CBX7 encodes a novel protein 
that is a part of the Polycomb Group protein.  
 Polycomb Group genes (PcG) are a set of genes linking histone modifications 
with transcriptional repression: they are structurally diverse but functionally 
epistatic (Otte and Kwaks 2003; Lund and Van Lohuizen 2004). PcG proteins are 
part of two complexes with high molecular weight called Polycomb repressive 
complexes 1 and 2, PRC1 and PRC2, (Figure 5) (Lund and Van Lohuizen 2004; 
Wang et al. 2004).  
 
 
 
Figure 5 Mechanism of transcriptional repression by Polycomb Group proteins. The 
binding of Polycomb repressive complex 2 (PRC2) to Polycomb responsive elements (PRE) 
triggers histone deacetylation, and methylation of lysine 27 in Histone H3, both around the PRE 
and in the promoter region of the genes silenced. This modification constitute one of the signals 
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for the recruitment of the Polycomb repressive complex 1 (PRC1), or maintenance complex, 
which repress gene expression by inhibiting transcription initiation (Gil et al. 2005). 
 
 The PRC1 complex can recognize and bind to trimethylated K27 of Histone 
H3 through Polycomb proteins, and contributes to gene repression by inhibiting 
transcription initiation (Cao et al. 2002). The components of the core of this 
complex in mammals are the homologs of Drosophila Polycomb (Pc), Posterior 
sex combs (Psc), Sex combs extra (Sce) and Polyhomeiotic (Ph). The PRC2 
complex, instead, has associated histone deacetylase and histone methyl 
transferase (specific for lysine of Histone H3, K27H3) activities, thus it 
contributes to establish an histone repressive marks (Kuzmichev et al. 2002; 
Kirmizis et al. 2004). Between the known mammalian components of this second 
complex are Enhancer of Zeste (EZH2), Early embryonic deficient (EED), 
Suppressor of Zeste (SUZ12) and other associated proteins.  
 It is well known that PcG proteins deregulation is involved in tumorigenesis in 
fact several studies have demonstrated that, for example, Bmi-1 is amplified in 
blood malignancies and medulloblastomas (Raaphorst et al. 2000; Bea et al. 2001; 
Van Kemenade et al. 2001; Lessard and Sauvageau 2003), EZH2 is involved in 
blood malignancies (Raaphorst et al. 2000; Visser et al. 2001), and its expression 
is increased during the process of metastasis of prostate and breast tumors 
(Varambally et al. 2002; Kleer et al. 2003), Mel18 has been suggested to act as a 
tumor suppressor gene (Kanno et al. 1995), Rae28/Ph1 alterations are observed in 
acute lymphoblastic leukemia (Tokimasa et al. 2001) and SUZ12 is up-regulated 
in colon tumors (Kirmizis et al. 2003). Evidence is rapidly increasing that PcG 
genes are a novel class of oncogenes and anti-oncogenes, which may in future 
years become central to the development of novel cancer therapies based on 
epigenetic gene silencing (Nakao et al. 2004, Egger et al. 2004). Not only are PcG 
genes such as BMI-1 and EZH2 capable of cellular transformation, but also they 
are vital for cell survival. To date, abnormal PcG genes expression has been 
described in most human cancers. Also, the correlation between PcG expression 
and biological behavior of clinically defined cancer subtypes suggests that these 
genes play a central role in oncogenesis, and holds a promise for discovery of 
novel diagnostic markers (Raaphorst et al. 2004). 
 CBX7 and the others PcG proteins contain a chromodomain in the N-terminus 
(CBX7 between amino acids 10 and 46). This domain was originally identified in 
Drosophila melanogaster as a 37-amino-acid region of homology shared by 
heterochromatin protein 1 (HP1) and Polycomb (Pc) proteins (Paro and Hogness 
1991). Phylogenetic and sequence analyses of the chromodomain (Figure 6A and 
B) revealed that CBX7 has a great similarity to other known or putative Pc 
proteins like CBX2 (Pc1), CBX4 (Pc2), CBX6 and CBX8 (Pc3). This similarity is 
less pronounced respect to the HP1 proteins, such as CBX1 (HP1β), CBX3 
(HP1γ), CBX5 (HP1α) and, moreover, CBX7 does not contain the “chromo-
shadow domain” that, instead, is a hallmark of HP1 proteins. CBX7 protein 
contains also other specific conserved residues that distinguish Pc and HP1 
chromodomains: these residues specific of the Pc proteins are necessary both for 
Pc dimerization and recognition of tri-methylated Lys 27 on histone H3 (Min et 
al. 2003). 
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Figure 6 CBX7 and chromodomain. Identification of CBX7 as a Polycomb protein. (A) 
Phylogenetic analysis of Chromobox (CBX) proteins. Lines grouped by open rectangles denote 
orthologs of a same CBX protein (name in the right). Full rectangles refer to proteins that cannot 
be considered purely orthologs of any of the CBX proteins. Pc proteins are shown in blue, and 
HP1 proteins in red. CBX7 and CBX6 are shown in black. (B) Alignment of CBX7 
chromodomain with that of other known and putative human Polycombs. Identical residues are 
shown in a yellow background, and similar residues are shown in a cyan background. (C) 
Alignment of CBX7 Polycomb box with that of other known and putative human Polycombs. 
Background colours are as described in (B) (from Gil et al. 2004). 
 
 In addition to the high homology within the chromodomain, CBX7 has also 
homology to Pc proteins in a carboxy-terminal region(Figure 6C) previously 
defined as the Pc box or C-box (Jones et al. 2000). It is known that either the Pc 
box (amino acids 231–243) and the chromodomain (Jones et al. 2000) are both 
necessary for CBX7 function. It was seen that a fusion protein between CBX7 and 
the DNA-binding domain of Gal4 is able to repress in a dose dependent manner, 
the transcription over a 4×Gal4-tk-luc reporter, suggesting that CBX7 functions 
by repressing transcription (Gil et al. 2004). So, CBX7 seems to act like the others 
Pc proteins exerting its effect through transcriptional repression. 
 CBX7 is highly expressed in a number of different normal tissue types, 
including brain, kidney, heart and skeletal muscle, although it has not previously 
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been investigated in tumor cells (Gil et al. 2004). A recent study has demonstrated 
that CBX7 expression is associated with extension of cellular life span in mouse 
embryonic fibroblasts and human prostate primary epithelial cells by 
downregulating expression of the Ink4a/Arf locus (Gil et al. 2004. Bernard et al. 
2005). However another study on ependymoma (Suarez-Merino et al. 2005) 
reported a consistent down-regulation of CBX7 in the tumor samples, with the 
loss of at least one copy of the gene in 55% of cases examined, and proposed 
other mechanisms than CBX7/p16 pathway, since in ependymoma although gene 
mutations are rare, hypermethylation of p16Ink4a, Rb and p14ARF has been 
reported in a subgroup of tumors (4%–32%) (Suarez-Merino et al. 2005). Mouse 
CBX7 is, moreover, able to associate with facultative heterochromatin and with 
the inactive X chromosome, which indicates that CBX7 is really involved in the 
repression of gene transcription (Bernstein et al. 2006). CBX7 is also capable to 
interact with different Pc group members. In fact, similarly to other Pc proteins, 
CBX7 is able to inter-functions with itself and with the ring-finger protein Ring1 
(Gil et al. 2004), as reported by the mean of Glutathione S-transferase (GST) pull-
down experiments (Satijn and Otte 1999; Satijn et al. 1997). In addition, within 
the nucleus, CBX7 co-localizes with Ring1 to distinct foci-like structures termed 
Pc-bodies (Saurin et al. 1998), in several cell lines, as demonstrated with 
immunofluorescence microscopy studies. However there is not association 
between CBX7 and other PcG proteins, such as Bmi1, EED or EHZ2 (Gil et al. 
2004) so this let think that CBX7 is part of different complexes than Bmi1 and 
Pc2. 
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2. AIMS OF THE STUDY 
 
 
 Thyroid tumors are the result of the accumulation of different modifications in 
critical genes involved in the control of cell proliferation. Although various 
therapeutic approaches are followed in clinical practice, most of them are not life-
saving. Hence, the discovery of ways to diagnose cancer at an early stage and to 
establish more effective therapies is a critical and urgent issue. To achieve this 
goal, identification and characterization of key molecules that participate in 
carcinogenesis are essential steps. 
 In this context, we studied the modulation of gene expression associated with 
the progression towards a malignant phenotype of thyroid cancer. To this aim, we 
used RNA samples extracted from human thyroid carcinoma cell lines to perform 
a screening with Affymetrix microarrays containing about 10.500 human genes.  
 The main aim of the study would be the identification and characterization of 
genes whose expression and function are deregulated in the carcinoma samples of 
human thyroid origin.  
 If the deregulated expression/function of these genes results strongly 
associated with the expression of a highly malignant phenotype, the final 
objective of this study would be the perspective to use them as new tools for 
diagnosis and prognosis. 
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3. MATERIALS AND METHODS 
 
 
3.1 Cell culture and transfections  
 We used the following human thyroid carcinoma cell lines in this study: TPC-
1, WRO, NPA, ARO, FRO, NIM 1, B-CPAP, FB-1, FB-2, Kat-4 and Kat-18, 
which are described elsewhere (Pallante et al. 2005). They were grown in DMEM 
(Gibco Laboratories, Carlsbad, CA) containing 10% fetal calf serum (Gibco 
Laboratories), glutamine (Gibco Laboratories) and ampicillin/streptomycin 
(Gibco Laboratories) in a 5% CO2 atmosphere. Normal human thyroid primary 
culture cells have been established and grown as already described (Curcio et al. 
1994). PC Cl 3 (Fusco et al. 1987) and FRTL-5 (Ambesi-Impiombato et al. 1980) 
cell lines were cultured in modified F12 medium supplemented with 5% calf 
serum (Gibco Laboratories) and six growth factors (thyrotropic hormone, 
hydrocortisone, insulin, transferrin, somatostatin and glycyl-histidyl-lysine) 
(Sigma, St. Louis, MO). PC CL 3 and FRTL-5 infected with several oncogenes 
PC KiMSV, PC HaMSV, PC v-raf, PC MPSV (Fusco et al. 1987), PC PyMLV 
(Berlingieri et al. 1988), PC E1A, PC E1A+v-raf (Berlingieri et al. 1993), PC 
RET/PTC, PC HaMSV+RET/PTC1 (Santoro et al. 1993), PC MPSV-HMGA2 
(Berlingieri et al. 1995), FRTL-5 KiMSV (Fusco et al. 1985), FRTL-5 KiMSV-
HMGA1 (Berlingieri et al. 2002) cells were cultured in the same medium as PC 
CL 3 and FRTL-5 cells but without the six growth factors.  
 Thyroid cells were transfected using Lipofectamine reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. The transfected cells 
were selected in a medium containing geneticin (G418) (Life Technologies, 
Milan, Italy). For each transfection, several G418 resistant clones and the mass 
cell population were isolated and expanded for further analysis. 
 
3.2 Human thyroid tissue samples  
 Neoplastic human thyroid tissues and normal adjacent tissue or the 
controlateral normal thyroid lobe were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. Thyroid tumors were collected at the 
Laboratoire d'Histologie et de Cytologie, Centre Hospitalier Lyon Sud, France, 
and at the Laboratoire d'Anatomie Pathologique, Hopital de L'Antiquaille Lyon, 
France. The tumor samples were stored frozen until RNA or protein extractions 
were performed. 
 
3.3 RNA isolation  
 Total RNA was extracted from tissues and cell cultures using the RNAeasy 
mini kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. The 
integrity of the RNA was assessed by denaturing agarose gel electrophoresis. 
 
3.4 Microarray analysis  
 In this study we used commercially available high density Affymetrix (Santa 
Clara, CA) oligonucleotide microarrays (HG_U95Av2) consisting of 12.625 
probe set each representing a transcript. cRNA preparation, hybridization, 
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scanning and analysis were performed as previously reported (Dyrskjot et al. 
2003). Briefly, after cRNA hybridization to microarray, analysis of the readings 
from the quantitative scanning was performed using the Affymetrix Gene 
Expression Analysis Software (Affymetrix), according to Affymetrix protocols. 
Comparisons were made for each carcinoma cell line sample versus normal 
thyroid primary culture, taking normal thyroid cells as baseline. The fold change 
values, indicating the relative change in the expression levels between 
transformed cell line and normal thyroid primary culture samples, were used to 
identify genes differentially expressed between these conditions. 
 
3.5 Reverse transcriptase and PCR analysis 
 
Reverse transcription  
 1 μg of total RNA from each sample was reverse-transcribed with 
QuantiTect® Reverse Transcription Kit (Qiagen) using an optimized blend of 
oligo-dT and random primers according to the manufacturer’s instructions. 
 
Semiquantitative RT-PCR  
 PCR was carried out on cDNA using the GeneAmp PCR System 9600 
(Applied Biosystems, Foster City, CA). The RNA PCR Core Kit (Applied 
Biosystems) was used to perform amplifications. After a first denaturing step 
(94°C for 3 min), PCR amplification was performed for 25-30 (variable) cycles 
(94°C for 30 s, 55-60°C (variable) for 30 s, 72°C for 30 s).  
 The sequences of primers used are shown in Table 1. To ensure that RNA 
samples were not contaminated with DNA, negative controls were obtained by 
carrying out the PCR on samples that were not reverse-transcribed, but otherwise 
identically processed. The PCR products were separated on a 2% agarose gel, 
stained with ethidium bromide and scanned with a Typhoon 9200 scanner (GE 
Healthcare, Piscataway, NJ).  
 
Selection of primers and probes for qRT-PCR  
 To design a qRT-PCR assay we used the Human ProbeLibraryTM system 
(Exiqon, Vedbaek, Denmark). Briefly, using locked nucleic acid (LNATM) 
technology (Obika et al. 1997; Koskhin et al. 1998), Exiqon provides 90 human 
prevalidatet TaqMan probes of only 8-9 nucleotides that recognize 99% of human 
transcripts in the RefSeq database at NCBI (Mouritzen et al. 2004; Mouritzen et 
al. 2005). Using the ProbeFinder assay design software (freely accessed on the 
web site www.probelibrary.com) we chose the best probe and primers pair. To 
amplify a fragment for Real-Time PCR of CBX7 mRNA, we entered its accession 
number (NM_175709.2) on the assay design page of the ProbeFinder software 
and we chose an amplicon of 71 nucleotides that spanned the 3rd and 4th exons. 
The probe number was “human 63” (according to the numbering of Exiqon’s 
Human ProbeLibrary kit) and the primer sequences are reported in Table 1. 
 The same procedure was used to choose the probe and primers for the 
housekeeping gene G6PD (accession number X03674). We opted for an amplicon 
of 106 nucleotides that spanned the 3rd and 4th exons. The probe number was 
“human 05” (according to the numbering of Exiqon’s Human ProbeLibrary kit) 
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and the primer sequences are reported in Table 1. All fluorogenic probes were 
dual-labeled with FAM at 5’-end and with a black quencher at the 3’-end. 
 
qRT-PCR  
 Real-Time Quantitative TaqMan PCR was carried out with the Chromo4 
Detector (MJ Research, Waltham, MA) in 96-well plates using a final volume of 
20 μl. For PCR we used 8 μl of 2.5x RealMasterMixTM Probe ROX (Eppendorf 
AG, Hamburg, Germany) 200 nM of each primer, 100 nM probe and cDNA 
generated from 50 ng of total RNA. The conditions used for PCR were 2 min at 
95°C and then 45 cycles of 20 sec at 95°C and 1 min a 60°C. Each reaction was 
carried out in duplicate. Fold mRNA overexpression was calculated according to 
the formula 2(Rt-Et)/2(Rn-En) as described previously (El-Rifai et al. 2001), where Rt 
is the threshold cycle number for the reference gene in the tumor, Et for the 
experimental gene in the tumor, Rn for the reference gene in the normal sample 
and En for the experimental gene in the normal sample.  
 We also carried out qRT-PCR reactions with mouse cDNA in a final volume of 
20 μl using 10 μl of 2x Power SYBR Green PCR Master Mix (Applied 
Biosystems), 200 nM of each primer and cDNA generated from 50 ng of total 
RNA. The conditions used for PCR were 10 min at 95°C and then 45 cycles of 30 
sec at 95°C and 1 min a 60°C. Each reaction was carried out in duplicate, and at 
the end of the PCR run, a dissociation curve was constructed using a ramping 
temperature of 0.2°C per sec from 65°C to 95°C. A single melting point was 
obtained for CBX7 and β-Actin amplicons (data not shown). The mouse β-Actin 
gene served as control. The primers used are reported in Table 1. 
 
3.6 Protein extraction, Western blotting, and antibodies  
 The detailed procedure for protein extraction and Western blotting for UbcH10 
has been described in detail in the original article by Pallante et al. (Pallante et al. 
2005).  
 
3.7 Immunohistochemistry 
 
Tissue samples  
 UbcH10 protein cellular distribution was assessed by immunohistochemical 
analysis and compared to that of the standard cell proliferation marker Ki-
67/MIB1. A series of surgical specimens from patients with thyroid diseases 
comprised of Hashimoto’s thyroiditis-HT (6 cases), nodular goiter (12 cases), 
follicular carcinoma (13 cases), papillary carcinoma (33 cases), poorly 
differentiated carcinoma (5 cases) and anaplastic carcinoma (15 cases) was 
chosen to represent a wide range of thyroid pathology. As control, ten areas of 
normal thyroid parenchyma were selected from the lobe contralateral to the tumor 
in surgical specimens of papillary carcinoma. 
 The cell distribution of the CBX7 protein was assessed by immunostaining 
formalin-fixed, paraffin-embedded thyroid tumor blocks retrieved from the files 
of the Dipartimento di Scienze Biomorfologiche e Funzionali at the University of 
Naples Federico II and selected to represent a wide range of thyroid neoplastic 
diseases. To ensure that we evaluated CBX7 expression only on technically 
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adequate slides, we discarded slides that lacked a convincing internal control, 
namely labeling of stromal, endothelial or lymphoid cell, shown to be positive in 
a preliminary normal tissue micro-array analysis (data not shown). Based on these 
criteria, we scored paraffin-embedded stained slides from 20 cases of FA, 30 
cases of classical PTC, 6 cases of TCV PTC, 32 cases of FTC, 12 cases of poorly 
differentiated carcinoma, and 12 cases of ATC. As controls, we selected areas of 
normal thyroid parenchyma from the lobe contralateral to the tumor in 20 surgical 
specimens of PTC. 
 
Immunostaining: technique, evaluation and statistical analysis 
 Xylene dewaxed and alcohol rehydrated paraffin sections were placed in 
Coplin jars filled with a 0.01 M tri-sodium citrate solution, and heated for 3 
minutes in a conventional pressure cooker (Troncone et al. 2003). After heating, 
slides were thoroughly rinsed in cool running water for 5 minutes. They were then 
washed in Tris-Buffered Saline (TBS) pH 7.4 before incubating overnight with 
the specific antibody, diluted as it follows: rabbit polyclonal α-UbcH10 
(BostonBiochem Inc, Cambridge, MA) 1:1000; α-MIB-1 (Novocastra, Newcastle 
upon Tyne, UK) 1:50; α-CBX7 1:500 [raised against the C-terminus of the human 
CBX7 protein (Neosystem, Strasbourg, France)].  
After incubation with the primary antibody, tissue sections were stained with 
biotinylated anti-rabbit or anti-mouse immunoglobulins, followed by peroxidase 
labelled streptavidine (Dako, Carpinteria, CA, USA); the signal was developed by 
using diaminobenzidine (DAB) chromogen as substrate. Incubations both 
omitting the specific antibody, and including unrelated antibodies, were used as 
negative controls. 
 Individual cells were scored for expression of UbcH10 and Ki-67 in similar 
areas of adjacent sections, and CBX7 by quantitative analysis performed with a 
computerised analyser system (Ibas 2000, Kontron, Zeiss), as already described. 
(Troncone et al. 2003). In each case the distribution of these proteins was 
evaluated in at least 500 epithelial follicular cells and expressed as a percentage of 
the total cell population.  
 The statistical analysis was performed using SPSS “Ver. 9.0.1 for Windows”. 
Data in the text and tables are expressed as median value and range. The 
nonparametric Mann Whitney U-test was used to compare differences in labelling 
indexes for UbcH10 and Ki-67 in thyroid carcinomas. The Spearman rank order 
correlation was used to verify the association between UbcH10 and Ki-67. A P-
value less that 0.05 was considered statistically significant. 
 
3.8 Thyroid Fine-Needle Aspiration Biopsies (FNAB)  
 The FNAB were carried out at the Dipartimento di Anatomia Patologica e 
Citopatologia (University of Naples Federico II) as described elsewhere (Zeppa et 
al. 1990; Troncone et al. 2000). Samples were obtained from 15 patients with 
thyroid neoplasias who subsequently underwent surgery because the FNAB 
cytology indicated a diagnosis of cancer. Normal thyroid cells, used as controls, 
were obtained from FNAB of thyroids carrying non-neoplastic nodules. FNAB 
samples were washed twice with 1x PBS and then processed for RNA extraction 
using the procedure detailed in a previous section. 
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3.9 Loss-of-heterozygosity (LOH) analysis  
 We used several SNP markers to evaluate LOH at the CBX7 locus on 
chromosome 22q13.1. We selected the SNP markers 
(http://www.ncbi.nih.gov/SNP/) that showed high average heterozygosity levels 
in order to obtain the highest number of informative cases. Briefly, genomic DNA 
was PCR-amplified in a region spanning about 200 bp around the SNP analyzed, 
then the purified PCR product was sequenced. We measured the height of the two 
peaks on the chromatogram and calculated the ratio of the two alleles in the 
matched tumor/normal samples: LOH was defined if the ratio in the carcinoma 
sample was less than 50%. SNPs and relative primers used to amplify them are 
reported in Table 1.  
 
3.10 Methylation analysis using bisulphite genomic sequencing  
 The promoter region and the entire coding sequence of the human CBX7 gene 
were analyzed for CG content; CpG islands were determined based on a 200-bp 
length of DNA with a CG content of >50% and a CpG/GpC ratio of >0.5, using 
the CpGplot program, available at http://www.ebi.ac.uk/emboss/cpgplot/. 
Bisulphite genomic sequencing was used to analyze the methylation patterns of 
individual DNA molecules. Sodium bisulphite conversion of genomic DNA 
(about 200 ng for each conversion) was obtained using the EZ DNA Methylation 
Kit® (Zymo Research, Orange, CA) following the manufacturer's instructions. 
The CpG islands identified were then PCR-amplified using the primers reported 
in Table 1. PCR reactions were carried out using FastStart Taq DNA polymerase 
(Roche, Basel, Switzerland) under the following conditions: (1) Pre-nested PCRs 
were normally carried out on 10 ng of bisulphite-treated DNA in a final reaction 
volume of 50 μl, using standard conditions with 5 min at 95°C, 2 min at 70°C, 
followed by 5 cycles of 1 min at 95°C, 2 min at 57-60°C, and 1.5 min at 72°C, 
then 25 cycles of 30 sec at 95°C, 1.5 min at 50-55°C, and 1.5 min at 72°C, then a 
final elongation of 5 min at 72°C before holding at 4°C; (2) Nested PCRs were 
carried out under the same conditions using 5 μl of the corresponding pre-nested 
PCRs in a final reaction volume of 50 μl. The PCR final products were cloned 
into the pGEM®-T Easy Vector System II (Promega, Madison, WI) following the 
supplier’s procedures. The positive screened colonies contained the sequence of 
one individual DNA molecule. The plasmid DNA from the selected positive 
colonies containing vectors with the insert was purified using the Qiagen plasmid 
Mini Kit. The purified plasmids were sequenced in both directions using T7 and 
Sp6 primers. Twenty independent clones for each genomic preparation and 
fragment of interest were sequenced to determine the methylation pattern of 
individual molecules. Sequencing was carried out at the CEINGE Sequencing 
Core Facility (Naples, Italy). 
 
3.11 Plasmid constructs and cell colony-forming assay 
 CBX7 expression plasmid was constructed by cloning the human cDNA 
sequence in a pCRTMII TA Cloning® vector (Invitrogen). The primers used were: 
CBX7 forward 5’-ATGGAGCTGTCAGCCATC-3’ and CBX7 reverse 5’-
TCAGAACTTCCCACTGCG-3’. The inserted cDNA was then subcloned into 
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the BamHI/XhoI sites of the mammalian expression vector pcDNA 3.1 
(Invitrogen). The expression of CBX7 was assessed by Western blotting. Cells, 
plated at a density of 90% in 100-mm dishes, were transfected with 5 ug 
pcDNA3.1 or pCBX7 and supplemented with geneticin (G418) 24 h later. Two 
weeks after the onset of drug selection, the cells were fixed and stained with 
crystal violet (0.1% crystal violet in 20% methanol). 
 
3.12 Preparation of recombinant adenovirus and infection protocol 
 The recombinant adenovirus was constructed using AdEasyTM Vector System 
(Quantum Biotechnologies, Montreal, Quebec). The cDNA fragment was inserted 
in the sense orientation into the NotI and HindIII sites of the pShuttle-CMV 
vector to generate the recombinant pShuttle-CBX7-CMV construct. It was 
linearized and co-transformed through electroporation with pAdEasy-1, which 
carries the adenovirus genome, in BJ5183 electrocompetent cells. After 
homologous recombination, a recombinant AdEasy-CMV-CBX7 plasmid was 
generated (Ad-CBX7), which was then extracted and linearized. QBI-293A cells 
were transfected with different clones to produce different viral particles, and the 
infectivity of each clone was tested. Viral stocks were expanded in QBI-293A 
cells, which were harvested 36-40 h after infection and lysed. The virus titer of 
the 293 cells was determined. The adenovirus AdCMV-GFP (Quantum 
Biotechnologies) was used as control. Cells (5 x 104) were seeded in a six-well 
plate. After 24 h, cells were infected at MOI 100 with Ad-CBX7 or Ad-GFP for 
90 min using 500 μl of infection medium (DMEM supplemented with 2% FBS) at 
37°C in a 5% CO2 incubator. Pilot experiments with Ad-GFP were carried out to 
determine the optimal MOI for each cell line. At MOI 100, the cell lines became 
GFP-positive without manifesting toxicity. Infected cells were harvested and 
counted daily in a hematocytometric chamber. 
 
3.13 RNA Interference 
 The detailed procedure for UbcH10 RNA interference expriments has been 
described in detail in the original article (Pallante et al. 2005).  
 
3.14 Assay of the transformed state 
 Tumorigenicity of the cell lines was tested by injecting 2x106 cells 
subcutaneously into athymic mice. Soft agar colony assay was performed as 
previously described (Macpherson et al. 1964). 
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Table 1 List of primers 
Expression Fwd 5'-->3' Rev 5'-->3'
Hs-KIF2C (U63743) CAGAACAAGGCTCACACC AGCAGGCTTCCATCTCTT
Hs-CXCL1 (X54489) CACCTGGATTGTGCCTAA TGCAGGCTCCTCAGAAAT
Hs-PHLDA2 (AF035444) GGCACGACATGAAATCC GTGGTGACGATGGTGAAGT
Hs-CDC20 (U05340) CCGTTACATTCCTTCCCT AGTTGCCCTCTTTGATCC
Hs-PIB5PA (U45975) TGGAGGTGGCAGATGAGT GGATGCTGTGGTTGTGAC
Hs-TFF3 (L08044) ATGTCACCCCCAAGGA TGGCAGCAATCACAGC
Hs-BTG2 (U72649) ACCTCAACCTGGGGAACT CCAAACGTCTCCCACTTC
Hs-RARRES3 (AF060228) GCTATCGGGTCAACAACA CCTAATCGCAAAAGAGCA
Hs-CBX7 CATGGAGCTGTCAGCCATC CTGTACTTTGGGGGCCATC
Hs-β-actin TCGTGCGTGACATTAAGGAG GTCAGGCAGCTCGTAGCTCT
Rn-CBX7 GTCATGGCCTACGAGGAGAA CTTGGGTTTCGGACCTCTCT
Rn-GAPDH TGATTCTACCCACGGCAAGTT TGATGGGTTTCCCATTGATGA
Hs-UbcH10 GCCCGTAAAGGAGCTGAG GGGAAGGCAGAAATCCCT
Hs-CBX7 qRT-PCR CGTCATGGCCTACGAGGA TGGGTTTCGGACCTCTCTT
Hs-G6PD qRT-PCR ACAGAGTGAGCCCTTCTTCAA GGAGGCTGCATCATCGTACT
Mm-CBX7 qRT-PCR AATGGCATGGCTAAGGATGG ACATAGGTTCGTATGGTAGCA
Mm-β-actin qRT-PCR TCAGAAGGACTCCTATGTGG CGCAGCTCATTGTAGAAGGT
LOH Fwd 5'-->3' Rev 5'-->3'
rs710190 - LOH1 TGAATCCACAGACCCACAGA GGTTCAGAGGGGACTCTTCC
rs5750753 - LOH2 GACAGCCAAGGAAAGACAGG GTGTGATGGGCAGGCTTT
rs713841 - LOH3 CCAGACGTCTCAAAGCCTGT CAGCACAAAAGACCTCACCA
rs2076476 - LOH4 ACAGGGCATCTTTGTGAAGC GTGAAAATGGTGGGCACTG
rs2281258 - LOH5 AGAACCATTCACAAGTGGGG TCTGGAAAGCACAGCAAATG
rs2235686 - LOH6 TGGCCTCAGCATGTTAAGAA GTTCCTTCCCCCACTTTGAT
rs714016 - LOH7 TGGCTGCACTGTAAGGACAC CTTCTGGGGGTCAGGAATTT
rs139390 - LOH8 CACCTGCCCTGTAGGCTTAG GCAGGATATTGGAAGCCAGA
rs139393 - LOH9 CCTTCACCCTGTCCTGGTAA TTCATCCTCTCTTGCCTGGT
Methylation analysis  5'-->3'
1F: -440 -407 TTC/GGGTTTTTGGTAGTTATTGGGAGGTTATGAGG
1Fn: -114 -84 AGGAAAAC/GGTTGC/GGTAGGTTTAAAAATGGAA
1R: +211+178 AAAACG/AAAAAAAACCCCACTAAAATCCTAAAAAC 
1Rn: +186 +155 CCTAAAAACCG/ACCCCCG/AAACAACCTCACCTTC
2F:+155 +186 GAAGGTGAGGTTGTTC/GGGGGGC/GGGTTTTTAGG
2R:+593 +560 CCG/AAAAAAAACTTTTCCAAAACTCCACTTACAAC
2Rn:+535 +503 CCAAAATCCCG/AAATTCAAAACCCAACTCTAACC
3Fn:+7005 +7031 GGTGTGGGAAGGGTGTTTTGGGATTTG
3R: +7259 +7230 CACCAACATCTTAATTATTTAAACCCAACC
3Rn: +7196 +7170 CCCTCCG/ACAATACAAAAACCCAAAAAC  
 
Hs: Homo sapiens;  
Rn: Rattus norvegicus;  
Mm: Mus musculus.
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4. RESULTS AND DISCUSSION 
 
 
4.1 Gene expression profile analysis of six thyroid carcinoma cell lines 
compared to normal human thyroid primary cells 
 To search for candidate genes involved in the neoplastic transformation of the 
thyroid gland, we hybridized the RNAs extracted from normal human thyroid 
primary cells and six human thyroid carcinoma cell lines of different origin 
(WRO cell line from a follicular carcinoma, TPC-1 and FB-2 cell lines, both 
deriving from papillary thyroid carcinoma, NPA cell line, which derives from a 
poorly differentiated papillary carcinoma, ARO and FRO cell lines originating 
from anaplastic carcinomas) to an U95Av2 Affymetrix oligonucleotide arrays 
containing 12.625 sequences. 
 Among the transcripts represented on the array, 510 have a fold change higher 
than 10 and 320 lower than -10 in most of the cell lines versus normal thyroid 
cells (data not shown). To validate the results obtained by the microarray analysis 
we evaluated the expression of 50 transcripts by semiquantitative RT-PCR in a 
large number of thyroid carcinoma cell lines. The results essentially overlapped 
those achieved by microarray analysis, thus validating them. Some representative 
RT-PCR analyses are shown in Figure 7: in the panel A it’s reported the 
expression of some genes, such as KIF2C, CXCL1, PHLDA2 and CDC20, that are 
up-regulated in thyroid carcinoma cell lines, while in panel B we show the 
expression of other genes down-regulated in the neoplastic cell lines, such as 
PIB5PA, TFF3, BTG2 and RARRES3. 
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Figure 7 Validation of microarray data by semiquantitative RT-PCR. (A) 
Semiquantitative RT-PCR of some up-regulated genes in a panel of 11 thyroid carcinoma cell 
lines versus the normal thyroid cell line and (B) some down-regulated genes resulting by the 
microarray analysis. In both cases human β-Actin gene expression was evaluated as control to 
normalize the amount of the used RNAs. 
 
 We have assumed that the up- or down-regulation of some genes in all of the 
thyroid carcinoma cell lines would indicate the presence of a general event linked 
to thyroid cell transformation, independently from the genetic mechanisms 
underlying this process. Therefore we focused on the genes up- or down-regulated 
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in all of the carcinoma cell lines with a higher fold change. Some of them were 
further analysed by other techinques. 
 
4.2 Expression of UbcH10 gene in normal human thyroid cells and thyroid 
carcinoma cell lines 
 Among the genes that were up-regulated more than 10 fold in thyroid 
carcinoma cell lines compared to the normal thyroid cells, we concentrated our 
attention on the UbcH10 gene that resulted up-regulated about 150 fold in all of 
the cell lines tested by the cDNA microarray. We confirmed this result by 
semiquantitative RT-PCR in a larger panel of thyroid carcinoma cell lines using 
as control normal thyroid primary culture (Figure 8A). Western blot analysis of 
UbcH10 expression, shown in Figure 8B, confirmed the RT-PCR data. In fact, the 
UbcH10 protein was abundantly expressed in all of the carcinoma cell lines, 
whereas it was barely detectable in normal thyroid cells. 
 
 
Figure 8 UbcH10 expression in human thyroid carcinoma cell lines. (A) UbcH10 gene 
expression analysis by RT–PCR in human thyroid carcinoma cell lines vs the normal human 
thyroid primary culture cells (NTPC). β-Actin gene expression was evaluated as control to 
normalise the amount of the used RNAs. (B) UbcH10 protein expression analysis by Western blot 
in human thyroid carcinoma cell lines. Blot against γ-Tubulin has been performed as control for 
equal protein loading. 
 
 
 30
4.3 Analysis of UbcH10 expression in normal and neoplastic thyroid tissues 
by immunohistochemistry, Western blot and RT-PCR 
 
 To evaluate whether the overexpression of UbcH10 is not only a feature of 
cultured thyroid carcinoma cell lines, but also of thyroid tumors, we performed an 
immunohistochemical analysis using a commercial antibody against UbcH10 
protein. This methodology allows a rapid and sensitive screening of thyroid 
pathological tissues and is amenable to regular use as a routine diagnostic test. To 
find the best experimental conditions, ARO cell line and tumors, induced by 
injecting the ARO cell line into athymic mice, were used as positive controls 
(Cerutti et al, 1996). No staining was observed with normal human thyroid 
primary cell culture, whereas a positive staining was obtained with ARO cell line 
and ARO induced tumors (data not shown). By analysing paraffin-embedded 
tissue sections we found that normal thyroid, nodular goiter and Hashimoto’s 
thyroiditis (HT) were almost always completely negative for UbcH10 expression. 
Only occasionally, single UbcH10 labelled thyroid epithelial cells showing 
mitotic figures could be observed by meticulous scrutiny (Figure 9A).  
 
 
Figure 9 UbcH10 staining pattern in normal, inflammatory and neoplastic thyroid 
tissues. Follicular epithelial cells of normal thyroid (A) and oxyphilic cells of Hashimoto’s 
thyroiditis (HT) (B) do not stain for UbcH10, with occasional mitotic figures (A, arrow) and 
lymphoid centroblasts of HT (B, arrow) providing the appropriate internal positive control. In 
neoplastic thyroid, UbcH10 staining pattern is strongly related to tumour grade, being weak in 
follicular adenoma (C), slightly more evident in well-differentiated papillary (D) and follicular (E) 
carcinomas, whereas stronger in poorly differentiated (F) and in anaplastic (G) carcinomas. In the 
latter, most of neoplastic cells show a very intense labelling, with intense nuclear staining (H), 
whereas signal disappeared by antigen incubation (I). 
 31
In HT sections there was a sharp contrast between the epithelial oxyphilic cells 
(negative) and the lymphoid germinal centers (positive) (Figure 9B). While a 
weak staining is detectable in follicular adenomas (Figure 9C), higher levels of 
UbcH10 were recorded in PTC (median value 2.2% of positive cells, range 0.9-
4.1%), FTC (median value 2.8% of positive cells, range 1-6.1%) and PDC 
(median value 10.4% of positive cells, range 8-14.9%), signal being always easily 
detectable in the nuclei of scattered neoplastic cells (Figure 9D, E and F). 
UbcH10 staining pattern was different in ATC, being large the percentage 
(median value 45.8% of positive cells, range 38.8-56.2%) of stained cells and 
strong the intensity of the neoplastic cells (Figure 9, G and H). No staining was 
observed when the same ATC samples were stained with antibodies pre-incubated 
with UbcH10 recombinant protein (Figure 9I) or in the absence of the primary 
antibodies (data not shown).  
 Therefore, as a general rule, UbcH10 expression is negligible in non neoplastic 
thyroid, noticeable in well-differentiated carcinomas and conspicuous in less 
differentiated tumors (Figure 10A). 
 
 
 
Figure 10A Statistical analysis of the immunohistochemical data. Protein expression of 
UbcH10 (% positive cells) progressively increases in the several diagnostic categories from 
thyroid goiter to the thyroid anaplastic carcinomas. The analysis has been carried out using the 
Kruskal-Wallis test. HT, Hashimoto’s thyroiditis; PTC, papillary thyroid carcinoma; FTC, 
follicular thyroid carcinoma; PDC, poorly differentiated thyroid carcinoma; ATC, anaplastic 
thyroid carcinoma. 
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 We correlated also the expression of UbcH10 in carcinomas with the 
proliferation rate of thyrocytes (as measured by Ki-67 staining) to determine the 
relationship between its expression and tissue proliferation. By the use of 
Spearman rank order correlation, we determined that the association between 
UbcH10 and Ki-67 expression in thyroid cancer was statistically significant (the 
value of the Spearman R was 0.4, P<0.001) (Figure 10B). 
 
 
Figure 10B Statistical analysis of the immunohistochemical data. Protein expression of 
UbcH10 (% positive cells) is correlated to that of Ki-67 (% positive cells) in the several diagnostic 
categories. The analysis has been carried out calculating the Spearman rank correlation coefficient. 
 
 Western blot analysis, performed on 30 surgically removed thyroid tumors, 
confirmed the immunohistochemical data. A representative Western blot is shown 
in Figure 11A. A strong band of 19.6 kDa corresponding to the UbcH10 protein 
was detected in ATC and a weak one in PDC, but not in PTC and normal 
thyroids. 
These data strongly indicate that the expression of UbcH10 is more abundant 
in highly malignant and aggressive thyroid carcinomas. Equal amounts of total 
proteins were used for each sample as demonstrated by the same gel analysed 
with an antibodies against γ-Tubulin. 
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Figure 11 UbcH10 expression in human thyroid fresh tumour samples. (A) Western 
blot analysis of UbcH10 protein expression in a panel of thyroid neoplasias. The level of γ-
Tubulin has been used as loading control. NT, normal thyroid tissue; PTC1 and PTC2, papillary 
thyroid carcinomas from two different patients; PDC1, poorly differentiated carcinoma; ATC1, 
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anaplastic thyroid carcinoma. (B) RT–PCR analysis of UbcH10 expression in human thyroid 
tumour samples vs their normal thyroid counterparts. β-Actin expression shows the same amount 
of RNAs used. NT, normal thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas from two 
different patients; PDC1, poorly differentiated carcinoma; ATC1 and ATC2, anaplastic thyroid 
carcinomas from two different patients. (C) Quantitative RT–PCR analysis was performed on 
human thyroid tumour samples of different histotype. The Fold Change values indicate the relative 
change in the expression levels between tumour samples and normal samples, assuming that the 
value of each normal sample is equal to 1. 
 
 We also evaluated UbcH10 expression on a panel of matched tumor/normal 
tissues by semiquantitative RT-PCR analysis. This analysis confirmed the protein 
data. In fact, an amplified band corresponding to UbcH10 was clearly detected in 
five ATCs, but not in the corresponding normal thyroid tissues (Figure 11B). 
Finally, quantitative RT-PCR analysis confirmed a great increase of UbcH10 
expression in thyroid anaplastic samples, whereas a light increase was observed in 
papillary carcinoma samples. (Figure 11C). 
 These data, therefore, strongly indicate that UbcH10 overexpression could be 
associated with the thyroid tumor progression since there is a good correlation 
with the late stage of thyroid neoplastic transformation. These findings are 
consistent with previous published data showing that UbcH10 was expressed at 
high levels in primary tumors of diverse anatomic origin (lung, stomach, uterus, 
and bladder) as compared with their corresponding normal tissues, suggesting that 
UbcH10 is involved in tumorigenesis or cancer progression (Wagner et al. 2004, 
Okamoto et al. 2003) 
 The low UbcH10 levels detected in the differentiated thyroid malignancies 
would appear in contrast with the data showing an abundant UbcH10 expression 
in the cell lines deriving from differentiated carcinomas. Really we retain that this 
discrepancy is only apparent since thyroid carcinoma cell lines, even deriving 
from differentiated tumors, cannot be completely compared to surgically removed 
tumors. These cell lines, in fact, harbour p53 mutations that are rare in thyroid 
differentiated neoplasias (Ito et al. 1992; Fagin et al. 1993; Dobashi et al. 1993; 
Fabien et al. 1994; Fiore et al. 1997; Basolo et al. 2002) and they have a high 
proliferation rate. However, this consideration does not exclude the validity of the 
use of the thyroid carcinoma cell lines as experimental model to draw new 
information that, however, need to be subsequently validated on fresh tumors. 
 Our results also indicate a correlation between UbcH10 overexpression and the 
proliferation status since there is a good association with the proliferation marker 
Ki-67/MIB1. 
 
4.4 UbcH10 expression in experimental models of thyroid carcinogenesis 
 Subsequently we analysed for UbcH10 expression thyroid neoplasias 
developing in transgenic animals lines expressing TRK (Tg-TRK) (Russell et al. 
2000), RET/PTC3 (Tg-RET/PTC3) (Powell et al. 1998) and large T SV40 (Tg-
SV40) (Ledent et al. 1991) oncogenes under the transcriptional control of the 
thyroglobulin (Tg) promoter. Transgenic mice carrying TRK and RET/PTC3 
oncogenes develop thyroid papillary carcinomas (Russell et al. 2000, Powell et al. 
1998), thyroid anaplastic carcinomas were, conversely, obtained in the Tg-SV40 
mice (Ledent et al. 1991). We observed elevated UbcH10 protein levels in the 
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ATC derived from large T SV40 transgenic mice (Figure 12). Conversely, 
UbcH10 protein was absent in normal mouse thyroid tissue and in the PTCs 
originating from TRK and RET/PTC3 mice. 
 
 
 
Figure 12 UbcH10 expression in experimental mouse thyroid tumours. Western blot 
analysis of experimental thyroid carcinomas developed in transgenic mice expressing TRK, RET-
PTC-3 and large T SV40 oncogenes. ARO cell line was used as positive control. γ-Tubulin shows 
the same amount of protein level. 
 
This results are consistent with previous findings showing that UbcH10 is up-
regulated in NIH 3T3 cell line transformed by EWS/FLI1, but not in 
untransformed NIH 3T3 cell clone expressing EWS/FLI1 (Arvand et al. 1998).  
 Therefore, this analysis seems to confirm that the UbcH10 overexpression is 
essentially restricted to the undifferentiated histotype. 
 
4.5 Suppression of the UbcH10 synthesis inhibits thyroid carcinoma cell 
growth 
 We asked whether UbcH10 overexpression had a role in the process of thyroid 
carcinogenesis by evaluating the growth rate of two thyroid carcinoma cell lines 
after the suppression of UbcH10 synthesis by RNA interference. The NPA and 
TPC-1 cell lines were treated with siRNA duplexes targeting to the UbcH10 
mRNA. After transfection we observed an efficient knock-down of the UbcH10 
protein levels at 48 h after treatment (Figure 13A).  
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Figure 13 The block of 
UbcH10 protein 
synthesis by RNA 
interference inhibits 
the proliferation of 
thyroid carcinoma 
cells. (A) Inhibition of 
UbcH10 protein expression 
by RNAi in NPA and TPC-
1 cell lines evaluated by 
Western blot analysis. At 
48 h after siRNA 
transfection, total cell 
lysates were prepared and 
normalised for protein 
concentration. The 
expression of γ-Tubulin 
was used to control equal 
protein loading (30 μg). In 
this figure, we also show 
the expression of a fast 
turning-over gene like c-
Fos to confirm the specific 
effect of siRNAs against 
UbcH10. (B) Growth 
curves of NPA and TPC-1 
cell lines after siUbcH10 
treatment. NPA and TPC-1 
cells were transfected with 
siUbcH10 duplexes 
(siUbcH10) and the 
relative number of viable 
cells was determined by 
MTT assay. Cells 
transfected with a 
scrambled duplex 
(siScrambled) and 
untransfected cells 
(Untransfected) were used 
as negative controls. 
Absorbance was read at 
570 nm and the data are the 
mean of triplicates. 
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The block of UbcH10 protein synthesis significantly inhibits thyroid carcinoma 
cell growth. In fact, as shown in Figure 13B, a significant reduction in cell growth 
rate was observed in NPA and TPC-1 cell lines treated with UbcH10 siRNA in 
comparison to the untreated cells or those treated with the control scrambled 
siRNA. Indeed, the block of proteins synthesis significantly inhibited the growth 
of several thyroid carcinoma cell lines, suggesting an important role of UbcH10 in 
thyroid cell proliferation, and then in the progression step of thyroid 
carcinogenesis. In fact, it has been shown that UbcH10 is required for override 
metaphase, likely degrading growth suppressor, and for destruction of mitotic 
cyclins, indicating a role of UbcH10 in cell cycle progression (Arvand et al. 
1998). 
 
4.6 UbcH10 overexpression is not sufficient to transform rat thyroid cells 
 We further characterized the role of UbcH10 in thyroid carcinogenesis 
transfecting normal rat thyroid cells with the UbcH10 gene under the 
transcriptional control of the cytomegalovirus promoter. The selected clones were 
shown to express high UbcH10 protein levels (data not shown). By evaluating the 
growth rate of the UbcH10 transfected PC Cl 3 cells and the same cells 
transfected with a backbone vector we did not observe any differences. Equally, 
we evaluated the neoplastic phenotype of the UbcH10-transfected PC Cl 3 cells 
by a soft agar colony assay and by injection into athymic mice. As reported in 
Table 2, the PC Cl 3 cells transfected with the UbcH10 expression vector were 
not able to give rise to colonies in soft agar and induce tumors in athymic mice.  
 
Table 2 Analysis of the neoplastic phenotype of the UbcH10-transfected rat 
thyroid cell lines 
 
Cell line Doubling time (h) Colony-forming a Tumor incidence b
efficiency (%)
PC CL 3 24 0 0/4
PC UbcH10 CL1 24 0 0/4
PC UbcH10 CL2 23 0 0/4
PC MPSV 18 70 4/4
 
 
a Colony-forming efficiency was calculated by the formula (number of colonies 
formed/number of plated cells) x100. b Tumorigenicity was assayed by injecting 2x106 
cells into athymic mice (4 to 6 week old). 
 
As a positive control we used the PC Cl 3 cells transformed with the 
Myeloproliferative sarcoma virus (PC MPSV): these cells have a very highly 
malignant phenotype (Fusco et al. 1987). 
 These results indicate that UbcH10 overexpression is not able to transform rat 
thyroid cells in vitro and, more generally, would indicate that UbcH10 
overexpression is not sufficient for malignant thyroid cell transformation. This 
might appear in contrast with other published results showing that NIH3T3 stable 
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transfectants overexpressing UbcH10 exhibited a malignant phenotype as 
compared with parental NIH3T3 cells (Okamoto et al. 2003). In our opinion the 
discrepancy is, just apparent since we have to consider that NIH 3T3 cells are 
preneoplastic cells, whereas PC Cl 3 cells are much more resistant to express the 
neoplastic phenotype, since even the expression of several oncogenes (v-ras-Ki, 
v-ras-Ha, etc) are not able to lead these cells to the fully malignant phenotype that 
is achieved only when there is a synergy of two different oncogenes (Fusco et al. 
1987).  
 
4.7 UbcH10 involvement in ovarian carcinoma 
 We extended the study of UbcH10 gene also to other neoplasias like ovary 
carcinoma (Berlingieri et al. 2006). As in thyroid carcinoma, we found that all the 
ovary carcinoma cell lines showed a high UbcH10 expression, which was barely 
detectable in the normal tissue. The same analyses, performed on ovarian 
carcinoma tissues, showed a different expression in the different histotypes 
analysed: UbcH10 was expressed at low levels in clear cell carcinomas, 
endometrioid carcinomas and serous cystadenocarcinomas, whereas the 
undifferentiated carcinomas expressed high level of UbcH10 (Berlingieri et al. 
2006). 
 Immunohistochemistry essentially confirmed the data obtained by RT–PCR 
and Western blot analyses. Abundant expression of UbcH10 was detected in 
primary ovarian tumors compared with benign ovarian tissues and significantly 
correlated to tumor grade (P=0.0008) and undifferentiated histotype (P=0.015). 
These results are consistent with our data in thyroid and further support the 
involvement of UbcH10 in the differentiation process of several human epithelial 
tissues (Wagner et al., 2004). UbcH10 is also a negative predictor of clinical 
outcome in our series, further suggesting its ability to confer a more aggressive 
phenotype to tumor cells. Studies are ongoing to assess this hypothesis on a larger 
series of patients with a longer follow-up. 
 Functional studies also demonstrated that the suppression of the UbcH10 
expression by RNA interference reduced the growth of one ovarian carcinoma 
cell line indicating a role of UbcH10 overexpression in ovarian carcinogenesis, in 
particular, in influencing the hyperproliferative status of the most malignant cells 
(Berlingieri et al. 2006). These results, therefore, indicate a role of UbcH10 also 
in neoplastic ovarian cell proliferation, and, for this reason we propose the 
UbcH10 expression as a possible tool to be used in the diagnosis and prognosis of 
ovarian carcinomas. 
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4.8 CBX7 gene expression is down-regulated in human thyroid carcinoma 
cell lines  
 Analysing the above mentioned Affymetrix microarray, we also concentrated 
our attention upon those genes that resulted down-regulated in the thyroid 
carcinoma cell lines, considering them as potential tumor suppressor genes. 
Among the down-regulated genes, CBX7 was drastically down-regulated in all 
the cell lines tested with the cDNA microarray (Figure 14A). 
 
 
Figure 14 CBX7 expression in human thyroid carcinoma cell lines. (A) CBX7 gene 
expression by microarray analysis in human thyroid carcinoma cell lines vs normal human thyroid 
primary culture cells (NTPC). Avg. Diff, average difference: it is a quantitative relative indicator 
of a transcript expression level (∑(PM-MM)/pairs on average). (B) CBX7 gene expression 
analysis by RT-PCR in human thyroid carcinoma cell lines vs the normal human thyroid primary 
culture cells (NTPC). β-Actin gene expression served as loading control.  
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 This result was confirmed by RT-PCR analysis in a large panel of thyroid 
carcinoma cell lines with normal thyroid primary culture cells as control (Figure 
14B). 
 
4.9 The loss of CBX7 expression correlates with a more aggressive phenotype 
of thyroid carcinomas 
 To determine whether the loss of CBX7 expression is a feature of thyroid 
tumors and not only of cultured thyroid carcinoma cell lines, we carried out an 
immunohistochemical analysis of paraffin-embedded tissues using polyclonal 
antibodies raised against the carboxy-terminal region of human CBX7 protein 
(see Methods). As shown in Table 3, all 20 samples of normal thyroid 
parenchyma expressed CBX7 at a very high level, which coincides with the 
strong CBX7 staining in all follicles (Figure 15A).  
 
Table 3 CBX7 expression in normal and neoplastic thyroid tissues by IHC 
Histotype Cases
Normal Thyroid Parenchyma n=20 100% (20/20) 0% (0/20)
Follicular Adenomas n=20 100% (20/20) 0% (0/20)
Follicular Carcinomas n=32 34% (11/32) 66% (21/32)
Papillary Carcinomas - Classic Variant n=30 43% (13/30) 57% (17/30)
Papillary Carcinomas - Tall Cell Variant n=6 17% (1/6) 83% (5/6)
Poorly Differentiated Carcinomas n=12 17% (2/12) 83% (10/12)
Anaplastic Carcinomas n=12 0% (0/12) 100% (12/12)
High Low
CBX7 expression a
 
 
aHigh: cases with more than 50% of neoplastic cells showing CBX7 staining; Low: 
caseswith less than 50% of neoplastic cells showing CBX7 staining. 
 
The intensity of nuclear labeling of epithelial thyroid cells in follicular adenoma 
was similar to that of the internal control stromal and endothelial cells (Figure 
15B). Conversely, CBX7 expression was reduced in malignant lesions. As shown 
in Table 3, and in Figure 15C and D, the percent of low expressors was high in 
well-differentiated tumors, namely FTC (66%; 21/32 samples) and PTC (57%; 
17/30 samples). It was even higher in the less differentiated tumors, namely PDC 
(83%; 10/12) (Table 3, and Figure 15F and G) and “tall cell variant”(TCV)-PTC 
(83%; 5/6) (Table 3, and Figure 15E). In the latter, neoplastic cells were almost 
devoid of CBX7 expression, which sharply contrasted with the intense staining of 
the infiltrating lymphocytes and stromal cells. Similarly, CBX7 expression was 
completely lost in all cases of ATC (100%; 12/12) (Table 3, Figure 15H). No 
staining was observed when normal thyroid gland samples were stained with 
antibodies pre-incubated with CBX7 recombinant protein (Figure 15I) or in the 
absence of the primary antibodies (data not shown). Therefore, CBX7 was 
expressed in normal thyroid and in benign neoplastic lesions, decreased in well-
differentiated carcinomas and was drastically reduced in aggressive thyroid 
tumors. 
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Figure 15 CBX7 staining in normal and neoplastic thyroid tissues. CBX7 nuclear 
staining was intense in benign follicular epithelial cells of normal thyroid (A) and of follicular 
adenoma (B), whereas it was weak in follicular carcinoma (C). CBX7 progressively decreased 
going from well-differentiated “classic variant” papillary (D) carcinomas to the “tall cell variant” 
of PTC (E), to poorly differentiated (F, G) and anaplastic (H) carcinomas. The signal disappeared 
after incubation of the sample with antigen (I). Sample showed in the G panel is the same of F, but 
magnified, to better show cell nuclei. Arrows with letters indicate the following sample features: 
(P→) nuclei showing cytological features of PTC negative for CBX7 expression; (F→) FTC 
nuclei negative for CBX7 expression; (L→) lymphocyte showing CBX7 expression and providing 
positive internal control; (E→) endothelial cells showing CBX7 expression and providing positive 
internal control.  
 
 
4.10 Analysis of CBX7 expression in normal and neoplastic thyroid tissues by 
semiquantitative RT-PCR and quantitative Real-Time PCR  
 We also evaluated CBX7 expression by semiquantitative RT-PCR in a panel of 
matched normal/tumor tissues. The results confirmed the immunohistochemical 
data. In fact, there was an amplified band corresponding to CBX7 in normal 
thyroid tissues (Figure 16A).  
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Figure 16 CBX7 expression in fresh thyroid tumor samples from patients. (A) RT–
PCR analysis of CBX7 expression in human thyroid tumor samples vs their normal thyroid 
counterparts. β-Actin expression served as loading control. NT, normal thyroid tissue; PTC1 to 
PTC6, papillary thyroid carcinomas from different patients; ATC1 to ATC5, anaplastic thyroid 
carcinomas from different patients. (B) qRT-PCR analysis of human thyroid tumor samples of 
different histotypes. The fold change indicates the relative change in expression levels between 
tumor samples and normal samples, assuming that the value of each normal sample is equal to 1. 
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The amplified band decreased in PTC samples and almost disappeared in ATC. 
qRT-PCR analysis of a large number of human thyroid carcinoma samples of 
different histotypes confirmed a correlation between the reduction of CBX7 
expression and a more malignant phenotype of thyroid neoplasias. In fact, as 
reported in Figure 16B, there was a negative fold change in CBX7 expression 
from –2.1 to –13 (average –4.8) in the PTC samples versus normal counterpart 
tissue. The reduction was even more pronounced in the anaplastic carcinoma 
samples, with a fold change ranging from –10.8 to –24.5 (average –14.6). These 
data are well correlated with the immunohistochemical data and suggest that 
CBX7 expression is controlled at transcriptional level. 
 
4.11 Analysis of human thyroid fine-needle aspiration biopsy  
 Fine-needle aspiration biopsy has become an integral part of the pre-operative 
evaluation of thyroid nodules. To evaluate whether CBX7 gene expression 
analysis can be applied to FNAB samples, we studied 15 cases of PTC by 
immunocytochemistry and qRT-PCR.  
 
 
Figure 17 FNAB analysis. Immunocytochemistry (A, B) and qRT-PCR (C) analyses of CBX7 
of fine needle aspiration biopsies (FNAB), whose PTC pre-operative cytological diagnosis was 
histologically proven. FNAB goiter samples were used as controls. The fold change indicates the 
relative change in expression levels between tumor and goiter samples, assuming that the value of 
the normal sample was equal to 1. FNAB 1 to 8, from different patients. 
 
In 8 cases out of 15, CBX7 expression was lower in FNABs from patients 
affected by a carcinoma (Figure 17B) than in FNABs from thyroid goiter (Figure 
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17A) as evaluated by immunocytochemistry (Figure 17A and B) and qRT-PCR 
(Figure 17C). 
 Based on these findings, it is feasible that CBX7 levels could serve to 
differentiate between benign and malignant thyroid neoplasms. Indeed, in clinical 
practice, it is difficult to distinguish between FTC and the benign FA (Yeh et al. 
2004; Segev et al. 2003). In the perspective of diagnosis/prognosis, CBX7 
expression level in FNAB may be used to identify PTC by immunohistochemistry 
and qRT-PCR. Interestingly, a recent paper concerning the cytogenetics of 
Chernobyl thyroid tumors identified a correlation between the deletion of the 
chromosomal region 22q13.1, where the CBX7 gene is located, and a worse 
prognosis (Richter et al. 2004). 
 
4.12 LOH at CBX7 locus (22q13.1) 
 In some types of cancers, LOH of tumor suppressor genes at region 22q is 
believed to be a key step in carcinogenesis (Wild et al. 2002; Iida et al. 1998; 
Allione et al. 1998). We, therefore, used several SNP markers to evaluate LOH on 
chromosome 22q13.1 (at the CBX7 locus) in 60 cases of thyroid carcinomas of 
different histotypes. As shown in Table 4, LOH at CBX7 locus occurred in 36.8% 
of the informative PTC (7 out of 19 cases), whereas in 68.7% (11/16 cases) of 
informative ATC. The percentage of LOH was much higher in the TCV variant of 
PTC (3/4 cases; 75%) than in classical PTC (7/19 cases; 36.8%). Again, LOH of 
CBX7 was well correlated with tumor phenotype, TCV being more aggressive 
than classical PTC (Nardone et al. 2003).  
 
Table 4 Loh frequency statistics at CBX7 locus (22q13.1) by SNP sequencing 
method. 
Histotype Cases (Inf a)
Papillary Carcinoma- Classic Variant n=36 (19) 36.8% (7/19)
Papillary Carcinoma- Tall Cell Variant n=6 (4) 75% (3/4)
Follicular Carcinomas n=5 (3) 66.6% (2/3)
Anaplastic Carcinomas n=20 (16) 68.7% (11/16)
LOH b
 
 
aInf: informative cases are samples showing SNP heterozygosity corresponding to two 
peaks (two alleles) on the sequencing chromatogram.bThe LOH frequency is equal to the 
ratio between allelic loss and informative cases. 
 
 We next looked for CBX7 gene mutations in human thyroid carcinoma 
samples. We analyzed 20 PTC samples and 6 ATC samples and found no 
mutations (data not shown). 
 
4.13 Methylation status of the CBX7 gene 
 To investigate the mechanisms underlying CBX7 downregulation in thyroid 
tumors, we evaluated DNA methylation of the CBX7 gene in normal and tumor 
tissues. An analysis of CBX7, carried out with the CpG plot program (see 
Methods), revealed two CpG islands. The first extended about 1000 nucleotides 
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around the transcription initiation site and the second was located at the distal part 
of intron 2 (Figure 18).  
 
Figure 18 Methylation analysis of the CBX7 gene. The structure of CBX7 is shown in the 
upper panel. The transcriptional start site is indicated as +1. The positions of the CpG islands and 
of the primers used for bisulfate analysis are indicated. The first part of the upstream portion of 
CpG island 1 (-84 to +155) and the CpG island 2 (+7031 to +7170) were unmethylated in normal, 
tumor tissues and in the tumoral cell line TPC1. Lower panel, methylation of the first intron (21 
CpG sites): two anaplastic tumors (43T and 107 T), one papillary tumor (10T) and its 
corresponding normal tissue (10N) are shown. The degree of methylation is reported as the 
percentage of m-C obtained for each CpG dimer on a total of 20 independent clones analyzed (see 
Methods). 
 
We analysed the putative promoter region (between –83 and +154) of genomic 
DNA extracted from five PTC and corresponding adjacent normal tissues, from 5 
ATC, and from the thyroid papillary carcinoma cell line TPC-1 (Figure 18, upper 
panel). We found no methylation in any of the 42 CpGs present in this region 
(data not shown). By contrast, methylation of the last part of this CpG island 
(from+187 to +502, Figure 18, upper panel), which contains 21 CpGs, was much 
higher in ATC than in PTC and normal tissues (Figure 18, lower panel). No 
significant methylation was found in the second CpG island. 
Indeed, there was a hypermethylation status in ATC, which are practically devoid 
of CBX7 expression, moreover, in ATC we also found a high percentage of LOH: 
this suggest that gene methylation, associated in most cases with LOH, might 
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account for the block of CBX7 expression in ATC, whereas the decreased 
expression in PTC may be due to an allelic loss plus other epigenetic mechanism. 
 
4.14 CBX7 expression in rat thyroid cells transformed by viral oncogenes  
The infection of two rat thyroid differentiated cell lines, PC Cl 3 (Fusco et al. 
1987) and FRTL-5 (Ambesi-Impiombato et al. 1980), with several murine 
retroviruses induces different effects on the differentiated and transformed 
phenotype (Berlingieri et al. 1988; Berlingieri et al. 1993; Santoro et al. 1993). PC 
MPSV and PC PyMLV cells are dedifferentiated and tumorigenic, whereas PC v-
raf, PC KiMSV and PC E1A cells are dedifferentiated, but not tumorigenic when 
injected into nude mice. PC E1A cells are transformed to an irrefutable neoplastic 
phenotype after introducing a second oncogene such as the polyoma middle-T 
antigen or v-raf genes (Berlingieri et al. 1993). Conversely, FRTL-5 cells become 
tumorigenic after infection with the Kirsten murina sarcoma virus carrying the v-
ras-Ki oncogene (Fusco et al. 1985). We evaluated CBX7 expression in these cell 
lines (Figure 19). 
 
 
Figure 19 CBX7 expression in rat models of thyroid carcinogenesis.  CBX7 expression 
by RT-PCR in rat thyroid cells transformed by several oncogenes. GAPDH gene expression was 
evaluated as control to normalize the amount of the used RNAs. 
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As shown in Figure 19, the gene was abundantly expressed in normal thyroid cells 
and in all cells that did not show the malignant phenotype, whereas its expression 
was abolished in the malignantly transformed cells FRTL-5 KiMSV and PC 
MPSV, and in PC E1A cells infected with a virus carrying the v-raf oncogene. 
Interestingly, CBX7 expression was retained in FRTL-5 KiMSV-HMGA1 and in 
PC MPSV-HMGA2, cells carring rispectively the HMGA1 and HMGA2 gene in 
an antisense orientation, able to prevent the malignant transformation of FRTL-5 
and PC Cl 3 cells (Berlingieri et al. 2002; Berlingieri et al. 1995). In fact, 
although these cells undergo morphological changes and lose the thyroid 
differentiation markers, they are unable to grow in soft agar and to induce tumors 
after injection into athymic mice (Berlingieri et al. 2002; Berlingieri et al. 1995).  
 In conclusion, also the analysis of rat thyroid cells transformed in vitro 
confirms that the loss of CBX7 expression is associated with the expression of a 
highly malignant phenotype. 
 
4.15 CBX7 expression in experimental mouse models of thyroid 
carcinogenesis  
 We used qRT-PCR analysis to evaluate CBX7 expression in thyroid neoplasias 
developing in the transgenic animal lines (described in the UbcH10 section) 
expressing TRK, RET/PTC3, large T SV40 and N-ras (Tg-N-ras) (Vitagliano et 
al. 2006) oncogenes under the transcriptional control of the thyroglobulin 
promoter. In this case we also used N-ras mice developing thyroid follicular 
neoplasms that undergo de-differentiation, predominantly FTC (Vitagliano et al. 
2006). As shown in Figure 20, CBX7 expression was much lower in ATC from 
large T SV40 transgenic mice compared with mouse normal thyroid tissue. CBX7 
mRNA expression was significantly, albeit not greatly, reduced in PTC from TRK 
and RET/PTC3 mice. CBX7 expression was also reduced in the FTC from N-ras 
mice. 
 
 
 
Figure 20 CBX7 expression in mouse models of thyroid carcinogenesis. CBX7 
expression by qRT-PCR in thyroid carcinomas developing in transgenic mice expressing RET-
PTC-3, TRK, N-ras and large T SV40 oncogenes. The fold change indicates the relative change in 
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expression levels between tumor samples and normal samples, assuming that the value of each 
normal sample is equal to 1. 
 
In summary, the analysis of the experimental models of thyroid carcinogenesis 
confirms that the loss of CBX7 expression is related to the undifferentiated 
histotype. 
 Therefore, also considering the results obtained in rat and mouse models of 
thyroid carcinogenesis, our data indicate that loss of CBX7 expression is well 
related with a more aggressive phenotype of thyroid carcinomas and perhaps with 
a worst prognosis. This result is consistent with our preliminary finding of a 
correlation between low CBX7 expression and reduced survival in colon 
carcinoma (Pallante and Terracciano, manuscript in preparation). Moreover, the 
association between lack of CBX7 expression and a more aggressive histotype 
seems to apply also to breast, ovary and prostate carcinomas (Pallante and 
Troncone, manuscript in preparation). 
 
4.16 Restoration of CBX7 gene expression inhibits the growth of thyroid 
carcinoma cell lines 
 To determine whether loss of CBX7 gene expression affects thyroid 
carcinogenesis, we evaluated the growth rate of thyroid carcinoma cell lines in 
which CBX7 expression had been restored. To this aim we carried out a colony 
forming assay with cell lines obtained from human thyroid carcinomas (NPA, 
TPC-1 and FB-2) after transfection with the vector carrying the CBX7 gene or the 
empty backbone vector (Figure 21)  
 
 
Figure 21 Colony-forming assay with 
CBX7 transfection in several thyroid 
carcinoma cell lines. NPA, FB-2 and TPC-
1 cells were transfected with a vector 
expressing CBX7 cDNA and its 
corresponding empty vector pcDNA3.1. Cells 
were selected for resistance to G418 and 
clones were stained and counted after 14 
days. 
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The colonies were scored after two weeks. As shown in Figure 21, cells 
transfected with the CBX7 gene generated a lower number of colonies than did 
cells transfected with the backbone vector: for the NPA cells the inhibition was 
about 48% (representative experiment: empty vector, 296 colonies; CBX7, 154 
colonies) while for FB-2 and TPC-1 cells the inhibition was even much higher. 
 
4.17 Generation of an adenovirus carrying the CBX7 gene  
 We generated a replication-defective adenovirus carrying the CBX7 gene in 
the sense (Ad-CBX7) orientation. We then infected thyroid carcinoma cell lines 
with the Ad-CBX7 virus, and measured protein levels in cell lysates collected at 
different time points after adenovirus infection. No CBX7 protein was detected in 
carcinoma cells infected with the control virus (Ad-GFP). We then constructed 
growth curves of cells infected with Ad-CBX7 and control adenovirus (Ad-GFP). 
As shown in Figure 22, cell growth rate was significantly lower in ARO and NPA 
cell lines infected with Ad-CBX7 than in the same cells infected with the control 
virus.  
The percentage of growth inhibition five days after infection was 38.5% in 
ARO cells and 54% in NPA cells. CBX7 expression clearly reduced cell growth 
rate, which indicates that the gene plays a critical role in thyroid carcinogenesis. 
One may speculate that restoration of CBX7 function by adenovirus-mediated 
delivery could be applied in the most highly aggressive thyroid tumors. 
 
4.18 CBX7 deregulation in other cancers 
 Since CBX7 expression levels were drastically down-regulated in thyroid 
carcinomas, the loss of this protein may be related also to the malignant 
phenotype in other cancers. To evaluate wheter loss of CBX7 was a common 
event in human malignancies, we screened its expression in normal and neoplastic 
tissues (Pallante and Troncone, Manuscript in preparation). Therefore a multi-
tumour tissue microarray (TMA), constructed using 968 samples taken from 484 
tumours of 56 (10 benign and 46 malignant) different types and a normal-tissue 
microarray, constructed using 310 samples from 42 different tissues, were stained 
for CBX7. The obtained results were further confirmed in selected tumour types 
(ovary, breast and colon carcinoma). CBX7 expression was always observed in all 
the different samples of the normal tissue microarray. Benign tumours also 
maintained CBX7 expression. 89% (41/46) of the malignant tumour types 
examined showed a variable degree of CBX7 loss of expression. The tumours 
showing the higher rate of CBX7 loss of expression (>75% of negative neoplastic 
cells) were Hodgkin lymphoma, germ cell of the testis and lung carcinoma. 
 Next we evaluated more approfonditely CBX7 expression in colon carcinoma 
(CRC) (Pallante and Terracciano, Manuscript in preparation). By using 
immunohistochemistry, we found that CBX7 could really be considered a critical 
prognostic marker for the survival of the CRC patients. In fact several 
associations were found among loss of CBX7 expression and clinico-pathological 
features. In particular, there was an association between the loss of CBX7 
expression and an advanced pT. Additionally, even more is significant is the 
relationship vobserved between CBX7 expression-staining and the survival in the 
whole series and in pT3N0 groups. 
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Figure 22 Inhibitory effects of Ad-CBX7 infection on the growth of human thyroid 
carcinoma cell lines. (A) The cell lines indicated were infected with Ad-CBX7 or Ad-GFP 
(control adenovirus) at MOI 100 and counted daily. Representative curves of three independent 
experiments are reported. (B) CBX7 protein expression was assessed 48 h after infection with Ad-
CBX7 at MOI 100 by Western blot with an anti CBX7 antibody. Blot against γ-Tubulin is to 
demonstrate an equal protein loading. 
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In general the prognosis is poorer when the protein is less expressed therefore it is 
conceivable that CBX7 might have a role in determining patient survival.  
 To validate a negative role of CBX7 in cell growth proliferation, colony assay 
experiments were performed: they showed that CBX7 was able to inhibit the 
growth of two colon carcinoma cell lines (Pallante and Terracciano, Manuscript in 
preparation). 
 In summary, our study in CRC has shown that loss of CBX7 expression is 
associated with a poorer in prognosis in CRC patients and that this gene might be 
promising in establishing a personalized prognosis and therapeutic approach for 
patients, in particular in association with other CRC phenotype markers. 
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5. CONCLUSIONS 
 
 
 Thyroid tumors are the result of the accumulation of different modifications in 
critical genes involved in the control of cell proliferation. Although various 
therapeutic approaches are followed in clinical practice, most of them are not life-
saving. Hence, the discovery of ways to diagnose cancer at an early stage and to 
establish more effective therapies is a critical and urgent issue. To achieve this 
goal, identification and characterization of key molecules that participate in 
carcinogenesis are essential steps. 
 In this study we show that by the use of cDNA microarray it is possible to 
identify genes potentially involved in human cancers. In fact we identified at least 
two genes, UbcH10 and CBX7, that could be actively involved in the process of 
thyroid carcinogenesis. 
 For UbcH10, no significant expression was observed in normal thyroids, 
goiters and adenomas, whereas a great expression induction was observed in 
human anaplastic thyroid carcinomas and in mouse experimental undifferentiated 
thyroid tumors. Just a weak expression of UbcH10 was observed in human 
follicular and papillary thyroid carcinomas indicating that UbcH10 
overexpression could be associated with the thyroid tumor progression since there 
is a good correlation with the late stage of thyroid neoplastic transformation. Our 
data propose the UbcH10 overexpression as a feature of the anaplastic carcinoma 
histotype. 
 Therefore, even though the mechanisms by which UbcH10 overproduction 
contributes to the neoplastic phenotype remains unclear, we can assume that it 
leads to a deregulation of cell growth. The block of UbcH10 expression 
significantly reduced the growth of thyroid carcinoma cell lines indicating an 
involvement of UbcH10 in the increased proliferation of these carcinoma cell 
lines.  
In conclusion, these results open the perspective of a therapy of the anaplastic 
thyroid carcinoma, one of the most aggressive tumors in mankind, based on the 
suppression of the UbcH10 synthesis and/or function. 
 CBX7, instead, is abundantly expressed in normal thyroid gland, but its 
expression decreased with malignancy grade and neoplasia stage. In fact, CBX7 
expression was comparable to normal thyroid tissue in benign follicular 
adenomas, slightly reduced in papillary thyroid carcinomas displaying the 
classical histotype, and drastically reduced, and in most cases absent, in follicular 
thyroid cacinomas, in the tall cell variant of papillary thyroid carcinomas, in 
poorly differentiated and in anaplastic thyroid carcinomas. Based on these 
findings, it is feasible that CBX7 levels could serve to differentiate between 
benign and malignant thyroid neoplasms. In the perspective of 
diagnosis/prognosis, CBX7 expression level in FNAB may be used to identify 
PTC by immunocytochemistry qRT-PCR.  
 Our finding of a decrease in CBX7 levels in relation to malignancy was 
supported by our model of rat thyroid cells transformed by several oncogenes and 
in transgenic mice carrying thyroglobulin promoter-driven oncogenes. Therefore, 
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our data indicate that the loss of CBX7 expression is related with a more 
aggressive phenotype of thyroid carcinomas and perhaps with a worst prognosis.  
 In an attempt to unravel the mechanism underlying the loss of CBX7 gene 
expression in malignant thyroid neoplasias, we analysed LOH at the CBX7 locus 
(22q13.1) and methylation status of its promoter: we suggest that gene 
methylation, associated in most cases with LOH, might account for the block of 
CBX7 expression at least in anaplastic carcinoma, whereas in papillary one the 
reduced CBX7 expression may be due to an allelic loss plus other epigenetic 
mechanism. 
 To determine whether CBX7 plays an important role in thyroid carcinogenesis, 
we restored its function in human thyroid cancer cell lines and examined cell 
growth rate: CBX7 expression clearly reduced cell growth rate, which indicates 
that the gene plays a critical role in thyroid carcinogenesis. One may speculate 
that restoration of CBX7 function by adenovirus-mediated delivery could be 
applied in the most highly aggressive thyroid tumors. 
 In conclusion, for CBX7 our data suggest that its low expression is associated 
with a malignant phenotype of thyroid neoplasias, and that its loss could play a 
critical role in thyroid cancer progression. 
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UbcH10 overexpression may represent a marker of anaplastic
thyroid carcinomas
P Pallante1, MT Berlingieri1, G Troncone2, M Kruhoffer3, TF Orntoft3, G Viglietto1, A Caleo2, I Migliaccio2,
M Decaussin-Petrucci4, M Santoro1, L Palombini2 and A Fusco*,1,5
1Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facolta` di Medicina e
Chirurgia di Napoli, Universita` degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy; 2Dipartimento di Anatomia Patologica e Citopatologia,
Facolta` di Medicina e Chirurgia di Napoli, Universita` di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy; 3Department of Clinical Biochemistry,
Aarhus University Hospital, Skejby DK 8200 Aarhus N, Denmark; 4Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Be´nite, France;
5NOGEC (Naples Oncogenomic Center)-CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 80131 Naples, Italy
The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell
lines and a normal human thyroid primary cell culture led us to the identification of the UbcH10 gene that was upregulated by 150-
fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin. Immunohistochemical
studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples,
whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters. Papillary and follicular
carcinomas were only weakly positive. These results were further confirmed by RT–PCR and Western blot analyses. The block of
UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines. Taken
together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a
marker of thyroid anaplastic carcinomas.
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Tumours are the result of the accumulation of different modifica-
tions in critical genes involved in the control of cell proliferation.
In a large number of carcinomas with worst prognosis, lesions are
not diagnosed until the disease is at an advanced stage. Although
various therapeutic approaches are followed in clinical practice,
most of them are not life saving. Hence, the discovery of ways to
diagnose cancer at an early stage and to establish more effective
therapies is a critical and urgent issue. To achieve this goal,
identification and characterisation of key molecules that partici-
pate in carcinogenesis are essential steps. Thyroid neoplasms
represent a good model for studying the events involved in
epithelial cell multistep carcinogenesis, because they comprise a
broad spectrum of lesions with different degrees of malignancy
from benign adenomas, which are not invasive and very well
differentiated, to the undifferentiated anaplastic thyroid carcino-
mas, which are very aggressive and always fatal; papillary and
follicular carcinomas, the most common forms of thyroid cancer,
represent intermediate forms of neoplasia being differentiated and
having a good prognosis (Hedinger et al, 1989; Wynford-Thomas,
1997).
The involvement of several oncogenes has been demonstrated in
papillary thyroid carcinomas. Activation of the RET/PTC onco-
gene, caused by rearrangements of the RET protooncogene, is
detectable in about 30% of the cases (Grieco et al, 1990; Tallini
et al, 1998). Mutations of the B-RAF gene have been demonstrated
in almost 40% of papillary carcinomas (Fukushima et al, 2003).
TRK gene rearrangements (Pierotti et al, 1995) and MET gene
overexpression are often found in papillary carcinomas (Di Renzo
et al, 1992). RAS gene mutations (Suarez et al, 1990) and PAX8-
PPAR-g rearrangements (Kroll et al, 2000) are frequently detected
in tumours of the follicular type. Impairment of the p53 tumour
suppressor gene function represents a typical feature of the
anaplastic carcinomas (Ito et al, 1992; Dobashi et al, 1993; Donghi
et al, 1993; Fagin et al, 1993; Matias-Guiu et al, 1994). Even though
critical molecular mechanisms of thyroid carcinogenesis have been
clarified, other molecular steps of neoplastic progression need to
be investigated.
Therefore, to identify the genes regulated in the process of
thyroid carcinogenesis, we analysed a microarray with RNAs
extracted from normal human thyroid primary cell culture
(NTPC), and six human thyroid carcinoma cell lines of different
histotype (one from a follicular carcinoma, three derived from
papillary carcinomas and two from anaplastic carcinomas). Our
attention was focused on the UbcH10 gene that was upregulated
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about 150-fold in all of the cell lines tested by the cDNA
microarray. The UbcH10 gene belongs to the E2 gene family and
codes for a protein of 19.6 kDa that is involved in the ubiquitin-
dependent proteolysis. In this pathway, ubiquitin-conjugating
enzyme (E2), together with ubiquitin ligase (E3), transfers
ubiquitin to specific substrate proteins (Hershko and Ciechanover,
1998; Joazeiro and Weissman, 2000).
The expression level of UbcH10 was extremely low in the normal
thyroid primary culture cells, but strong in all the cancerous cell
lines. Immunohistochemical and RT–PCR analyses on a large
panel of thyroid neoplasms of different histotypes revealed an
increased UbcH10 expression in anaplastic thyroid carcinomas,
whereas follicular and papillary carcinomas were just weakly
positive. The block of UbcH10 protein synthesis by RNA
interference inhibited the growth of two thyroid carcinoma cell
lines.
MATERIALS AND METHODS
Cell culture and transfections
The human thyroid carcinoma cell lines used in this study are:
TPC-1 (Tanaka et al, 1987), WRO (Estour et al, 1989), NPA and
ARO (Pang et al, 1989), FRO (Fagin et al, 1993), NIM 1 (Zeki et al,
1993), B-CPAP (Fabien et al, 1994), FB-1 (Fiore et al, 1997), FB-2
(Basolo et al, 2002), Kat-4 and Kat-18 (Ain et al, 1997). They were
grown in DMEM (Gibco Laboratories, Carlsbad, CA, USA)
containing 10% fetal calf serum (Gibco Laboratories), glutamine
(Gibco Laboratories) and ampicillin/streptomycin (Gibco Labora-
tories) in a 5% CO2 atmosphere. Normal human thyroid primary
culture cells have been established and grown as already described
(Curcio et al, 1994). PC Cl 3 cell line derived from Fischer rat
thyroid (Fusco et al, 1987) was cultured in modified F12 medium
supplemented with 5% calf serum (Gibco Laboratories) and six
growth factors (thyrotropic hormone, hydrocortisone, insulin,
transferrin, somatostatin and glycyl-histidyl-lysine; Sigma, St
Louis, MO, USA). Thyroid cells were transfected using Lipofecta-
mine reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The transfected cells were selected in
a medium containing geneticin (G418) (Life Technologies, Italy).
For each transfection, several G418-resistant clones and the mass
cell population were isolated and expanded for further analysis.
Human thyroid tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or
the controlateral normal thyroid lobe were obtained from surgical
specimens and immediately frozen in liquid nitrogen. Thyroid
tumours were collected at the Service d’Anatomo-Pathologie,
Centre Hospitalier Lyon Sud, Pierre Be´nite, France. The tumour
samples were stored frozen until RNA or protein extractions were
performed.
RNA isolation
Total RNA was extracted from tissues and cell cultures using the
RNAeasy mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. The integrity of the RNA was assessed
by denaturing agarose gel electrophoresis.
Reverse transcriptase – PCR analysis
In total, 5mg of total RNA from each sample, digested with DNAseI
(Invitrogen), were reverse transcribed using random hexanucleo-
tides and MuLV reverse transcriptase (Applied Biosystems, Foster
City, CA, USA). PCR was carried out on cDNA using the GeneAmp
PCR System 9600 (Applied Biosystems). RNA PCR Core Kit
(Applied Biosystems) was used to perform RT–PCR reactions.
For the UbcH10 gene, after a first denaturing step (941C for 3 min),
PCR amplification was performed for 25 cycles (941C for 30 s, 571C
for 30 s, 721C for 30 s). The sequences of forward and reverse
primers, amplifying a fragment of 115 bp in the UbcH10 cDNA,
were: forward 50-GCCCGTAAAGGAGCTGAG-30 and reverse 50-
GGGAAGGCAGAAATCCCT-30. The human b-actin gene primers,
amplifying a 109 bp cDNA fragment, were used as control;
amplification was performed for 25 cycles (941C for 30 s, 551C for
30 s, 721C for 30 s). b-Actin-forward, 50-TCGTGCGTGACATTAAG
GAG-30; b-actin-reverse, 50-GTCAGGCAGCTCGTAGCTCT-30. To
ensure that RNA samples were not contaminated with DNA,
negative controls were obtained by performing the PCR on samples
that were not reverse-transcribed, but otherwise identically
processed. The PCR products were separated on a 2% agarose gel,
stained with ethidium bromide and scanned using a Typhoon 9200
scanner. Quantitative PCR was performed in triplicate using iCycler
(Bio-Rad, Hercules, CA, USA) with SYBRs Green PCR Master Mix
(Applied Biosystems) as follows: 951C 10 min and 40 cycles (951C
15 s and 601C 1 min). Fold mRNA overexpression was calculated
according to the formula 2(RtEt)/2(RnEn) as described previously
(El-Rifai et al, 2001), where Rt is the threshold cycle number for the
reference gene in the tumour, Et for the experimental gene in the
tumor, Rn for the reference gene in the normal sample and En for
the experimental gene in the normal sample.
Protein extraction, Western blotting and antibodies
Cells were washed once in cold PBS and lysed in a lysis buffer
containing 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
10% glycerol, 1% Triton-X-100, 1 mM phenylmethylsulphonyl
fluoride, 1 mg aprotinin, 0.5 mM sodium orthovanadate, 20 mM
sodium pyrophosphate. The lysates were clarified by centrifuga-
tion at 14 000 r.p.m. 10 min. Protein concentrations were esti-
mated by a Bio-Rad assay (Bio-Rad), and boiled in Laemmli buffer
(Tris-HCl pH 6.8, 0.125 M, SDS 4%, glycerol 20%, 2-mercaptoetha-
nol 10%, bromophenol blue 0.002%) for 5 min before electrophor-
esis. Proteins were subjected to SDS–PAGE (15% polyacrylamide)
under reducing condition. After electrophoresis, proteins were
transferred to nitrocellulose membranes (Immobilon-P Millipore
Corp., Bedford, MA, USA); complete transfer was assessed using
prestained protein standards (Bio-Rad). After blocking with TBS-
BSA (25 mM Tris, pH 7.4, 200 mM NaCl, 5% bovine serum
albumin), the membrane was incubated with the primary antibody
against UbcH10 (Boston Biochem Inc., Cambridge, MA, USA) for
60 min (at room temperature). Primary antibody against c-Fos
protein (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was
used to confirm the specificity of siRNAs against UbcH10 protein.
To ascertain that equal amounts of protein were loaded, the
Western blots were incubated with antibodies against the g-tubulin
protein (Sigma). Membranes were then incubated with the
horseradish peroxidase-conjugated secondary antibody (1 : 3000)
for 60 min (at room temperature) and the reaction was detected
with a Western blotting detection system (ECL; Amersham
Biosciences, UK).
Immunohistochemistry: tissue samples
UbcH10 protein cellular distribution was assessed by immunohis-
tochemical analysis and compared to that of the standard cell
proliferation marker Ki-67/MIB1. A series of surgical specimens
from patients with thyroid diseases comprised of Hashimoto’s
thyroiditis-HT (six cases), nodular goiter (12 cases), follicular
carcinoma (13 cases), papillary carcinoma (33 cases), poorly
differentiated carcinoma (five cases) and anaplastic carcinoma (15
cases) was chosen to represent a wide range of thyroid pathology.
As control, 10 areas of normal thyroid parenchyma were selected
from the lobe controlateral to the tumour in surgical specimens of
papillary carcinoma.
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Immunostaining: technique, evaluation and statistical
analysis
Xylene dewaxed and alcohol-rehydrated paraffin sections were
placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution,
and heated for 3 min in a conventional pressure cooker (Troncone
et al, 2003). After heating, slides were thoroughly rinsed in cool
running water for 5 min. They were then washed in Tris-Buffered
Saline (TBS) pH 7.4 before incubating overnight with the specific
antibody, diluted as follows: rabbit polyclonal a-UbcH10 (Boston
Biochem) 1 : 1000; a-MIB-1 (Novocastra, Newcastle upon Tyne,
UK) 1 : 50. After incubation with the primary antibody, tissue
sections were stained with biotinylated anti-rabbit or anti-mouse
immunoglobulins, followed by peroxidase-labelled streptavidine
(Dako, Carpinteria, CA, USA); the signal was developed by using
diaminobenzidine (DAB) chromogen as substrate. Incubations
both omitting the specific antibody, and including unrelated
antibodies, were used as negative controls.
Individual cells were scored for expression of UbcH10 and Ki-67
in similar areas of adjacent sections by quantitative analysis
performed with a computerised analyser system (Ibas 2000,
Kontron, Zeiss), as already described (Troncone et al, 2003). In
each case, the distribution of these proteins was evaluated in at
least 500 epithelial follicular cells and expressed as a percentage of
the total cell population. The statistical analysis was performed
using SPSS ‘Ver. 9.0.1 for Windows’. Data are expressed as median
value and range. The nonparametric Mann–Whitney U-test was
used to compare differences in labelling indexes for UbcH10 and
Ki-67 in thyroid carcinomas. The Spearman rank order correlation
was used to verify the association between UbcH10 and Ki-67. A
P-value less than 0.05 was considered statistically significant.
RNA interference
For small interfering RNA (siRNA) experiments, the following
double-strand RNA oligo specific for UbcH10 coding region was
used: 50-AACCTGCAAGAAACCTACTCA-30 as previously de-
scribed (Wagner et al, 2004). As negative control, we used a
corresponding scrambled sequence as follows: 50-AACTAACAC
TAGCTCAAGACC-30. All of the siRNA duplexes were purchased
from Qiagen and were transfected using Oligofectamine (Invitro-
gen) according to the manufacturer’s recommendations. Small
interfering RNAs were used at a final concentration of 100 nM and
12 105 cells well1 were plated in a six-well format plates.
Proteins were extracted 48 h after siRNA treatment and the levels
of the UbcH10 protein were evaluated by Western blot.
Assay of the transformed state
Tumorigenicity of the cell lines was tested by injecting 2 106 cells
subcutaneously into athymic mice. Soft agar colony assay was
performed as previously described (Macpherson and Montagnier,
1964).
RESULTS
Expression of UbcH10 gene in normal human thyroid cells
and thyroid carcinoma cell lines
To search for candidate genes involved in the neoplastic
transformation of thyroid gland, RNAs extracted from normal
human thyroid primary cells and six human thyroid carcinoma
cell lines of different origin (WRO cell line from a follicular
carcinoma, TPC-1 and FB-2 cell lines, both deriving from papillary
thyroid cancers, NPA cell line, which derives from a poorly
differentiated papillary carcinoma, ARO and FRO cell lines
originating from anaplastic carcinomas) were hybridised to
U95Av2 Affymetrix oligonucleotide arrays (data not shown). We
concentrated our attention on the UbcH10 gene that was
upregulated about 150-fold in all of the cell lines tested by the
cDNA microarray. This result was confirmed by RT– PCR in a
larger panel of thyroid carcinoma cell lines using as control normal
thyroid primary culture (Figure 1A). Western blot analysis of
UbcH10 expression, shown in Figure 1B, confirmed the RT–PCR
data. In fact, the UbcH10 protein was abundantly expressed in all
of the carcinoma cell lines, whereas it was barely detectable in
normal thyroid cells.
Analysis of UbcH10 expression in normal and neoplastic
thyroid tissues by immunohistochemistry, Western blot
and RT– PCR
In order to evaluate whether the overexpression of UbcH10 is a
feature of the thyroid tumours and not only of cultured thyroid
carcinoma cell lines, we performed immunohistochemical analysis
using a commercial antibody against UbcH10 protein. This
methodology allows a rapid and sensitive screening of thyroid
pathological tissues and is amenable to regular use as a routine
diagnostic test. To find the best experimental conditions, ARO cell
line and tumours, induced by injecting the ARO cell line into
athymic mice, were used as positive controls (Cerutti et al, 1996).
No staining was observed with normal human thyroid primary cell
culture, whereas a positive staining was obtained with ARO cell
line and ARO-induced tumours (data not shown). We found that
normal thyroid, nodular goiter and Hashimoto’s thyroiditis (HT)
were almost always completely negative for UbcH10 expression.
Only occasionally, single UbcH10-labelled thyroid epithelial cells
showing mitotic figures could be observed by meticulous scrutiny
(Figure 2A). In HT, there was a sharp contrast between the
negative epithelial oxyphilic cells and the positive lymphoid
germinal centers (Figure 2B). While a weak staining is detectable
in follicular adenomas (Figure 2C), higher levels of UbcH10 were
recorded in papillary (median value 2.2% of positive cells; range
0.9–4.1%), follicular (median value 2.8% of positive cells; range 1–
6.1%) and poorly differentiated (median value 10.4% of positive
cells; range 8 –14.9%) carcinomas, signal being always easily
detectable in the nuclei of scattered neoplastic cells (Figure 2D, E
and F). UbcH10 staining pattern was somewhat different in
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Figure 1 UbcH10 expression in human thyroid carcinoma cell lines. (A)
UbcH10 gene expression analysis by RT–PCR in human thyroid carcinoma
cell lines vs the normal human thyroid primary culture cells (NTPC). b-
Actin gene expression was evaluated as control to normalise the amount of
the used RNAs. (B) UbcH10 protein expression analysis by Western Blot
in human thyroid carcinoma cell lines. Blot against g-tubulin has been
performed as control for equal protein loading.
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anaplastic carcinomas, the percentage (median value 45.8% of
positive cells; range 38.8–56.2%) of stained cells being large and
the intensity of the neoplastic cells being strong (Figure 2G and H).
No staining was observed when the same anaplastic carcinoma
samples were stained with antibodies preincubated with UbcH10
recombinant protein (Figure 2I) or in the absence of the primary
antibodies (data not shown). Therefore, as a general rule, UbcH10
expression is negligible in non-neoplastic thyroid, noticeable in
well-differentiated carcinomas and conspicuous in less-differen-
tiated tumours (Figure 3A).
To determine the relationship between UbcH10 expression and
tissue proliferation, we correlated its expression in carcinomas
with the proliferation rate of thyrocytes, as measured by Ki-67
staining; this latter showed the same tissue distribution of UbcH10,
which was evident when adjacent (mirror) sections were stained.
By using the Spearman rank order correlation, we determined that
the association between UbcH10 and Ki-67 expression in thyroid
cancer was statistically significant. In fact, the value of the
Spearman R was 0.4 (Po0.001) (Figure 3B).
Western blot analysis, performed on 30 surgically removed
thyroid tumours, confirmed the immunohistochemical data. A
representative Western blot is shown in Figure 4A. A strong band
of 19.6 kDa corresponding to the UbcH10 protein was detected in
anaplastic thyroid carcinomas and a weak one in poorly
differentiated carcinomas, but not in papillary carcinomas and
normal thyroids. These data strongly indicate that the expression
of UbcH10 is more abundant in thyroid carcinomas characterised
by a highly malignant and aggressive phenotype. Equal amounts of
total proteins were used for each sample as demonstrated by the
same gel analysed with an antibody against g-tubulin.
UbcH10 expression was also evaluated by RT–PCR analysis on a
panel of matched tumour/normal tissues. This analysis confirmed
the protein data. In fact, as shown in Figure 4B, an amplified band
of 115 bp was clearly detected in the anaplastic and poorly
differentiated carcinoma samples, but not in the papillary ones and
in all the corresponding normal thyroid tissues. Finally, quanti-
tative RT– PCR analysis confirmed a great increase of UbcH10
expression in thyroid anaplastic samples, whereas a light increase
was observed in papillary carcinoma samples (Figure 4C).
UbcH10 expression in experimental models of thyroid
carcinogenesis
Thyroid neoplasias developing in transgenic animal lines expres-
sing TRK (Tg-TRK) (Russell et al, 2000), RET/PTC3 (Tg-RET/
PTC3) (Powell et al, 1998) and large T SV40 (Tg-SV40) (Ledent
et al, 1991) oncogenes under the transcriptional control of the
thyroglobulin promoter have been analysed for UbcH10 expres-
sion by Western blot analysis. Transgenic mice carrying TRK and
RET/PTC3 oncogenes develop thyroid papillary carcinomas
(Powell et al, 1998; Russell et al, 2000); thyroid anaplastic
carcinomas were, conversely, obtained in the Tg-SV40 mice
A B C
F
IH
ED
G
Figure 2 UbcH10 staining pattern in normal, inflammatory and neoplastic thyroid tissues. Follicular epithelial cells of normal thyroid (A) and oxyphilic cells
of Hashimoto’s thyroiditis (HT) (B) do not stain for UbcH10, with occasional mitotic figures (A, arrow) and lymphoid centroblasts of HT (B, arrow)
providing the appropriate internal positive control. In neoplastic thyroid, UbcH10 staining pattern is strongly related to tumour grade, being weak in follicular
adenoma (C), slightly more evident in well-differentiated papillary (D) and follicular (E) carcinomas, whereas stronger in poorly differentiated (F) and in
anaplastic (G) carcinomas. In the latter, most of neoplastic cells show a very intense labelling, with intense nuclear staining (H), whereas signal disappeared by
antigen incubation (I).
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(Ledent et al, 1991). As shown in Figure 5, elevated UbcH10
protein levels were observed in the thyroid anaplastic carcinomas
derived from large TSV40 transgenic mice. Conversely, UbcH10
protein was absent in normal mouse thyroid tissue and in the
papillary carcinomas originating from TRK and RET/PTC3 mice.
Therefore, the analysis of the experimental models of thyroid
carcinogenesis seems to confirm that the UbcH10 overexpression
is essentially restricted to the undifferentiated histotype.
Suppression of the UbcH10 synthesis inhibits thyroid
carcinoma cell growth
We asked whether UbcH10 overexpression had a role in the
process of thyroid carcinogenesis by evaluating the growth rate of
two thyroid carcinoma cell lines, in which UbcH10 protein was
suppressed by RNA interference. The NPA and TPC-1 cell lines
were treated with siRNA duplexes targeting to the UbcH10 mRNA.
After transfection, we observed an efficient knockdown of the
UbcH10 protein levels at 48 h after treatment (Figure 6A). The
analysis of cell growth of these cell lines in the presence or absence
of the UbcH10 siRNA duplexes revealed that the block of the
UbcH10 protein synthesis significantly inhibits thyroid carcinoma
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Figure 3 Statistical analysis of the immunohistochemical data. (A)
Protein expression of UbcH10 (% positive cells) progressively increases in
the several diagnostic categories from thyroid goiter to the thyroid
anaplastic carcinomas. The analysis has been carried out using the Kruskal–
Wallis test. HT, Hashimoto’s thyroiditis; PTC, papillary thyroid carcinoma;
FTC, follicular thyroid carcinoma; PDC, poorly differentiated thyroid
carcinoma; ATC, anaplastic thyroid carcinoma. (B) Protein expression of
UbcH10 (% positive cells) is correlated to that of Ki-67 (% positive cells) in
the several diagnostic categories. The analysis has been carried out
calculating the Spearman rank correlation coefficient.
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Figure 4 UbcH10 expression in human thyroid fresh tumour samples.
(A) Western blot analysis of UbcH10 protein expression in a panel of
thyroid neoplasias. The level of g-tubulin has been used as loading control.
NT, normal thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas
from two different patients; PDC1, poorly differentiated carcinoma; ATC1,
anaplastic thyroid carcinoma. (B) RT–PCR analysis of UbcH10 expression
in human thyroid tumour samples vs their normal thyroid counterparts. b-
Actin expression shows the same amount of RNAs used. NT, normal
thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas from two
different patients; PDC1, poorly differentiated carcinoma; ATC1 and ATC2,
anaplastic thyroid carcinomas from two different patients. (C) Quantitative
RT–PCR analysis was performed on human thyroid tumour samples of
different histotype. The Fold Change values indicate the relative change in
the expression levels between tumour samples and normal samples,
assuming that the value of each normal sample is equal to 1.
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Figure 5 UbcH10 expression in experimental mouse thyroid tumours.
Western blot analysis of experimental thyroid carcinomas developed in
transgenic mice expressing TRK, RET-PTC-3 and large T SV40 oncogenes.
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amount of protein level.
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cell growth. In fact, as shown in Figure 6B, a significant reduction
in cell growth rate was observed in NPA and TPC-1 cell lines
treated with UbcH10 siRNA in comparison to the untreated cells or
those treated with the control scrambled siRNA.
These results indicate a role of UbcH10 in neoplastic thyroid cell
proliferation.
UbcH10 overexpression is not sufficient to transform rat
thyroid cells
To further characterise the role of UbcH10 in thyroid carcinogen-
esis, we transfected normal rat thyroid cells with an expression
vector carrying the UbcH10 gene under the transcriptional control
of the cytomegalovirus promoter. The selected clones were shown
to express high UbcH10 protein levels (data not shown). We
evaluated the growth rate of the UbcH10-transfected PC Cl 3 cells
and the same cells transfected with a backbone vector: no
differences were observed. Equally, the neoplastic phenotype of
the UbcH10-transfected PC Cl 3 cells was evaluated by a soft agar
colony assay and by injection into athymic mice. As reported in
Table 1, the PC Cl 3 cells transfected with the UbcH10 expression
vector were not able to give rise to colonies in soft agar and induce
tumours in athymic mice. As a positive control, we used the PC Cl
3 cells transformed with the Myeloproliferative sarcoma virus (PC
MPSV): these cells have a very highly malignant phenotype (Fusco
et al, 1987).
These results indicate that UbcH10 overexpression is not able to
transform rat thyroid cells in vitro.
DISCUSSION
Thyroid neoplasms represent an excellent model for studying the
process of cell transformation since they include a broad spectrum
of histotypes showing different degree of malignancy (Hedinger
et al, 1989; Wynford-Thomas, 1997). From the Affymetrix
microarray analysis, we found the UbcH10 gene that appeared
greatly increased in all of the thyroid carcinoma cell lines. UbcH10
was previously identified as a human homologue of the cyclin-
selective E2 (E2-c), which is required for the destruction of mitotic
cyclins by the ubiquitination pathway. The UbcH10 gene belongs
to the E2 gene family and codes for a protein of 19.6 kDa that is
involved in the ubiquitin-dependent proteolysis. In this system,
three distinct enzymes cooperate to process target proteins for
degradation. More precisely, the ubiquitin-conjugating enzyme
(E2) transfers activated ubiquitin by ubiquitin-activating enzyme
(E1) to a lysine residue of the target proteins in cooperation with
the ubiquitin-ligase (E3). Polyubiquitinated proteins are then
recognised by the 26S proteasome and rapidly degraded (Hershko
and Ciechanover, 1998; Joazeiro and Weissman, 2000).
In our study, we have evaluated the expression of UbcH10 in
human thyroid neoplasias and in mouse experimental tumours. No
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Figure 6 The block of UbcH10 protein synthesis by RNA interference
inhibits the proliferation of thyroid carcinoma cells. (A) Inhibition of
UbcH10 protein expression by RNAi in NPA and TPC-1 cell lines
evaluated by Western blot analysis. At 48 h after siRNA transfection, total
cell lysates were prepared and normalised for protein concentration. The
expression of g-tubulin was used to control equal protein loading (30 mg).
In this figure, we also show the expression of a fast turning-over gene like c-
Fos to confirm the specific effect of siRNAs against UbcH10. (B) Growth
curves of NPA and TPC-1 cell lines after siUbcH10 treatment. NPA and
TPC-1 cells were transfected with siUbcH10 duplexes (siUbcH10) and the
relative number of viable cells was determined by MTT assay. Cells
transfected with a scrambled duplex (siScrambled) and untransfected cells
(Untransfected) were used as negative controls. Absorbance was read at
570 nm and the data are the mean of triplicates.
Table 1 Analysis of the neoplastic phenotype of the UbcH10-
transfected rat thyroid cell lines
Cell line
Doubling time
(h)
Colony-
forminga
efficiency (%)
Tumourb
incidence
PC CL 3 24 0 0/4
PC UbcH10 CL1 24 0 0/4
PC UbcH10 CL2 23 0 0/4
PC MPSV 18 70 4/4
aColony-forming efficiency was calculated by the formula (number of colonies
formed/number of plated cells) 100. bTumorigenicity was assayed by injecting
2 106 cells into athymic mice (4–6 weeks old).
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significant UbcH10 expression was observed in normal thyroids,
goiters and adenomas, whereas a great induction of UbcH10
expression was observed in anaplastic human thyroid carcinomas
and in experimental undifferentiated thyroid tumours. Just a weak
expression of UbcH10 was observed in follicular and papillary
human thyroid carcinomas. Therefore, these data strongly indicate
that UbcH10 overexpression could be associated with the thyroid
tumour progression since there is a good correlation with the late
stage of thyroid neoplastic transformation. The low UbcH10 levels
detected in the differentiated thyroid malignancies would appear
in contrast with the data showing an abundant UbcH10 expression
in the cell lines deriving from differentiated carcinomas. We retain
this discrepancy only apparent since thyroid carcinoma cell lines,
even deriving from differentiated tumours, cannot be completely
compared to surgically removed tumours. In fact, these cell lines
harbour p53 mutations that are rare in thyroid differentiated
neoplasias (Tanaka et al, 1987; Estour et al, 1989; Pang et al, 1989;
Ito et al, 1992; Dobashi et al, 1993; Donghi et al, 1993; Fagin et al,
1993; Zeki et al, 1993; Fabien et al, 1994; Matias-Guiu et al, 1994;
Ain et al, 1997; Fiore et al, 1997; Basolo et al, 2002) and they have a
high proliferation rate. However, this consideration does not
exclude the validity of the use of the thyroid carcinoma cell lines as
experimental model to draw new information that, however, need
to be subsequently validated on fresh tumours.
Our results also indicate a correlation between UbcH10 over-
expression and the proliferation status since there is a good
association with the proliferation marker Ki-67/MIB1.
An aim of our work was to evaluate the possible causal role of
UbcH10 overexpression in thyroid carcinogenesis. Indeed, the
block of protein synthesis significantly inhibited the growth of
several thyroid carcinoma cell lines, suggesting an important role
of UbcH10 in thyroid cell proliferation, and then in the
progression step of thyroid carcinogenesis.
Therefore, even though the mechanisms by which UbcH10
overproduction contributes to the neoplastic phenotype remains
unclear, we can assume that it leads to a deregulation of cell
growth. These results are quite consistent with previous published
data showing that UbcH10 was expressed at high levels in primary
tumours derived from the lung, stomach, uterus, and bladder as
compared with their corresponding normal tissues, suggesting that
UbcH10 is involved in tumorigenesis or cancer progression
(Okamoto et al, 2003; Wagner et al, 2004). It has also been shown
that UbcH10 is upregulated in NIH3T3 cell line transformed by
EWS/FLI1, but not in untransformed NIH3T3 cell clone expressing
EWS/FLI1 (Arvand et al, 1998). Moreover, it has been shown that
UbcH10 is required for override metaphase, likely degrading
growth suppressor, and for destruction of mitotic cyclins,
indicating a role of UbcH10 in cell cycle progression (Arvand
et al, 1998).
However, overexpression of UbcH10 in normal rat thyroid cells
did not affect cell growth neither induced a malignant phenotype,
indicating that UbcH10 overexpression is not sufficient for
malignant thyroid cell transformation. This result might appear
in contrast with those showing that NIH3T3 stable transfectants
overexpressing UbcH10 exhibited a malignant phenotype as
compared with parental NIH3T3 cells (Okamoto et al, 2003). This
discrepancy is, in our opinion, just apparent since we have to
consider that NIH 3T3 cells are preneoplastic cells, whereas PC Cl 3
cells are much more resistant to express the neoplastic phenotype,
since even the expression of several oncogenes (v-ras-Ki, v-ras-Ha,
etc.) are not able to lead these cells to the fully malignant
phenotype that is achieved only when there is a synergy of two
different oncogenes (Fusco et al, 1987). In conclusion, our data
propose the UbcH10 overexpression as a feature of the anaplastic
carcinoma histotype. The block of UbcH10 expression significantly
reduced the growth of thyroid carcinoma cell lines indicating an
involvement of UbcH10 in the increased proliferation of these
carcinoma cell lines. Therefore, these results open the perspective
of a therapy of the anaplastic thyroid carcinoma, one of the most
aggressive tumours in mankind, based on the suppression of the
UbcH10 synthesis and/or function.
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UbcH10 expression may be a useful tool in the prognosis of
ovarian carcinomas
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The UbcH10 gene codes for a protein that belongs to the
ubiquitin-conjugating enzyme family. Previous studies of
our group suggest UbcH10 expression as a valid indicator
of the proliferative and aggressive status of thyroid
carcinomas. Therefore, to better understand the process
of ovarian carcinogenesis, and to look for possible tools to
be used as prognostic markers in these neoplasias, we
decided to extend the analysis of the UbcH10 expression
to the ovarian neoplastic disease. We found that the
UbcH10 gene was upregulated in some ovarian carcinoma
cell lines analysed. Then, immunohistochemical studies
demonstrate that UbcH10 expression signiﬁcantly corre-
lates with the tumor grade and the undifferentiated
histotype of the ovarian carcinomas. Furthermore, a
signiﬁcant relationship between UbcH10 expression and
overall survival was observed. Finally, the block of
UbcH10 protein synthesis by RNA interference inhibited
the growth of ovarian carcinoma cell lines, suggesting a
role of UbcH10 overexpression in ovarian carcinogenesis.
Therefore, all these data taken together suggest the
possibility to use UbcH10 detection as a marker for the
diagnosis and prognosis of these neoplastic diseases and
open the perspective of a therapy of some ovarian
carcinomas based on the suppression of the UbcH10
synthesis and/or function.
Oncogene advance online publication, 2 October 2006;
doi:10.1038/sj.onc.1210010
Keywords: UbcH10; ovarian; carcinomas; immunohis-
tochemistry
Ovarian carcinomas have a great impact in human
pathology, in fact ovarian cancer is the leading cause of
death from gynecological neoplasias and the ﬁfth most
common cancer among women worldwide (Ozols et al.,
2004; Jemal et al., 2005).
Research aimed to determine the speciﬁc genes
involved in the development of ovarian cancers would
help to understand how normal ovarian epithelial cells
escape regulation of proliferation, apoptosis and sene-
scence. It has been already (Welcsh and King, 2001)
determined that approximately 10% of ovarian cancers
arises in women who have inherited mutations in cancer-
susceptibility genes such as BRCA1, BRCA2 and other
DNA repair genes. Conversely, the vast majority of
ovarian cancers are sporadic, presumably resulting from
the accumulation of genetic damage over lifetime.
Several genes involved in ovarian carcinogenesis have
been identiﬁed, most notably the p53 tumor suppressor
(Feki and Irminger-Finger, 2004).
Recently in our laboratory, by a microarray gene
expression proﬁling, we found a gene, UbcH10, that was
upregulated in thyroid anaplastic carcinoma samples vs
the normal thyroid tissues, suggesting a correlation with
the malignant progression (Pallante et al., 2005). A high
expression of UbcH10 has also been found in carcino-
mas of different anatomic origin (Wagner et al., 2004).
The UbcH10 gene belongs to the E2 gene family
and codes for a protein of 19.6 kDa that is involved
in the ubiquitin-dependent proteolysis. In this path-
way, ubiquitin-conjugating enzyme (E2), together with
ubiquitin ligase (E3), transfers ubiquitin to speciﬁc
substrate proteins (Hershko and Ciechanover, 1998;
Joazeiro and Weissman, 2000).
The aim of our work was to investigate whether the
UbcH10 expression might be a new useful indicator for
the diagnosis and prognosis of ovarian cancer.
Therefore, we evaluated the expression of UbcH10
by reverse transcription–polymerase chain reaction
(RT–PCR) and Western blot in ovarian carcinoma cell
lines in comparison with the normal ovarian tissue. AllReceived 29 June 2006; revised 27 July 2006; accepted 7 August 2006
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Figure 1 UbcH10 expression in human ovarian carcinoma cell lines and tissues. (a) UbcH10 gene expression analysis by RT–PCR in
human ovarian carcinoma cell lines (SKOV-3, IGROV, OVCAR-3, OVCAR-4, OVCAR-5 and OVCAR-8; Masciullo et al., 2003) vs
normal tissue. b-Actin gene expression was evaluated as control to normalize the amount of the used RNAs. (b) UbcH10 protein
expression analysis by Western blot in the same human ovarian carcinoma cell lines. Blot against a-tubulin has been performed as control
for equal protein loading. (c) RT–PCR analysis of UbcH10 expression in human ovarian tumor samples (thirty ovarian carcinoma
samples were collected) vs their normal ovarian counterparts. b-Actin expression shows the same amount of RNAs used. NO, normal
ovarian tissue. (d) Western blot analysis of UbcH10 protein expression in a panel of ovarian neoplasias. The level of a-tubulin has been
used as loading control. NO, normal ovarian tissue. PCR reactions, primers and conditions to amplify UbcH10 and b-actin are as reported
elsewhere (Pallante et al., 2005). Protein extraction was performed according to standard procedure as reported by Pierantoni et al. (2005).
Figure 2 Immunostaining pattern of UbcH10 expression in ovarian cancer. In all different histotypes of ovarian carcinoma, there was a
clear relationship between loss of tumor differentiation and the gain of UbcH10 reactivity. Whereas in differentiated histotypes, as in
mucinous (original magniﬁcation, 25 ) (a), serous (original magniﬁcation, 25 ) (b), clear cell (original magniﬁcation, 25 ) (c) and
endometrioid (original magniﬁcation, 25 ) (d) carcinomas, there was variability in the levels of UbcH10 expression, all cases of
undifferentiated ovarian carcinomas (original magniﬁcation, 25 ) (e) had levels of UbcH10 expression higher than the median value. No
immunoreactivity occurred in normal ovarian tissue (original magniﬁcation, 25 ) (f). UbcH10 immunoreactivity has been evaluated in
two TMAs (constructed at the Department of Histopathology, S Chiara Hospital, Trento, Italy), as described (Aldovini et al., 2006).
TMAs included 60 carcinomas arising from the ovarian surface epithelium, each represented by three different 0.6mm cores. Pathological
data (tumor type, grade and stage), IHC proﬁle (p53, RB245 and ER status) and clinical follow-up data (relapse-free and overall survival
rates) were available for analysis. Tumors were typed according to the WHO criteria (Tavassoli and Devilee, 2003), including serous
(n¼ 38), mucinous (n¼ 1), clear cell (n¼ 4), endometrioid (n¼ 6) and undifferentiated (n¼ 7) carcinomas; four cases were excluded for
technical reason. Staging was assessed in accordance with the International Federation of Gynecology and Obstetrics (FIGO) (Benedet
et al., 2000). Grading informations were derived from the original diagnostic reports. As the tumors composing the TMAs were diagnosed
in different years, special care was taken to adopt the same grading system and to grade consistently all cases, by using the same criteria.
Consequently, the same four-tier classiﬁcation system (Vacher-Lavenu et al., 1993), employed in the 1990s and used to diagnose the
earlier cases included in the TMAs (with a longer follow-up) was consistently used also to score the cases more recently diagnosed. Thus,
tumors were graded into well differentiated (G1), moderately well differentiated without nuclear atypia (G2), moderately well
differentiated with nuclear atypia (G3) and poorly differentiated or undifferentiated (G4) (Vacher-Lavenu et al., 1993). Further details on
TMAs generation are reported elsewhere (Aldovini et al., 2006). Complete follow-up data were available for all patients from the
Departments of Gynecological Surgery and Medical Oncology of the S Chiara Hospital of Trento. Follow-up time was based on patient
date of death or the last information in the medical records. As control carried out to assess UbcH10 expression in benign ovary, ﬁve
samples of normal ovary were also processed. Special care was taken to evaluate UbcH10 expression only on adequately stained TMA
slides. Immunostaining was processed by routine methods (Troncone et al., 2003). UbcH10 expression was evaluated by two pathologists
in a double-blind fashion and any discordance was resolved after consultation at the double-headed microscope. Values relative to each
tumor sample, present in triplicate, were derived by combining the percentage of any single cores. To analyse tissue microarrays, we
employed maximum, minimum and mean as pooling methods for the replicates (Liu et al., 2004) and statistical analysis was carried out.
We dichotomized biomarker expression against its median values, so as to ease biological interpretation. Finally, to account for the
heterogeneity of protein expression across tumor tissues, cases with only one core section with valid staining were excluded by the
statistical analysis. This resulted in 56 cases for ovarian data set. Statistical analysis was performed with R statistical package
(R Development Core Team, 2004) and SPSS ver. 11.5 for Windows. (g) Correlation between ovarian tumor grade and UbcH10 expression.
The correlation of UbcH10 expression vs tumor grade is well established as low levels of UbcH10 expression were recorded in the G1
well-differentiated tumors whereas there was a signiﬁcant relationship between increasing cytological grading of malignancy and
protein expression (P¼ 0.002 Kruskall–Wallis test). Comparisons between UbcH10 expression and clinical–pathological data
(histotype, grading, T, N), as well as with other biomarkers (p53, RB245, ER) were performed with Wilcoxon’s signed rank test or w2 or
Kruskall–Wallis test on numerical expression data and with Fisher’s exact test on categorized data.
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of the carcinoma cell lines showed a high UbcH10
expression, which was barely detectable in the normal
tissue (Figure 1a and b).
The same analyses, performed on ovarian carcinoma
tissues, showed a different expression in the different
histotypes analysed. In fact, as shown in Figure 1c
and d, UbcH10 is expressed at low levels in clear
cell carcinomas, endometrioid carcinomas and serous
cystadenocarcinomas, whereas the undifferentiated
carcinomas express high level of UbcH10.
Immunohistochemistry essentially conﬁrms the data
obtained by RT–PCR and Western blot analyses.
Whereas benign ovary lacked UbcH10 expression
(Figure 2f), the different histotypes of ovarian carcino-
mas showed certain variability in the range of neoplastic
cells expressing UbcH10 (Figure 2a–e). However, there
was a clear relationship between the loss of tumor
differentiation and the gain of UbcH10 reactivity. This
was evident both when examining tumor type and tumor
grade: the average levels of UbcH10 expression were low
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in tumors belonging to the differentiated histotypes, as
in serous (16.6% mean, range: 12.3–19.8%), clear cell
(7.1% mean, range: 1.3–10.0%) and endometrioid
(9.2% mean, range: 8.3–10.8%) carcinomas. Similarly
the only case examined of the mucinous histotype
showed a low level of expression (5%). On the contrary,
higher levels (33.6% mean, range: 22.9–42.1%) of
UbcH10 expression were observed in the undifferen-
tiated histotype of ovarian cancer. All seven cases of
undifferentiated ovarian carcinomas had levels of
UbcH10 expression higher than the median value
(P¼ 0.015).
Similarly, UbcH10 expression was also related to the
tumor grade, as signiﬁcant differences were recorded
among the different grades (P¼ 0.002 Kruskall–Wallis
test). In fact, as shown in Figure 2g, low levels of
UbcH10 expression were recorded in the G1 well-
differentiated tumors (0.8%), whereas there was a
signiﬁcant relationship between increasing cytological
grading of malignancy and protein expression. In G2
and in G3 carcinomas, the cells expressing UbcH10
were, respectively, 12.3 and 22%, whereas G4 high-
grade tumors showed staining in more than a third of
neoplastic cells (34.7%). The correlation with tumor
grade is further established if we compare G1 and
G2 vs G3 and G4 grades and UbcH10 expression
(P-value¼ 0.023 Fisher’s exact test) (data not shown).
As far as the overall survival is concerned, there
is a signiﬁcant relationship with UbcH10 expression
(P-value¼ 0.044 – log-rank test), as shown in Figure 3,
only if we consider the mean as pooling method.
Regarding the other pooling methods, as well as for
relapse-free survival, no statistical signiﬁcant correlation
was found.
We asked whether UbcH10 overexpression had a role
in the process of ovarian carcinogenesis by evaluating
the growth rate of one ovarian carcinoma cell line, in
which the synthesis of UbcH10 protein was suppressed
by RNA interference. The SKOV-3 cell line was treated
with siRNA duplexes targeting to the UbcH10 mRNA.
After transfection, we observed an efﬁcient knock down
of the UbcH10 protein levels at 48 h after treatment
(Figure 4a). The cell growth analysis, in the presence or
absence of the UbcH10 siRNA duplexes, revealed that
the block of the UbcH10 protein synthesis signiﬁcantly
inhibits ovarian carcinoma cell growth. In fact, as
shown in Figure 4b, a signiﬁcant reduction in cell
growth rate was observed in SKOV-3 cell line treated
with UbcH10 siRNA in comparison with the untreated
cells or those treated with the control scrambled siRNA.
Figure 3 Kaplan–Meier survival analysis with log-rank test was
carried out both for overall and relapse-free survival. Fifty-six
patients were included in the survival analysis as clinical informa-
tion was entirely available. The picture shows the results for overall
survival analysis. The median age at surgery is 61 years (range
34–84) and the median follow-up time is 62 months (range 0–121
months). A P-value less than 0.05 was considered statistically
signiﬁcant for each analysis. Cases showing higher levels of
UbcH10 expression (>¼median) were associated with a lower
rate of overall survival.
Figure 4 The block of UbcH10 protein synthesis by RNA
interference inhibits the proliferation of ovarian carcinoma cells.
(a) Inhibition of UbcH10 protein expression by RNAi in SKOV-3
cell line evaluated by Western blot analysis. At 48 h after siRNA
transfection, total cell lysates were prepared and normalized for
protein concentration. The expression of a-tubulin was used to
control equal protein loading (30mg). (b) SKOV-3 cell line growth
curve after siUbcH10 treatment. SKOV-3 cells were transfected
with siUbcH10 duplexes (siUbcH10) and the relative number of
viable cells was determined by MTT assay. Cells transfected with a
scrambled duplex (siScrambled) and untransfected cells (Untrans-
fected) were used as negative controls. Absorbance was read at
570 nm and the data are the mean of triplicates.
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These results indicate a role of UbcH10 in neoplastic
ovarian cell proliferation, for this reason we propose the
UbcH10 expression as a possible tool to be used in the
diagnosis and prognosis of ovarian carcinomas. Abun-
dant expression of UbcH10 was detected in primary
ovarian tumors compared with benign ovarian tissues
and signiﬁcantly correlated to tumor grade (P¼ 0.0008)
and undifferentiated histotype (P¼ 0.015). These re-
sults are consistent with our previous published data
(Pallante et al., 2005) and further support the involve-
ment of UbcH10 in the differentiation process of several
human epithelial tissues (Wagner et al., 2004).
UbcH10 is also a negative predictor of clinical
outcome in our series, further suggesting its ability to
confer a more aggressive phenotype to tumor cells.
Studies are ongoing to assess this hypothesis on a larger
series of patients with a longer follow-up.
Functional studies also demonstrate that the suppres-
sion of the UbcH10 expression by RNA interference
reduced the growth of one ovarian carcinoma cell line
indicating a role of UbcH10 overexpression in ovarian
carcinogenesis, in particular, in inﬂuencing the hyper-
proliferative status of the most malignant cells.
In conclusion, all these data taken together suggest
the possibility to use this gene as a marker for the
diagnosis and prognosis of these neoplastic diseases.
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 Loss of the CBX7 gene correlates with a more malignant phenotype in thyroid 
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 ABSTRACT  
Using gene expression profiling we found that the CBX7 gene was drastically down-
regulated in six thyroid carcinoma cell lines versus control cells. This suggested that 
CBX7 is an oncosuppressor. The aim of this study was to determine whether CBX7 is 
related to thyroid cancer phenotype, and to try to identify new tools for the diagnosis and 
prognosis of thyroid cancer. We thus evaluated CBX7 expression in various snap-frozen 
and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by 
quantitative RT-PCR and immunohistochemistry, respectively. CBX7 expression 
progressively decreased with malignancy grade and neoplasia stage. Indeed, it decreased 
in an increasing percentage of cases going from benign adenomas to papillary (PTC), 
follicular and anaplastic (ATC) thyroid carcinomas. This finding coincides with results 
obtained in rat and mouse models of thyroid carcinogenesis. CBX7 loss of heterozygosity 
occurred in 36.8% of PTC and in 68.7% of ATC. Restoration of CBX7 expression in 
thyroid cancer cells reduced growth rate, which indicates that CBX7 plays a critical role 
in the regulation of transformed thyroid cell proliferation. In conclusion, loss of CBX7 
expression correlates with a highly malignant phenotype in thyroid cancer patients. 
Consequently, CBX7 monitoring could contribute to thyroid cancer diagnosis and 
prognosis. 
 INTRODUCTION 
 
Human tumorigenesis is a multistep process in which the alterations that confer a 
transformed and malignant phenotype to the normal cells of a tissue reflect several 
genetic alterations (1). Thyroid tumors originating from follicular cells are a good model 
with which to investigate the events involved in carcinogenesis because they differ in 
malignant potential from differentiated to undifferentiated phenotypes (1, 2). Papillary 
thyroid carcinoma (PTC), which is differentiated and has a good prognosis, is the most 
frequent malignancy of the thyroid gland (2). The tall cell variant (TCV) of PTC has a 
worse prognosis than conventional PTC (3). Insular carcinomas have a less differentiated 
phenotype and a poor 5-year survival rate (2). Finally, anaplastic carcinomas (ATC) are 
completely undifferentiated, very aggressive and always fatal (2). 
Point mutations, rearrangements that activate proto-oncogenes, and loss-of-function in 
tumor suppressor genes have been identified in thyroid tumors (2). In PTC, activation of 
the RET/PTC oncogene, caused by rearrangements of the RET proto-oncogene, occurs in 
about 30% of cases (2), whereas the B-RAF gene is mutated in about 40% of cases (4). 
These tumors have also been associated with TRK gene rearrangements (5) and MET 
gene overexpression (6). RAS gene mutations (7) and PAX8-PPAR-γ rearrangements (8) 
are frequent in follicular thyroid carcinomas (FTC), whereas impaired function of the p53 
tumor suppressor gene is typical of ATC (9-11). Other genes, including CBX7, have been 
implicated in thyroid neoplasias.  
Within the context of a microarray study, we found that the CBX7 gene was down-
regulated in thyroid carcinoma-derived cell lines and thyroid fresh tumors. CBX7, which 
 is located on chromosome 22q13.1, encodes a novel Polycomb protein (Pc) of 28.4 kDa 
of 251 amino acids that contains a “chromodomain” between amino acids 10 and 46. The 
chromodomain was originally defined as a 37-amino-acid region of homology shared by 
heterochromatin protein 1 (HP1) and Pc proteins from Drosophila melanogaster (12, 13). 
The CBX7 protein appears to be involved in the control of normal cell growth (13, 14). 
Moreover, mouse CBX7 associates with facultative heterochromatin and with the 
inactive X chromosome, which indicates that CBX7 is involved in the repression of gene 
transcription (15). 
Thyroid cancer is the most prevalent endocrine neoplasia. About 20,000 new cases are 
diagnosed in the United States each year, and more than 1,500 patients die of thyroid 
cancer annually. Given the poor prognosis associated with the less differentiated 
histologic types, namely TCV PTC and Hurthle variants, and the undifferentiated ATC, 
there is a need for molecular markers that can help to predict prognosis, so that patients 
with a dismal prognosis can be offered different, perhaps, innovative therapy.  
In an attempt to determine whether CBX7 is related to thyroid cancer phenotype, and to 
find new tools for the diagnosis and prognosis of thyroid cancer, we have evaluated its 
expression in a large number of thyroid carcinoma tissues, and in rat and mouse models 
of thyroid carcinogenesis.  
 RESULTS 
 
CBX7 gene expression is down-regulated in human thyroid carcinoma cell lines. In a 
first step, we looked for genes potentially involved in the neoplastic transformation of the 
thyroid gland. To this aim, we extracted RNAs from normal human thyroid primary cells 
and six human thyroid carcinoma cell lines (the follicular carcinoma WRO cell line, the 
PTC TPC-1 and FB-2 cell lines, the NPA cell line that originates from a poorly 
differentiated PTC, and the ATC ARO and FRO cell lines) and hybridized them to 
U95Av2 Affymetrix oligonucleotide arrays (Affymetrix, Santa Clara, CA) containing 
12.625 transcripts (16). We looked for genes whose expression was drastically (at least 
10 fold) up- or down-regulated in all the six thyroid carcinoma cell lines versus normal 
thyroid primary cell culture, on the assumption that genes whose expression was altered 
in all carcinoma cell lines could be involved in thyroid cell transformation. Thus, genes 
that were decreased in all the carcinoma cell lines were considered candidate tumor 
suppressor genes. Among the down-regulated genes, CBX7 was the only gene drastically 
down-regulated in all the cell lines tested with the cDNA microarray (Figure 1A). This 
result was confirmed by RT-PCR analysis in a large panel of thyroid carcinoma cell lines 
with normal thyroid primary culture cells as control (Figure 1B). 
 
The loss of CBX7 expression correlates with a more aggressive phenotype of thyroid 
carcinomas. To determine whether the loss of CBX7 expression is a feature of thyroid 
tumors and not only of cultured thyroid carcinoma cell lines, we carried out an 
immunohistochemical analysis of paraffin-embedded tissues using polyclonal antibodies 
 raised against the carboxy-terminal region of human CBX7 protein (see Methods). As 
shown in Table 1, all 20 samples of normal thyroid parenchyma expressed CBX7 at a 
very high level, which coincides with the strong CBX7 staining in all follicles (Figure 
2A). The intensity of nuclear labeling of epithelial thyroid cells in FA was similar to that 
of the internal control stromal and endothelial cells (Figure 2B). Conversely, CBX7 
expression was reduced in malignant lesions. As shown in Table 1, and in Figure 2C and 
D, the percent of low expressors was high in well-differentiated tumors, namely FTC 
(66%; 21/32 samples) and PTC (57%; 17/30 samples). It was even higher in the less 
differentiated tumors, namely poorly differentiated carcinomas (83%; 10/12) (Table 1, 
and Figure 2F and G) and TCV PTC (5/6; 83%) (Table 1, and Figure 2E). In the latter, 
neoplastic cells were almost devoid of CBX7 expression, which sharply contrasted with 
the intense staining of the infiltrating lymphocytes and stromal cells. Similarly, CBX7 
expression was completely lost in all cases of anaplastic carcinoma (12/12) (Table 1, 
Figure 2H). No staining was observed when normal thyroid gland samples were stained 
with antibodies pre-incubated with CBX7 recombinant protein (Figure 2I) or in the 
absence of the primary antibodies (data not shown). Therefore, CBX7 was expressed in 
normal thyroid and in benign neoplastic lesions, decreased in well-differentiated 
carcinomas and was drastically reduced in aggressive thyroid tumors. 
 
Analysis of CBX7 expression in normal and neoplastic thyroid tissues by 
semiquantitative RT-PCR and quantitative Real-Time PCR. We also evaluated CBX7 
expression by semiquantitative RT-PCR in a panel of matched normal/tumor tissues. The 
results confirmed the immunohistochemical data. In fact, there was an amplified band 
 corresponding to CBX7 in normal thyroid tissues (Figure 3A). The amplified band 
decreased in PTC samples and almost disappeared in ATC. qRT-PCR analysis of a large 
number of human thyroid carcinoma samples of different histotypes confirmed a 
correlation between the reduction of CBX7 expression and a more malignant phenotype 
of thyroid neoplasias. In fact, as reported in Figure 3B, there was a negative fold change 
in CBX7 expression from –2.1 to –13 (average, –4.8) in the PTC samples versus normal 
counterpart tissue. The reduction was even more pronounced in the anaplastic carcinoma 
samples, with a fold change ranging from –10.8 to –24.5 (average, –14.6). These data are 
well correlated with the immunohistochemical data, and suggest that CBX7 expression is 
controlled at transcriptional level. 
Analysis of human thyroid fine-needle aspiration biopsy. Fine-needle aspiration 
biopsy has become an integral part of the preoperative evaluation of thyroid nodules. 
To evaluate whether CBX7 gene expression analysis can be applied to FNAB samples, 
we studied 15 cases of thyroid papillary carcinoma by immunohistochemistry and 
qRT-PCR. In 8 cases out of 15, CBX7 expression was lower in FNABs from patients 
affected by a carcinoma than in FNABs from thyroid goiter as evaluated by 
immunohistochemistry (Figure 4A) and qRT-PCR (Figure 4B). 
 
LOH at CBX7 locus (22q13.1). In some types of cancers, LOH of tumor suppressor 
genes at region 22q is believed to be a key step in carcinogenesis (17-19). We there used 
several SNP markers to evaluate LOH on chromosome 22q13.1, at the CBX7 locus in 60 
cases of thyroid carcinomas of different histotypes. As shown in Table 2, LOH at CBX7 
locus occurred in 36.8% of the informative PTC (7 out of 19 cases), whereas in 68.7% 
 (11/16 cases) of informative ATC. The percentage of LOH was much higher in the TCV 
variant of PTC (3/4 cases; 75%) than in classical PTC (7/19 cases; 36.8%). Again, LOH 
of CBX7 was well correlated with tumor phenotype, TCV being more aggressive than 
classical PTC (3). We next looked for CBX7 gene mutations in human thyroid carcinoma 
samples. We analyzed 20 PTC samples and 6 ATC samples and found no mutations (data 
not shown). 
 
Methylation status of the CBX7 gene. To investigate the mechanisms underlying CBX7 
downregulation in thyroid tumors, we evaluated DNA methylation of the CBX7 gene in 
normal and tumor tissues. An analysis of CBX7, carried out with the CpG plot program 
(see Methods), revealed two CpG islands. The first extended about 1000 nucleotides 
around the transcription initiation site and the second was located at the distal part of 
intron 2 (Figure 5). We analyzed the putative promoter region (between –83 and +154) of 
genomic DNA extracted from five PTC and corresponding adjacent normal tissues, from 
5 ATC, and from the thyroid papillary carcinoma cell line TPC-1 (Figure 5, upper panel). 
We found no methylation in any of the 42 CpGs present in this region (data not shown). 
By contrast, methylation of the last part of this CpG island (from+187 to +502, Figure 5, 
upper panel), which contains 21 CpGs, was much higher in ATC than in PTC and normal 
tissues (Figure 5, lower panel). No significant methylation was found in the second CpG 
island. 
 
CBX7 expression in rat thyroid cells transformed by viral oncogenes. The infection of 
two rat thyroid differentiated cell lines, PC Cl 3 (20) and FRTL-5 (21), with several 
 murine retroviruses induces different effects on the differentiated and transformed 
phenotype (22-24). PC MPSV and PC PyMLV cells are dedifferentiated and tumorigenic, 
whereas PC v-raf, PC KiMSV and PC E1A cells are dedifferentiated but not tumorigenic 
when injected into nude mice. PC E1A cells are transformed to an irrefutable neoplastic 
phenotype after introducing a second oncogene such as the polyoma middle-T antigen or 
v-raf genes (23). Conversely, FRTL-5 cells become tumorigenic after infection with the 
Kirsten murina sarcoma virus carrying the v-ras-Ki oncogene (25). We evaluated CBX7 
expression in these cell lines. As shown in Figure 6A, the gene was abundantly expressed 
in normal thyroid cells and in all cells that did not show the malignant phenotype, 
whereas its expression was abolished in the malignantly transformed cells FRTL-5 
KiMSV and PC MPSV, and in PC E1A cells infected with a virus carrying the v-raf 
oncogene. Interestingly, CBX7 expression was retained in FRTL-5 KiMSV-HMGA1 and 
in PC MPSV-HMGA2, cells previously transfected with a vector carrying respectively 
HMGA1 and HMGA2 gene in an antisense orientation, able to prevent the malignant 
transformation of FRTL-5 and PC Cl 3 cells (26, 27), and then with the relative 
oncogene. In fact, although these cells undergo morphological changes and lose the 
thyroid differentiation markers, they are unable to grow in soft agar and to induce tumors 
after injection into athymic mice (26, 27). In conclusion, also the analysis of rat thyroid 
cells transformed in vitro confirms that the loss of CBX7 expression is associated with 
the expression of a highly malignant phenotype. 
 
CBX7 expression in experimental mouse models of thyroid carcinogenesis. We used 
qRT-PCR analysis to evaluate CBX7 expression in thyroid neoplasias in transgenic 
 animal lines expressing TRK (Tg-TRK) (28), RET/PTC3 (Tg-RET/PTC3) (29), N-ras 
(Tg-N-ras) (30) and large T SV40 (Tg-SV40) (31) oncogenes under the transcriptional 
control of the thyroglobulin promoter. Transgenic mice carrying TRK and RET/PTC3 
oncogenes develop PTC (28, 29), whereas N-ras mice develop thyroid follicular 
neoplasms that undergo de-differentiation, predominantly FTC (30). ATC were obtained 
from Tg-SV40 mice (31). As shown in Figure 6B, CBX7 expression was much lower in 
ATC from large T SV40 transgenic mice compared with mouse normal thyroid tissue. 
CBX7 mRNA expression was significantly, albeit not greatly, reduced in PTC from TRK 
and RET/PTC3 mice. CBX7 expression was also reduced in the FTC from N-ras mice. In 
summary, the analysis of the experimental models of thyroid carcinogenesis confirms that 
the loss of CBX7 expression is related to the undifferentiated histotype. 
 
Restoration of CBX7 gene expression inhibits the growth of thyroid carcinoma cell lines. 
To determine whether loss of CBX7 gene expression affects thyroid carcinogenesis, we 
evaluated the growth rate of thyroid carcinoma cell lines in which CBX7 expression had 
been restored. To this aim we carried out a colony forming assay with cell lines obtained 
from human thyroid carcinomas (NPA, TPC-1 and FB-2) after transfection with the vector 
carrying the CBX7 gene or the empty backbone vector. The colonies were scored after two 
weeks. As shown in Figure 7, cells transfected with the CBX7 gene generated a lower 
number of colonies than did cells transfected with the backbone vector: for the NPA cells 
the inhibition was about 48% (representative experiment: empty vector, 296 colonies; 
CBX7, 154 colonies) while for FB-2 and TPC-1 cells the inhibition was even much higher. 
 
 Generation of an adenovirus carrying the CBX7 gene. We generated a replication-
defective adenovirus carrying the CBX7 gene in the sense (Ad-CBX7) orientation. We 
then infected thyroid carcinoma cell lines with the Ad-CBX7 virus, and measured protein 
levels in cell lysates collected at different time points after adenovirus infection. No 
CBX7 protein was detected in carcinoma cells infected with the control virus (Ad-GFP). 
We then constructed growth curves of cells infected with Ad-CBX7 and control 
adenovirus (Ad-GFP). As shown in Figure 8, cell growth rate was significantly lower in 
ARO and NPA cell lines infected with Ad-CBX7 than in the same cells infected with the 
control virus. The percentage of growth inhibition five days after infection was 38.5% in 
ARO cells and 54% in NPA cells. 
 DISCUSSION 
 
The results of this study show that CBX7 is abundantly expressed in normal thyroid 
gland, but is drastically down-regulated or absent in all the thyroid carcinoma cell lines. 
Interestingly, CBX7 expression decreased with malignancy grade and neoplasia stage. In 
fact, CBX7 expression was comparable to normal thyroid tissue in FA, which is benign, 
slightly reduced in PTC displaying the classical histotype, and drastically reduced, and in 
most cases absent, in FTC, in the TCV of PTC, in poorly differentiated carcinomas and in 
ATC. Based on these findings, it is feasible that CBX7 levels could serve to differentiate 
between benign and malignant thyroid neoplasms. Indeed, in clinical practice, it is 
difficult to distinguish between FTC and the benign FA (32, 33). In the perspective of 
diagnosis/prognosis, CBX7 expression level in FNAB may be used to identify PTC by 
immunohistochemistry and by qRT-PCR. Interestingly, a recent paper concerning the 
cytogenetics of Chernobyl thyroid tumors identified a correlation between the deletion of 
the chromosomal region 22q13.1, where the CBX7 gene is located, and a worse 
prognosis (34). 
Our finding of a decrease in CBX7 levels in relation to malignancy was supported by our 
model of rat thyroid cells transformed by several oncogenes and in transgenic mice 
carrying thyroglobulin promoter-driven oncogenes. CBX7 expression was absent from 
thyroid cells that show a highly malignant phenotype and in ATC that develop in large T 
SV40 transgenic mice. Differently, CBX7 expression was retained, albeit at a low level, 
in transformed rat thyroid cells that are not yet tumorigenic and in PTC developing in 
RET/PTC and TRK mice. Therefore, our data indicate that loss of CBX7 expression 
 correlates with a more aggressive phenotype of thyroid carcinomas and perhaps with a 
worst prognosis. This result is consistent with our preliminary finding of a correlation 
between low CBX7 expression and reduced survival in colon carcinoma (Pallante and 
Terracciano, manuscript in preparation). Moreover, the association between lack of 
CBX7 expression and a more aggressive histotype seems to apply also to breast, ovary 
and prostate carcinomas (Pallante and Troncone, manuscript in preparation). 
In an attempt to unravel the mechanism underlying loss of CBX7 gene expression in 
malignant thyroid neoplasias, we analyzed LOH at the CBX7 locus (22q13.1). We 
detected LOH in 36.8% and 68.7% of the PTC and ATC, respectively. However, no 
mutations were found in thyroid carcinomas. Conversely, there was a hypermethylation 
status in ATC, which are practically devoid of CBX7 expression. Therefore, we suggest 
that gene methylation, associated in most cases with LOH, might account for the block of 
CBX7 expression in ATC, whereas the decreased expression in PTC may be due to an 
allelic loss plus other epigenetic mechanism. 
The biological characteristics of the CBX7 protein suggests that it acts as a tumor 
suppressor. In fact, like other Pc proteins that exert their effects through transcriptional 
repression, CBX7 is involved in the mechanism of transcriptional repression. Moreover, 
the expression of a fusion protein between CBX7 and the DNA-binding domain of Gal4 
(Gal4/CBX7) caused a dose-response repression of the reporter gene versus the control 
(13). These studies suggest that the CBX7 protein could be involved in maintaining the 
transcriptionally repressive state of genes by modifying chromatin and rendering it 
heritably changed in its expressibility. To determine whether CBX7 plays an important 
role in thyroid carcinogenesis, we restored the CBX7 function in human thyroid cancer 
 cell lines and examined cell growth rate. CBX7 expression clearly reduced cell growth 
rate, which indicates that the gene plays a critical role in thyroid carcinogenesis. One may 
speculate that restoration of CBX7 function by adenovirus-mediated delivery could be 
applied in the most highly aggressive thyroid tumors. 
In conclusion, our data suggest that low CBX7 gene expression is associated with a 
malignant phenotype of thyroid neoplasias, and that loss of CBX7 could play a critical 
role in thyroid cancer progression.  
 
 METHODS 
 
Cell Culture and Transfections. We used the following human thyroid carcinoma cell 
lines in this study: TPC-1, WRO, NPA, ARO, FRO, NIM 1, B-CPAP, FB-1, FB-2, Kat-4 
and Kat-18, which are described elsewhere (16). They were grown in DMEM (Gibco 
Laboratories, Carlsbad, CA) containing 10% fetal calf serum (Gibco Laboratories), 
glutamine (Gibco Laboratories) and ampicillin/streptomycin (Gibco Laboratories) in a 5% 
CO2 atmosphere. Normal human thyroid primary culture cells have been established and 
grown as already described (35). PC Cl 3 (20) and FRTL-5 (21) cell lines were cultured in 
modified F12 medium supplemented with 5% calf serum (Gibco Laboratories) and six 
growth factors (thyrotropic hormone, hydrocortisone, insulin, transferrin, somatostatin and 
glycyl-histidyl-lysine) (Sigma, St. Louis, MO). PC CL 3 and FRTL-5 infected with 
several oncogenes PC KiMSV, PC HaMSV, PC v-raf, PC MPSV (20), PC PyMLV (22), 
PC E1A, PC E1A+v-raf (23), PC RET/PTC, PC HaMSV+RET/PTC1 (24), PC MPSV-
HMGA2 (27), FRTL-5 KiMSV (25), FRTL-5 KiMSV-HMGA1 (26) cells were cultured 
in the same medium as PC CL 3 and FRTL-5 cells but without the six growth factors. 
Thyroid cells were transfected using Lipofectamine reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. The transfected cells were selected in a 
medium containing geneticin (G418) (Life Technologies, Milan, Italy). For each 
transfection, several G418 resistant clones and the mass cell population were isolated and 
expanded for further analysis. 
 
 Human Thyroid Tissue Samples. Neoplastic human thyroid tissues and normal adjacent 
tissue or the contralateral normal thyroid lobe were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. Thyroid tumors were collected at the Service 
d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France. The tumor 
samples were stored frozen until required for RNA or protein extraction. 
 
RNA Isolation. Total RNA was extracted from tissues and cell cultures using the 
RNAeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. 
The integrity of the RNA was assessed by denaturing agarose gel electrophoresis. 
 
Reverse Transcriptase and PCR Analysis 
Reverse Transcription. 1 μg of total RNA from each sample was reverse-transcribed 
with QuantiTect® Reverse Transcription Kit (Qiagen) using an optimized blend of oligo-
dT and random primers according to the manufacturer’s instructions. 
Semiquantitative RT-PCR. PCR was carried out on cDNA using the GeneAmp PCR 
System 9600 (Applied Biosystems, Foster City, CA). The RNA PCR Core Kit (Applied 
Biosystems) was used to perform amplifications. After a first denaturing step (94°C for 3 
min), PCR amplification was performed for 25 cycles (94°C for 30 s, 60°C for 30 s, 72°C 
for 30 s).  
The primers used are:  
Human CBX7 forward 5’-CATGGAGCTGTCAGCCATC-3’ 
Human CBX7 reverse 5’-CTGTACTTTGGGGGCCATC-3’ 
Human β-actin forward 5’-TCGTGCGTGACATTAAGGAG-3’ 
 Human β-actin reverse 5’-GTCAGGCAGCTCGTAGCTCT-3’ 
Rat CBX7 forward 5’-GTCATGGCCTACGAGGAGAA-3’, 
Rat CBX7 reverse 5’-CTTGGGTTTCGGACCTCTCT-3’; 
Rat GAPDH forward 5’-TGATTCTACCCACGGCAAGTT-3’ 
Rat GAPDH reverse 5’-TGATGGGTTTCCCATTGATGA-3’ 
To ensure that RNA samples were not contaminated with DNA, negative controls were 
obtained by carrying out the PCR on samples that were not reverse-transcribed, but 
otherwise identically processed. The PCR products were separated on a 2% agarose gel, 
stained with ethidium bromide and scanned with a Typhoon 9200 scanner (GE 
Healthcare, Piscataway, NJ).  
 
Selection of primers and probes for qRT-PCR. To design a qRT-PCR assay we used the 
Human ProbeLibraryTM system (Exiqon, Vedbaek, Denmark). Briefly, using locked 
nucleic acid (LNATM) technology (36, 37), Exiqon provides 90 human prevalidatet 
TaqMan probes of only 8-9 nucleotides that recognize 99% of human transcripts in the 
RefSeq database at NCBI (38, 39). Using the ProbeFinder assay design software (freely 
accessed on the web site www.probelibrary.com) we chose the best probe and primers 
pair. To amplify a fragment for Real-Time PCR of CBX7 mRNA, we entered its 
accession number (NM_175709.2) on the assay design page of the ProbeFinder software 
and we chose an amplicon of 71 nucleotides that spanned the 3rd and 4th exons. The 
probe number was “human 63” (according to the numbering of Exiqon’s Human 
ProbeLibrary kit) and the primer sequences were: CBX7 forward 5’-
CGTCATGGCCTACGAGGA-3’; CBX7 reverse 5’-TGGGTTTCGGACCTCTCTT-3’.  
 The same procedure was used to choose the probe and primers for the housekeeping gene 
G6PD (accession number X03674). We opted for an amplicon of 106 nucleotides that 
spanned the 3rd and 4th exons. The probe number was “human 05” (according to the 
numbering of Exiqon’s Human ProbeLibry kit) and the primer sequences were: G6PD 
forward 5’-ACAGAGTGAGCCCTTCTTCAA-3’; G6PD reverse 5’-
GGAGGCTGCATCATCGTACT-3’. All fluorogenic probes were dual-labeled with 
FAM at 5’-end and with a black quencher at the 3’-end. 
 
qRT-PCR. Real-Time Quantitative TaqMan PCR was carried out with the Chromo4 
Detector (MJ Research, Waltham, MA) in 96-well plates using a final volume of 20 μl. 
For PCR we used 8 μl of 2.5x RealMasterMixTM Probe ROX (Eppendorf AG, Hamburg, 
Germany) 200 nM of each primer, 100 nM probe and cDNA generated from 50 ng of 
total RNA. The conditions used for PCR were 2 min at 95°C and then 45 cycles of 20 sec 
at 95°C and 1 min a 60°C. Each reaction was carried out in duplicate. We used the 2-ΔΔCT 
method to calculate relative expression levels (40). 
We also carried out qRT-PCR reactions with mouse cDNA in a final volume of 20 μl 
using 10 μl of 2x Power SYBR Green PCR Master Mix (Applied Biosystems), 200 nM 
of each primer and cDNA generated from 50 ng of total RNA. The conditions used for 
PCR were 10 min at 95°C and then 45 cycles of 30 sec at 95°C and 1 min a 60°C. Each 
reaction was carried out in duplicate, and at the end of the PCR run, a dissociation curve 
was constructed using a ramping temperature of 0.2°C per sec from 65°C to 95°C. A 
single melting point was obtained for CBX7 and β-actin amplicons (data not shown). The 
mouse β-actin gene served as control. We used the following primers: mouse CBX7 
 forward 5’-AATGGCATGGCTAAGGATGG-3’and mouse CBX7 reverse 5’-
ACATAGGTTCGTATGGTAGCA-3’; mouse β -actin forward 5’-
TCAGAAGGACTCCTATGTGG-3’ and mouse β -actin reverse 5’-
CGCAGCTCATTGTAGAAGGT-3’. 
 
Protein Extraction, Western Blotting and Antibodies. Protein extraction and western 
blotting procedure were carried out as reported elsewhere (16). Membranes were 
incubated with a primary antibody raised against the C-terminus of the human CBX7 
protein (Neosystem, Strasbourg, France) for 60 min (at room temperature). To ascertain 
that equal amounts of protein were loaded, the western blots were incubated with 
antibodies against the γ-tubulin protein (Sigma). Membranes were then incubated with 
the horseradish peroxidase-conjugated secondary antibody (1:3000) for 60 min (at room 
temperature) and the reaction was detected with a western blotting detection system 
(ECL) (GE Healthcare). 
 
Immunostaining: Technique. The cell distribution of the CBX7 protein was assessed by 
immunostaining formalin-fixed, paraffin-embedded thyroid tumor blocks retrieved from 
the files of the Dipartimento di Scienze Biomorfologiche e Funzionali at the University 
of Naples Federico II and selected to represent a wide range of thyroid neoplastic 
diseases. Briefly, xylene-dewaxed and alcohol-rehydrated paraffin sections were placed 
in Coplin jars filled with a 0.01 M tri-sodium citrate solution, and heated for 3 min in a 
conventional pressure cooker (16). After heating, slides were thoroughly rinsed in cool 
running water for 5 min. They were washed in Tris-buffered saline pH 7.4 and then 
incubated overnight with the specific rabbit polyclonal primary antibody. Subsequently, 
 tissue sections were stained with biotinylated anti-rabbit immunoglobulins, and then with 
peroxidase-labelled streptavidine (Dako, Carpinteria, CA). The signal was developed by 
using diaminobenzidine chromogen as substrate. Incubations both omitting and pre-
adsorbing the specific antibody, were used as negative controls. 
 
Immunohistochemistry: Evaluation. To ensure that we evaluated CBX7 expression only 
on technically adequate slides, we discarded slides that lacked a convincing internal 
control, namely labeling of stromal, endothelial or lymphoid cell, shown to be positive in 
a preliminary normal tissue micro-array analysis (data not shown). Based on these 
criteria, we scored paraffin-embedded stained slides from 20 cases of FA, 30 cases of 
classical PTC, 6 cases of TCV PTC, 32 cases of FTC, 12 cases of poorly differentiated 
carcinoma, and 12 cases of ATC. As controls, we selected areas of normal thyroid 
parenchyma from the lobe contralateral to the tumor in 20 surgical specimens of PTC. 
Individual cells were scored for the expression of CBX7 by quantitative analysis 
performed with a computerized analyzer system (Ibas 2000, Kontron, Zeiss), as described 
previously (16), and tumors were subdivided in low-expressors (less than 50% of positive 
cells) and in high-expressors (more than 50% of positive cells). 
 
Thyroid Fine-Needle Aspiration Biopsies (FNAB). The FNAB were carried out at the 
Dipartimento di Anatomia Patologica e Citopatologia (University of Naples Federico II) 
as described elsewhere (41, 42). Samples were obtained from 15 patients with thyroid 
neoplasias who subsequently underwent surgery because the FNAB cytology indicated a 
diagnosis of cancer. Normal thyroid cells, used as controls, were obtained from FNAB of 
 thyroids carrying non-neoplastic nodules. FNAB samples were washed twice with 1x PBS 
and then processed for RNA extraction using the procedure detailed in a previous section. 
 
Loss-of-heterozygosity (LOH) analysis. We used several SNP markers to evaluate LOH 
at the CBX7 locus on chromosome 22q13.1. We selected the SNP markers 
(http://www.ncbi.nih.gov/SNP/) that showed high average heterozygosity levels in order 
to obtain the highest number of informative cases. Briefly, genomic DNA was PCR-
amplified in a region spanning about 200 bp around the SNP analyzed, then the purified 
PCR product was sequenced. We measured the height of the two peaks on the 
chromatogram and calculated the ratio of the two alleles in the matched tumor/normal 
samples: LOH was defined if the ratio in the carcinoma sample was less than 50%. SNPs 
and relative primers used to amplify them are as follows:  
rs710190 (LOH1-L 5’-TGAATCCACAGACCCACAGA-3’, LOH1-R 5’-
GGTTCAGAGGGGACTCTTCC-3’); rs5750753 (LOH2-L 5’-
GACAGCCAAGGAAAGACAGG-3’, LOH2-R 5’-GTGTGATGGGCAGGCTTT-3’); 
rs713841 (LOH3-L 5’-CCAGACGTCTCAAAGCCTGT-3’, LOH3-R 5’-
CAGCACAAAAGACCTCACCA-3’); rs2076476 (LOH4-L 5’-
ACAGGGCATCTTTGTGAAGC-3’, LOH4-R 5’-GTGAAAATGGTGGGCACTG-3’); 
rs2281258 (LOH5-L 5’-AGAACCATTCACAAGTGGGG-3’, LOH5-R 5’-
TCTGGAAAGCACAGCAAATG-3’); rs2235686 (LOH6-L 5’-
TGGCCTCAGCATGTTAAGAA-3’, LOH6-R 5’-GTTCCTTCCCCCACTTTGAT-3’); 
rs714016 (LOH7-L 5’-TGGCTGCACTGTAAGGACAC-3’, LOH7-R 5’-
CTTCTGGGGGTCAGGAATTT-3’); rs139390 (LOH8-L 5’-
 CACCTGCCCTGTAGGCTTAG-3’, LOH8-R 5’-GCAGGATATTGGAAGCCAGA-3’); 
rs139393 (LOH9-L 5’-CCTTCACCCTGTCCTGGTAA-3’, LOH9-R 5’-
TTCATCCTCTCTTGCCTGGT-3’). 
 
Methylation analysis using bisulphite genomic sequencing. The promoter region and 
the entire coding sequence of the human CBX7 gene were analyzed for CG content; CpG 
islands were determined based on a 200-bp length of DNA with a CG content of >50% 
and a CpG/GpC ratio of >0.5, using the CpGplot program, available at 
http://www.ebi.ac.uk/emboss/cpgplot/. Bisulphite genomic sequencing was used to 
analyze the methylation patterns of individual DNA molecules. Sodium bisulphite 
conversion of genomic DNA (about 200 ng for each conversion) was obtained using the 
EZ DNA Methylation Kit™ (Zymo Research, Orange, CA) following the manufacturer's 
instructions. The CpG islands identified were then PCR-amplified using the following 
primers:  
1F: -440 -407  5’-TTC/GGGTTTTTGGTAGTTATTGGGAGGTTATGAGG-3’ 
1Fn: -114 -84 5’-AGGAAAAC/GGTTGC/GGTAGGTTTAAAAATGGAA-3’ 
1R: +211+178 5’- AAAACG/AAAAAAAACCCCACTAAAATCCTAAAAAC -3’ 
1Rn: +186 +155 5’-CCTAAAAACCG/ACCCCCG/AAACAACCTCACCTTC-3’ 
 
2F:+155 +186 5’-GAAGGTGAGGTTGTTC/GGGGGGC/GGGTTTTTAGG-3’ 
2R:+593 +560 5’- CCG/AAAAAAAACTTTTCCAAAACTCCACTTACAAC-3’ 
2Rn:+535 +503 5’- CCAAAATCCCG/AAATTCAAAACCCAACTCTAACC-3’ 
 
 3Fn:+7005 +7031 5’- GGTGTGGGAAGGGTGTTTTGGGATTTG-3’ 
3R: +7259 +7230 5’-CACCAACATCTTAATTATTTAAACCCAACC-3’ 
3Rn: +7196 +7170 5’-CCCTCCG/ACAATACAAAAACCCAAAAAC-3’ 
 
PCR reactions were carried out using FastStart Taq DNA polymerase (Roche, Basel, 
Switzerland) under the following conditions: 1) Pre-nested PCRs were normally carried 
out on 10 ng of bisulphite-treated DNA in a final reaction volume of 50 μl, using 
standard conditions with 5 min at 95°C, 2 min at 70°C, followed by 5 cycles of 1 min at 
95°C, 2 min at 57-60°C, and 1.5 min at 72°C,  then 25 cycles of 30 sec at 95°C, 1.5 min 
at 50-55°C, and 1.5 min at 72°C, then a final elongation of 5 min at 72°C before holding 
at 4°C; 2) Nested PCRs were carried out under the same conditions using 5 μl of the 
corresponding pre-nested PCRs in a final reaction volume of 50 μl. The PCR final 
products were cloned into the pGEM®-T Easy Vector System II (Promega, Madison, WI) 
following the supplier’s procedures. The positive screened colonies contained the 
sequence of one individual DNA molecule. The plasmid DNA from the selected positive 
colonies containing vectors with the insert was purified using the Qiagen plasmid Mini 
Kit. The purified plasmids were sequenced in both directions using T7 and Sp6 primers. 
Twenty independent clones for each genomic preparation and fragment of interest were 
sequenced to determine the methylation pattern of individual molecules. Sequencing was 
carried out at the CEINGE Sequencing Core Facility (Naples, Italy). 
 
Plasmid constructs and cell colony-forming assay. CBX7 expression plasmid was 
constructed by cloning the human cDNA sequence in a pCRTMII TA Cloning® vector 
 (Invitrogen). The primers used were: CBX7 forward 5’-ATGGAGCTGTCAGCCATC-3’ 
and CBX7 reverse 5’-TCAGAACTTCCCACTGCG-3’. The inserted cDNA was then 
subcloned into the BamHI/XhoI sites of the mammalian expression vector pcDNA 3.1 
(Invitrogen). The expression of CBX7 was assessed by Western blotting. Cells, plated at 
a density of 90% in 100-mm dishes, were transfected with 5 ug pcDNA3.1 or pCBX7 and 
supplemented with geneticin (G418) 24 h later. Two weeks after the onset of drug 
selection, the cells were fixed and stained with crystal violet (0.1% crystal violet in 20% 
methanol). 
 
Preparation of recombinant adenovirus and infection protocol. The recombinant 
adenovirus was constructed using AdEasyTM Vector System (Quantum Biotechnologies, 
Montreal, Quebec). The cDNA fragment was inserted in the sense orientation into the NotI 
and HindIII sites of the pShuttle-CMV vector to generate the recombinant pShuttle-
CBX7-CMV construct. It was linearized and co-transformed through electroporation with 
pAdEasy-1, which carries the adenovirus genome, in BJ5183 electrocompetent cells. After 
homologous recombination, a recombinant AdEasy-CMV-CBX7 plasmid was generated 
(Ad-CBX7), which was then extracted and linearized. QBI-293A cells were transfected 
with different clones to produce different viral particles, and the infectivity of each clone 
was tested. Viral stocks were expanded in QBI-293A cells, which were harvested 36-40 h 
after infection and lysed. The virus titer of the 293 cells was determined. The adenovirus 
AdCMV-GFP (Quantum Biotechnologies) was used as control. Cells (5 x 104) were 
seeded in a six-well plate. After 24 h, cells were infected at MOI 100 with Ad-CBX7 or 
Ad-GFP for 90 min using 500 μl of infection medium (DMEM supplemented with 2% 
 FBS) at 37°C in a 5% CO2 incubator. Pilot experiments with Ad-GFP were carried out to 
determine the optimal MOI for each cell line. At MOI 100, the cell lines became GFP-
positive without manifesting toxicity. Infected cells were harvested and counted daily in a 
hematocytometric chamber. 
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NONSTANDARD ABBREVIATIONS USED 
 
ATC, anaplastic thyroid carcinoma; FNAB, fine-needle aspiration biopsy; FA, follicular 
adenoma; FTC, follicular thyroid carcinoma; G6PD, glucose-6-phosphate 
dehydrogenase; LOH, loss of heterozygosity; PTC, papillary thyroid carcinoma; qRT-
PCR, quantitative RT-PCR; SNP, single nucleotide polymorphism; TCV, tall cell variant; 
Tg, thyroglobulin. 
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 FIGURE LEGENDS 
 
Figure 1. CBX7 expression in human thyroid carcinoma cell lines. (A) CBX7 gene 
expression by microarray analysis in human thyroid carcinoma cell lines vs normal 
human thyroid primary culture cells (NTPC). Avg. Diff, average difference: it is a 
quantitative relative indicator of a transcript expression level (∑(PM-MM)/pairs on 
average). (B) CBX7 gene expression analysis by RT-PCR in human thyroid carcinoma 
cell lines vs the normal human thyroid primary culture cells (NTPC). β-actin gene 
expression served as loading control.  
 
Figure 2. CBX7 staining in normal and neoplastic thyroid tissues. CBX7 nuclear staining 
was intense in benign follicular epithelial cells of normal thyroid (A) and of follicular 
adenoma (B), whereas it was weak in follicular carcinoma (C). CBX7 progressively 
decreased going from well-differentiated “classic variant” papillary (D) carcinomas to the 
“tall cell variant” of PTC (E), to poorly differentiated (F, G) and anaplastic (H) 
carcinomas. The signal disappeared after incubation of the sample with antigen (I). 
Sample showed in the G panel is the same of F, but magnified, to better show cell nuclei. 
Arrows with letters indicate the following sample features: (P→) nuclei showing 
cytological features of PTC negative for CBX7 expression; (F→) FTC nuclei negative for 
CBX7 expression; (L→) lymphocyte showing CBX7 expression and providing positive 
internal control; (E→) endothelial cells showing CBX7 expression and providing positive 
internal control.  
 
 Figure 3. CBX7 expression in fresh thyroid tumor samples from patients. (A) RT–PCR 
analysis of CBX7 expression in human thyroid tumor samples vs their normal thyroid 
counterparts. β-actin expression served as loading control. NT, normal thyroid tissue; 
PTC1 to PTC6, papillary thyroid carcinomas from different patients; ATC1 to ATC5, 
anaplastic thyroid carcinomas from different patients. (B) qRT-PCR analysis of human 
thyroid tumor samples of different histotypes. The fold change indicates the relative 
change in expression levels between tumor samples and normal samples, assuming that 
the value of each normal sample is equal to 1. 
 
Figure 4. Immunocytochemistry (A, B) and qRT-PCR (C) analyses of CBX7 of fine 
needle aspiration biopsies (FNAB), whose PTC pre-operative cytological diagnosis was 
histologically proven. FNAB goiter samples were used as controls. The fold change 
indicates the relative change in expression levels between tumor and goiter samples, 
assuming that the value of the normal sample was equal to 1. FNAB 1 to 8, from different 
patients. 
 
Figure 5. Methylation analysis of the CBX7 gene. The structure of CBX7 is shown in the 
upper panel. The transcriptional start site is indicated as +1. The positions of the CpG 
islands and of the primers used for bisulfate analysis are indicated. The first part of the 
upstream portion of CpG island 1 (-84 to +155) and the CpG island 2 (+7031 to +7170) 
were unmethylated in normal, tumor tissues and in the tumoral cell line TPC1. Lower 
panel, methylation of the first intron (21 CpG sites): two anaplastic tumors (43T and 107 
T), one papillary tumor (10T) and its corresponding normal tissue (10N) are shown. The 
 degree of methylation is reported as the percentage of m-C obtained for each CpG dimer 
on a total of 20 independent clones analyzed (see Methods). 
 
Figure 6. CBX7 expression in experimental models of thyroid carcinogenesis. (A) CBX7 
expression by RT-PCR in rat thyroid cells transformed by several oncogenes. GAPDH 
gene expression was evaluated as control to normalize the amount of the used RNAs. (B) 
CBX7 expression by qRT-PCR in thyroid carcinomas developing in transgenic mice 
expressing RET-PTC-3, TRK, N-ras and large T SV40 oncogenes. The fold change 
indicates the relative change in expression levels between tumor samples and normal 
samples, assuming that the value of each normal sample is equal to 1. 
 
Figure 7. Colony-forming assay with CBX7 transfection in several thyroid carcinoma 
cell lines. NPA, FB-2 and TPC-1 cells were transfected with a vector expressing CBX7 
cDNA and its corresponding empty vector pcDNA3.1. Cells were selected for resistance 
to G418 and clones were stained and counted after 14 days. 
 
Figure 8. Inhibitory effects of Ad-CBX7 infection on the growth of human thyroid 
carcinoma cell lines. (A) The cell lines indicated were infected with Ad-CBX7 or Ad-
GFP (control adenovirus) at MOI 100 and counted daily. Representative curves of three 
independent experiments are reported. (B) CBX7 protein expression was assessed 48 h 
after infection with Ad-CBX7 at MOI 100 by western blot with an anti CBX7 antibody. 
Blot against γ-tubulin is to demonstrate an equal protein loading. 
 Table 1. CBX7 expression in normal and neoplastic thyroid tissues by IHC.
Histotype Cases
Normal Thyroid Parenchyma n=20 100% (20/20) 0% (0/20)
Follicular Adenomas n=20 100% (20/20) 0% (0/20)
Follicular Carcinomas n=32 34% (11/32) 66% (21/32)
Papillary Carcinomas - Classic Variant n=30 43% (13/30) 57% (17/30)
Papillary Carcinomas - Tall Cell Variant n=6 17% (1/6) 83% (5/6)
Poorly Differentiated Carcinomas n=12 17% (2/12) 83% (10/12)
Anaplastic Carcinomas n=12 0% (0/12) 100% (12/12)
with less than 50% of neoplastic cells showing CBX7 staining.
High Low
CBX7 expression a
aHigh : cases with more than 50% of neoplastic cells showing CBX7 staining; Low : cases
 
 
 Table 2. Loh frequency statistics at CBX7 locus (22q13.1) by SNP sequencing method.
Histotype Cases (Inf a)
Papillary Carcinoma- Classic Variant n=36 (19) 36.8% (7/19)
Papillary Carcinoma- Tall Cell Variant n=6 (4) 75% (3/4)
Follicular Carcinomas n=5 (3) 66.6% (2/3)
Anaplastic Carcinomas n=20 (16) 68.7% (11/16)
aInf : informative cases are samples showing SNP heterozygosity corresponding to
 two peaks (two alleles) on the sequencing chromatogram.
bThe LOH frequency is equal to the ratio between allelic loss and informative cases. 
LOH b
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ABSTRACT 
In the last years, an increasing number of experiments has provided compelling 
evidence for a casual role of Ras protein mutations, resulting in their constitutive 
activation, in thyroid carcinogenesis. However, despite the clear involvement of Ras 
proteins in thyroid carcinogenesis, the nature of most of the target genes, whose 
expression is modulated by the Ras-induced signaling pathways and that are 
ultimately responsible for Ras-induced cellular transformation, remains largely 
unknown. To analyze Ras-dependent modulation of gene expression in thyroid cells 
we took advantage of a differentiated rat thyroid cell line, FRTL-5. As a model for 
Ras-dependent thyroid transformation, we used FRTL-5 cells infected with the 
Kirsten murine sarcoma virus, carrying the v-Ki-Ras oncogene. The infected cells 
(FRTL-5 v-Ki-Ras) have lost expression of the thyroid differentiation markers and are 
also completely transformed. We hybridized two different Affimetrix chips containing 
probe sets interrogating both known rat genes and ESTs for a total of more than 
17,000 sequences using mRNA extracted from FRTL-5 and FRTL-5 v-Ki-Ras cell 
lines. We identified about 1,000 genes whose expression was induced and about 1,500 
genes whose expression was downregulated more than two fold by Ras. We 
confirmed the differential expression of many of these genes in FRTL-5 v-Ki-Ras as 
compared to parental cells by using alternative techniques. Remarkably, we 
investigated the expression of some of the Ras-regulated genes in human thyroid 
carcinoma cell lines and tumor samples, our results, therefore, providing a new 
molecular profile of the genes involved in thyroid neoplastic transformation. 
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INTRODUCTION 
Thyroid cancer is the most common form of endocrine malignancy, causing 
significant morbility and mortality (1). Still, risk factors for this form of tumor are 
relatively debated; however, exposure to ionizing radiation, especially in childhood, is 
a well-established cause of thyroid carcinogenesis in humans (2). In fact, head, neck, 
or thorax irradiation administered in childhood to treat diseases such as lymphoid 
hyperplasia of the tonsils or enlarged thymus gland or radiation exposure during the 
atomic explosions in Japan increased the risk of developing thyroid tumors (3, 4).  
Finally, in the last fifteen years, the frequency of thyroid carcinomas is dramatically 
increased in the population exposed to the massive release of radionuclides that 
followed the explosion of the nuclear reactor in Chernobyl (2). 
Besides their clinical relevance, thyroid tumors have been deeply investigated also 
because they represent an excellent multi-stage model for epithelial tumor 
progression. In fact, thyroid neoplasms comprise a broad spectrum of malignancies 
with different phenotypic characteristics and a variable biological and clinical 
behavior: from the benign adenomas through the slowly progressive differentiated 
papillary and follicular carcinomas to the invariably fatal anaplastic carcinomas (1). 
The several studies on thyroid tumors have allowed the identification of many genetic 
alterations. Thus, mutations of the TSH receptor and of the α subunit of the adenylate 
cyclase stimulatory protein Gαs have been described in hyperfunctioning adenomas 
(5, 6). Studies on papillary thyroid carcinomas revealed that the prevalence of 
chromosomal rearrangements leading to oncogene formations is quite high in tumors 
of such hystotype, the rearrangements being, indeed, more common in tumors 
associated with radiation exposure (7). In about 40% of papillary thyroid carcinomas 
the kinase domain of the tyrosine kinase receptor c-Ret is fused with the N-terminal 
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region of heterologous genes (8). Moreover, rearrangements of the NTRK1 gene, 
coding for the nerve growth factor receptor, have been described in about 10% of 
papillary carcinomas (9). Furthermore, a common feature of both sporadic and 
radiation-induced papillary thyroid carcinomas is the activation of the serine-
threonine kinase BRAF. Interestingly, the molecular mechanisms causing activation 
of the BRAF kinase activity is different in sporadic versus post-Chernobyl tumors, 
BRAF being activated by point mutation in sporadic tumors and by rearrangements in 
radiation-induced tumors (10, 11). In addition, p53 mutations have been frequently 
observed in undifferentiated thyroid carcinomas (12-14). Finally, mutations of the Ras 
proteins, resulting in their constitutive activation, have been found in a high 
percentage of follicular and anaplastic carcinomas (15, 16). Of note, such Ras 
mutations have been found in very early malignancies and in benign tumors (17), 
thereby suggesting a very high sensitivity of the thyroid to Ras-induced 
transformation. Indeed, besides epidemiological data, in vitro gene transfer 
experiments have provided compelling evidence for a casual role of Ras mutations in 
thyroid carcinogenesis. Introduction of mutated Ras into normal adult human thyroid 
follicular cells results in fact in a dramatic stimulation of cell proliferation (18). 
Moreover, it has been demonstrated that infection of normal rat thyroid cells with the 
Kirsten murine sarcoma virus carrying the v-Ki-Ras oncogene results in the loss of the 
differentiated functions and in the acquisition of a completely transformed phenotype, 
the cells being able to grow in soft agar and to cause tumors when injected in athymic 
mice (19). A role for Ras mutations in thyroid carcinogenesis has been demonstrated 
also in vivo. It has been in fact shown that the injection of the Kirsten murine sarcoma 
virus into the thyroid gland of adult Fischer rats induces thyroid carcinomas when the 
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animals are treated with a goitrogenic agent (20). Finally, transgenic mice expressing 
the Ki-Ras oncogene in the thyroid do develop tumors (21). 
Mutations in Ras proteins have been described not only in thyroid neoplasias but also 
in a wide variety of tumors, Ras being, indeed, one of the dominantly acting 
oncogenes most frequently implicated in human cancer (22). The evidences for a 
causative role of Ras mutations in the process of carcinogenesis are persuasive in all 
the cell types and tissues examined so far. Still, the molecular mechanisms of Ras-
dependent cellular transformation have remained elusive.  
The four human Ras genes (R-, Ha-, Ki- and N-Ras) code for 21-kD proteins that 
function as GDP/GTP molecular switches (23). They are located at the inner surface 
of the plasma membrane downstream of growth factor receptors and, upon activation, 
control a cytoplasmic cascade of kinases, including the extracellular-regulated protein 
kinases (Erks) (23). In turn, the kinases regulate the activity of several nuclear 
transcription factors, ultimately controlling the expression of specific target genes 
(24). Thus, Ras proteins are crucial for converting growth-promoting signals into 
specific changes in gene expression. Indeed, activation of the Ras-induced signaling 
pathways appears to be central for the proliferative response to many growth factors, 
and, upon Ras mutation, the persistent activation of most of these signaling routes is 
sufficient for transformation. However, the nature of most of the target genes, whose 
expression is modulated by the Ras downstream effectors and that are ultimately 
responsible for Ras-induced cellular transformation, remains largely unknown. Thus, 
we have used the powerful oligonucleotide microarray hybridization technique to 
analyze Ras-dependent modulation of gene expression in thyroid cells. We identified 
about 1,000 genes whose expression is induced and about 1,500 genes whose 
expression is downregulated more than twofold by Ras. We confirmed the expression 
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of some of the Ras-regulated genes in human thyroid carcinoma cell lines and tumor 
samples, these data providing new molecular basis for understanding the biological 
properties of thyroid cancer and the mechanisms of Ras-induced cellular 
transformation.  
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MATERIALS AND METHODS 
Cell culture. FRTL-5 and PC Cl3 are thyroid epithelial cell lines derived from 3- to 
4-weeks and from 18-month-old Fisher rats, respectively (25, 26). FRTL-5 v-Ki-Ras, 
PC Cl3 v-mos, PC Cl3 v-raf, PC Cl3 E1A, PC Cl3 E1A v-raf cell lines have been 
described (26, 19, 27). All rat thyroid cell lines were cultured in Coon’s modified 
Ham’s F12 medium supplemented with 5% calf serum (Gibco Laboratories). Normal, 
but not virally  infected, FRTL-5 and PC Cl3 cells required six growth factors (1 x  
10-10 M TSH, 10µg/ml insulin, 1x10-8M hydrocortisone, 5µg/ml human transferrin, 
10ng/ml somatostatin, 10ng/ml glycyl-L-histidyl-L-lysine acetate). 
The human thyroid carcinoma cell lines studied were: WRO (28), FB-2 (29), NPA 
(30), TPC-1 (31), B-CPAP (32), FRO (14) and ARO (30). They were grown in 
Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum (Gibco 
Laboratories).  
 
Tissue samples and RNA preparation. Samples of thyroid cancer tissues and of the 
corresponding adjacent noncancerous thyroid tissues were obtained from patients that 
underwent thyrodectomy. Samples were immediately snap-frozen in liquid nitrogen. 
A pathologist determined histological classification according to WHO’s 
classification. Total RNAs were extracted from tissues and cell culture using TRI 
REAGENT method, following the instructions of Molecular Research Center, Inc.  
 
High-density oligonucleotide microarray analysis. cRNA was prepared from total 
RNA, hybridized to Affimetrix oligonucleotide arrays (containing rat transcripts), 
scanned and analyzed according to Affimetrix (Santa Clara, CA) protocols. Scanned 
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image files were visually inspected for artifacts and normalized by using 
GENECHIP3.3 software (Affimetrix). Comparisons were made for the transformed 
sample versus the wild-type sample, taking the wild type as baseline, by using 
GENECHIP3.3. The fold-change values, indicating the relative change in the 
expression levels between the Ras-transformed sample and the wild-type sample, 
were used to identify genes differentially expressed between these conditions.  
 
Semiquantitative RT-PCR. RT-PCR was performed with Applied Biosystems 
reagents. 500ng of DNase I (Invitrogen)-treated total RNA from FRTL-5 and FRTL-5 
v-Ki-Ras were reverse-transcribed in single-stranded cDNA in a 20µl reaction 
containing 5mM MgCl2, PCR buffer 1X (500mM KCl, 100mM Tris-HCl, pH 8.3), 
dNTPs 1mM each, a mixture of 2.5mM random examers, 1U/µl RNase Inhibitor, 
2.5U/µl Murine Leukemia Virus Reverse Transcriptase. To ensure that RNA samples 
were not contaminated with DNA, negative controls were obtained by performing 
PCR on samples that were not reverse-transcribed but otherwise identically processed. 
The cDNAs were then amplified by PCR in a 25µl reaction tube containing 1mM 
MgCl2, PCR buffer 0.8X, 100ng of each primer, 0.25U/µl AmpliTaq DNA 
Polymerase. In the co-amplification experiments, the gene of interest and the β-actin 
gene were amplified using a 6:1 ratio of the respective primers. The PCR products 
were separated on a 2% agarose gel, stained with ethidium bromide and scanned using 
a Typhoon 9200 scanner. Digitized data were analyzed using Imagequant (Molecular 
Dynamics). The primers sequences are available upon request. 
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RESULTS 
Identification of genes regulated by Ki-Ras in thyroid cells. To identify the genes 
regulated by Ras oncogenes in thyroid cells, we took advantage of a rat thyroid cell 
line, FRTL-5, expressing all the markers of thyroid differentiation (i.e., they express 
thyroglobulin and TSH-R, they trap iodide and are dependent on TSH for growth). 
We have previously demonstrated that the same cells infected with a retrovirus 
carrying the v-Ki-Ras oncogene (FRTL-5 v-Ki-Ras) not only lost all the markers of 
thyroid differentiation but were also completely transformed as they were able to 
grow in soft agar and to cause tumors when injected in nude mice (19). To identify 
genes regulated by v-Ki-Ras in thyroid cells, RNA was extracted from FRTL-5 and 
FRTL-5 v-Ki-Ras and utilized for hybridizing a set of high-density synthetic 
oligonucleotide array capable of analyzing about 17,000 rat genes and expressed 
sequence tags (ESTs). The expression profile of the Ras-transformed cells was 
compared with that of the wild-type FRTL-5 cells that were used as a common 
reference (33). We applied an arbitrary filter level of twofold change in the ratios of 
gene expression. Figure 1A shows the number of transcripts increased or decreased in 
the Ras-transformed cells. For practical reasons, we downsized the list to those genes 
that showed a tenfold change of expression and ended up with a list of about 100 
genes. Figure 1B shows a list of these genes and their accession numbers. To assess 
the predictive value of the microarray analysis, we first looked at the genes already 
known to be differentially regulated in FRTL-5 v-Ki-Ras versus wild type cells. As 
expected, all the markers of thyroid differentiation resulted to be highly 
downregulated in FRTL-5 v-Ki-Ras versus FRTL-5 (data not shown). Remarkably, 
Ki-Ras gene expression resulted highly upregulated in FRTL-5 v-Ki-Ras cells 
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compared to FRTL-5 (data not shown), further confirming the high quality of the gene 
expression profile analysis.  
 
Validation of the microarray analysis. To validate the expression changes detected 
by the oligonucleotide array, we analyzed the mRNA levels of some of the genes 
more significantly regulated in FRTL5 v-Ki-Ras cells using an alternative technique, 
i.e. semiquantitative RT-PCR. All the genes that resulted highly up or downregulated 
in the microarray analysis were confirmed to be expressed at higher or lower levels, 
respectively, in FTL5 v-Ki-Ras cells versus the wild type cells by RT-PCR. Although 
the precise magnitude of change in expression was not always recapitulated, both the 
direction and the order of magnitude of change predicted by the array were confirmed 
by the RT-PCR experiments. Some representative RT-PCR analyses are shown in 
figures 2A and 2B. 
 
Analysis of the Ras-dependent genes in different rat transformed cell systems. To 
investigate the expression of the Ras-dependent genes in another cellular system, we 
took advantage of a different rat thyroid cell line, PC Cl3, expressing the thyroid 
differentiation markers (i.e. thyrotropin-dependency, ability to trap iodide, 
thyroglobulin synthesis and secretion) (19). We have previously demonstrated that 
infection with the v-mos oncogene confer to the PC Cl3 cells the typical markers of 
neoplastic transformation, the PC Cl3 v-mos cells being able to grow in soft agar and 
to induce tumors after injection into athymic mice. We analyzed, by semiquantitative 
RT-PCR, the expression of a Ras-dependent gene, RalA, in PC Cl3 and PC Cl3 v-mos 
cells. As shown in figure 3A, RalA gene was highly upregulated in transformed cells 
as compared to the wild-type PC Cl3 cells. To further investigate the expression of the 
RalA gene, we took advantage of other cell lines available in our laboratory, 
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representing a good model of multistep malignant progression. In fact, we have 
previously demonstrated that the infection with the E1A or the v-raf oncogenes 
completely de-differentiated PC Cl3 cells but still the cells were unable to grow in 
soft agar or to induce tumors in athymic mice (19). On the other hand, the cooperation 
of the two oncogenes completely transformed the PC Cl3 cells (27). As shown in 
figure 3B, RalA was not induced in PC Cl3 E1A cells compared to the parental PC 
Cl3 cells. Interestingly, however, it was induced in both PC Cl3 v-raf and in PC Cl3 
E1A v-raf cells, this strongly suggesting that RalA expression is upregulated not only 
by Ras but also by its downstream effector Raf.  
 
Analysis of the Ras-dependent genes in human thyroid carcinoma cell lines. Next, 
we investigate by RT-PCR the expression of the identified Ras-regulated genes in 
seven thyroid carcinoma cell lines. These cell lines are representative of human 
thyroid tumors of different hystotypes: in fact, one (WRO) is derived from a follicular 
carcinoma, four (FB-2, NPA, TPC-1 and B-CPAP) are derived from papillary 
carcinomas and two (FRO and ARO) are derived from anaplastic carcinomas. Figure 
4A shows the levels of five different Ras-induced genes. Annexin A2 and RalA, two 
genes whose expression was induced by Ras in rat thyroid cells, were, as expected, 
upregulated in all seven carcinoma cell lines. Ehd4 and Ler3 were induced in all but 
two carcinomas cell lines while Prxx1 was induced only in the NPA cell line. We next 
verified in the human thyroid carcinoma cell lines the expression of Dusp1 and CD24, 
two genes whose expression was downregulated by Ras in rat thyroid cells. As shown 
in figure 4B, both genes were significantly downregulated in all the human thyroid 
carcinoma cell lines analyzed. Remarkably, the expression of CD24 was completely 
undetectable in four out of the seven carcinoma cell lines. 
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Analysis of the Ras-dependent genes in human thyroid carcinomas. To further 
analyze the expression of Ras-regulated genes in human thyroid tumors, we analyzed 
by RT-PCR human carcinomas of different hystotypes. In all the experiments the 
expression of the Ras-regulated genes in the carcinoma samples was compared to the 
expression of the same gene in the normal tissue obtained from the same patient. As 
shown in figure 5A, Annexin A2, RalA and Ler3, three Ras-induced genes, were 
significantly upregulated in the vast majority of the tumor samples. Accordingly, as 
shown in figure 5B, the expression of Dusp1, whose expression was reduced in the 
tumoral cell lines analyzed, was downregulated in a great fraction of the thyroid 
carcinomas analyzed when compared with normal tissue. Remarkably, the expression 
of CD24, whose expression was undetectable in most of the thyroid carcinoma cell 
lines analyzed, resulted strongly downregulated in all the anaplastic thyroid tumor 
samples investigated.  
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DISCUSSION 
In this study, we have globally analyzed gene expression of Ras transformed thyroid 
cells to reveal characteristic changes in gene expression associated with 
carcinogenesis in thyroid cells. We have focused our attention on thyroid cells 
transformed by Ras as several data provided by us as well by other laboratories have 
shown the clear involvement of this protein in thyroid neoplastic transformation.  
To begin the analysis of our data, it should be observed that all the established marker 
genes of normal thyroid cells, such as thyroglobulin and TSH receptor, were found to 
be severely downregulated in v-Ki-Ras transformed cells, reflecting their less 
differentiated state.  
Moreover, as described previously, even by setting a tenfold threshold of induction or 
downregulation in transformed versus wild type cells, the number of genes whose 
expression is modulated by Ras is quite high. Most of these genes could be sort out in 
two main groups: 1) genes already correlated to a tumor phenotype, even though not 
always in the thyroid, or, conversely, 2) novel or known genes never correlated to any 
tumor phenotype. Among the genes already described as modulated in cancer and 
found by our analysis as regulated by Ras, CD24, coding for a small heavily 
glycosylated glycosylphosphatidylinositol-linked cell surface protein, appears to be 
particularly interesting. We have, in fact data showing that CD24 expression is 
undetectable in most of the carcinoma cell lines analyzed and is greatly 
downregulated only and in all the anaplastic carcinomas we have analyzed. This data 
is not in accordance with most of the literature about CD24 expression in cancer. In 
fact, high levels of CD24 expression detected by immunohistochemistry have been 
found in epithelial ovarian, breast, non-small cell lung, prostate and pancreatic cancer 
(34). With the exception of pancreatic cancer, high rates of CD24 are significantly 
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associated with a bad prognosis (34). As CD24 is a ligand of the adhesion receptor P-
selectin (35), it has been hypothesized that its overexpression on cancer cells might 
enhance their metastatic potential. Thus, our finding that CD24 is downregulated only 
in thyroid carcinomas of anaplastic hystotype is in conflict with the other data 
available in literature suggesting CD24 as marker for the most aggressive forms of 
cancer. Hence, studies aimed at the evaluation of CD24 expression in a larger tumor 
collection of anaplastic thyroid carcinomas are currently ongoing in our laboratory.  
As discussed above, among the genes found as Ras-regulated in our screening, many 
have never been globally analyzed in human tumor samples. Among them, the 
interferon-induced mRNA, a gene whose expression is dowregulated in FRTL-5 v-Ki-
Ras cells when compared to the parental cells, is particularly of interest. Although not 
shown in this paper, we have preliminary results demonstrating that the human 
homolog of interferon-induced mRNA is severely downregulated in many thyroid 
tumors. This is particularly intriguing: as the gene has been cloned because greatly 
induced by the interferons, potent antiproliferative cytokines (36), it could be 
hypothesized a role for the interferon-induced mRNA as tumor suppressor. 
Remarkably, interferon-induced mRNA has been found as severely downregulated 
also in mouse fibroblasts and rat ovarian cells transformed by Ras (37, 38). The 
physiological function of this gene as well as its role in Ras-mediated transformation 
will warrant further investigations. 
Despite the key role in tumorigenesis, few studies have assessed the gene expression 
profile of cells transformed by mutated Ras proteins. It has been reported the gene 
expression pattern of mast cells expressing a Ras oncogene (39) and of transformed 
fibroblasts expressing mutant H-Ras, Ki-Ras and N-Ras genes (37). However, both 
mast cells and fibroblasts are not the ideal cell systems to investigate the effects of 
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Ras genetic alterations, as the epithelial cells are predominantly affected by Ras 
mutations that cause in this case carcinomas. Only recently a study addressing the 
trascriptome profiling of a rat cell culture model of ovarian epithelial cells 
transformed by the Ki-Ras oncogene has been published (38). By subtractive 
suppression hybridizations the authors recovered genes encoding negative and 
positive regulators of cellular transformation, survival, angiogenesis and invasiveness, 
not verifying, however, the expression of the genes modulated by Ras in human 
tumors. Conversely, in this study, we have shown that some of the genes identified by 
the microarray analysis as modulated by Ras in cell lines are overexpressed or 
downregulated in human tumors as well. Moreover, relevantly, the expression of the 
Ras modulated genes was verified in thyroid tumors, where the prevalence of Ras 
mutations is quite high. Thus, we expect that some of these genes, once systematically 
analyzed in a large spectrum of thyroid tumors, could provide useful markers for the 
diagnosis and prognosis of the thyroid tumors as well potential targets for the 
development of new, improved therapeutic drugs. 
In summary, using a microarray approach, we have detected more than 100 genes 
whose expression is modulated more than tenfold by Ki-Ras in rat thyroid cells. More 
relevantly, we have shown that there is complete concordance among the results 
obtained in rat thyroid cells, in human thyroid carcinoma cell lines and in human 
tumor samples. Thus, the genes identified as modulated by Ras in rat cells provide a 
wealth of data that will be opportune to investigate further in human tumors.  
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LEGENDS TO FIGURES 
Figure 1: Changes of gene expression in FRTL-5 and FRTL-5 v-Ki-Ras cells. 
A) Scatter plot of changes of gene expression in FRTL-5 and FRTL-5 v-Ki-Ras cells. 
For each gene, the RNA expression level in the wild type cells is given on the X axis 
and the expression level for the same gene in the transformed cells is plotted on the Y 
axis. The upper and lower boundaries represent a twofold difference.  
B) List of the genes, identified by their accession numbers, up and downregulated 
more than tenfold in FRTL-5 v-Ki-Ras vs. FRTL-5 cells. 
 
Figure 2: RT-PCR verification of genes differentially expressed in FRTL-5 v-Ki-
Ras transformed cells compared to wild type cells.  
A) RT-PCR verification of genes upregulated in FRTL-5 v-Ki-Ras cells. Total RNA 
isolated from the indicated cell lines was retrotranscribed in presence or absence of 
the reverse transcriptase enzyme (RT). The cDNAs were analyzed for the expression 
of the designated genes by PCR. The reaction products were electrophoresed and 
images of the ethidium bromide stained gels are shown. β-actin was used as a control 
for the amount of RNAs. β-actin was either amplified at the same time and in the 
same conditions of the investigated genes (upper panel) or co-amplified with the RNA 
of interest (lower panel). In the last two lanes the negative control, lacking RNA, is 
showed.  
B) RT-PCR verification of genes downregulated in FRTL-5 v-Ki-Ras cells. Total 
RNA isolated from the indicated cell lines was retrotranscribed in presence or absence 
of the reverse transcriptase enzyme (RT). The cDNAs were analyzed for the 
expression of the designated genes by PCR. The reaction products were 
electrophoresed and images of the ethidium bromide stained gels are shown. β-actin 
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was used as a control for the amount of RNAs. In the last two lanes the negative 
control, lacking RNA, is showed.  
 
Figure 3: RalA gene expression is upregulated in thyroid cells infected with 
retroviruses carrying the v-mos and v-raf oncogenes.  
A and B) Total RNA isolated from the indicated cell lines was retrotranscribed in 
presence or absence of the reverse transcriptase enzyme (RT). The cDNAs were 
analyzed for the expression of RalA by PCR. The reaction products were 
electrophoresed and images of the ethidium bromide stained gels are shown. β-actin, 
co-amplificated in the same reaction tube with RalA, was used as a control for the 
amount of RNAs. In the last two lanes the negative control, lacking RNA, is showed.  
 
Figure 4: RNA levels of selected genes in human thyroid cell lines. 
A and B) Total RNA isolated from the indicated cell lines was retrotranscribed in 
presence or absence of the reverse transcriptase enzyme (RT). The cDNAs were 
analyzed for the expression of the designated genes by PCR. The reaction products 
were electrophoresed and images of the ethidium bromide stained gels are shown. β-
actin, co-amplificated in the same reaction tube with the genes of interest, was used as 
a control for the amount of RNAs. In the last two lanes the negative controls, lacking 
RNA, are showed.  
The bar-graph quantification is showed under each ethidium bromide gel, with the 
exception of Ler-3 gene which levels of expression were undetectable in the normal 
thyroid. The expression levels of the genes of interest were normalized with respect to 
that of normal thyroid, whose value was arbitrarily taken as 1. β-actin levels were 
used to normalize the expression of the genes of interest to the RNA levels.  
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 Figure 5: RNA levels of selected genes in human thyroid tumors. 
A and B) Bar-graph quantification of the expression of selected genes verified by RT-
PCR as described previously. The expression levels of the genes of interest in the 
tumor samples were normalized with respect to that of normal tissue. On each bar is 
indicated the histotype of the tumor sample: Ad= follicular adenoma; P= papillary 
carcinoma; A= anaplastic carcinoma.   
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